Progesterone receptors in the human placenta : expression, signalling characteristics and functional relevance by Karteris, M et al.
  
 
 
PROGESTERONE RECEPTORS IN THE HUMAN PLACENTA: 
EXPRESSION, SIGNALLING CHARACTERISTICS AND 
FUNCTIONAL RELEVANCE 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy by 
 
 
 
Elena Barbara Zachariades  
 
 
 
 
 
 
 
 
School of Health Sciences and Social Care 
Brunel University 
UK 
 
 
 
 
 
October 2011 
 
 
 
Abstract  and Contents   
 
I 
 
Abstract 
The human placenta is a transient life sustaining organ which is responsible for mediating all 
the physiological exchanges between the mother and the fetus. The steroid hormone 
progesterone, often referred to as the hormone of pregnancy, is critical for the establishment 
and for maintaining the pregnancy. During the gestation period the human placenta produces 
progesterone which via interacting with the progesterone receptors exerts its many effects. 
Specific intracellular progesterone receptors (PRs) have been reported to mediate the 
genomic signalling of progesterone whereas recently two novel receptor families which are 
phylogenetically distinct to the nuclear receptor superfamily have been characterised, and 
shown to mediate progesterone’s non genomic actions. These are the multiple membrane 
progestin receptors (mPRα, mPRβ, and mPRγ) and progesterone membrane receptor 
component 1 (PGMRC-1). The rapid progesterone actions mediated via these non-classical 
progesterone receptors have received attention with main focus on their reproductive 
functions. Our aim is to elucidate the expression of the receptors in the human placenta, 
further understand the signalling pathways via which progesterone mediates its effects and 
lastly examine the functional relevance of these receptors in this organ. Choriocarcinoma cell 
lines are used frequently as placental models for investigations of steroid hormone actions, 
but until now little is known about the expression of progesterone receptors (PRs) in these 
cell lines. Quantitative RT-PCR revealed that in fully syncytialized BeWo cells (treated with 
50 µM forskolin for 72 h) there was a significant down-regulation of mPRα and up-regulation 
of mPRβ and of the PGRMC1 when compared with non-syncytialized BeWo cells. 
Expression of all the mPR and PGRMC1 mRNAs was significantly lower in JEG-3 cells 
compared to non-syncytialized BeWo cells. Expression of PR-B was unaltered between the 
two BeWo states but was significantly higher in JEG-3 cells. Immunofluorescence analysis 
revealed that mPR proteins are differentially expressed in these choriocarcinoma cell lines as 
well as in the human placenta. The functionality of mPRs was investigated in vitro, using 
BeWo and JEG-3 cells that were treated with Org OD-02 (a specific mPR agonist), 
progesterone (P4) and R5020 (a specific nuclear PR agonist) in the presence or absence of the 
pro-inflammatory cytokine inteleukin-1β (IL-1β) at a concentration of 10ng/μl.  The effect 
was more exacerbated in JEG-3 cells, where IL-1β induced 40% cell death when compared to 
BeWo cells that reached a modest but significant 15% cell death.  
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When JEG-3 cells were treated with IL-1β and progesterone, there was a significant decrease 
in cell death at concentrations of 100nM and 1000nM. When cells were treated with 1000nM 
progesterone, IL-1β’s effect was completely abolished. Progesterone was also able to induce 
phosphorylation of ERK1/2 in these cells. Pretreatment of JEG-3 cells with a specific MAPK 
inhibitor (UO126) inhibited substantially the progesterone’s proliferative effect. Moreover, 
using the specific mPR agonist Org OD 02-0, we have shown that that the progestin 
antagonism of apoptotic effects of IL-1β on BeWo cells is mediated through mPRs. 
Quantitative PCR in clinical samples revealed a 2.8 fold decrease of mPRβ in labouring 
comparing to non-labouring tissues and 4.6 fold higher levels of mPRγ in preterm mPRγ 
compared to term placentas. The ratio of mPRα to PR-B was increased in term compared to 
preterm samples, whereas it was decreased in labour compared to non-labour placentas. 
There was also a high correlation between mPRα and PGRMC1 expression irrespective of 
pathologies. This study addressed many fundamental questions regarding how progestins 
exert their effect at placental level. It is evident that there is a higher order of complexity and 
changes in the ratios of placental progesterone receptors rather than individual fluctuations 
might affect subsequent signalling events.  
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                    CHAPTER 1 
1. INTRODUCTION 
1.1. Placental Physiology 
1.1.1. Formation of the human placenta - Placentation 
The placenta is the organ which a successful pregnancy outcome fully depends on. Therefore 
the successful development of this highly specialised organ is a very crucial step of 
pregnancy (Gude et al., 2004). The placenta is a transient life - sustaining organ which 
mediates all the physiological exchanges such as oxygen and nutrient supply as well as waste 
removal, between the mother and the fetus (Jurisicova et al., 2005; Gude et al., 2004). 
Beyond these abilities, the placenta also poses endocrine activity and acts as an 
immunological barrier to prevent maternal rejection of the developing fetal allograft 
(Benirschke et al., 2005). During the gestation period which lasts 40 weeks approximately 
(Patel et al., 2003), the development and normal growth of the fetus is supported by the 
placenta synergistically with the fetal membranes and the amniotic fluid (Gude et al., 2004). 
There are different types of placentation and these are classified depending upon the number 
and types of layers present between the maternal and fetal circulations (Loke & King, 1995). 
The human placenta is classified as a haemochorial villous organ, where the maternal blood 
comes into direct contact with the placental trophoblast cells creating an intimate relationship 
between the developing fetus and the maternal nutrient source (Loke & King, 1995). 
1 
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The development of the human placenta begins with a successful implantation where the 
outer trophoblast cells of the blastocyst invade the uterine lining to be embedded in the 
uterine stroma. The outer cell layer situated at the implantation pole of the blastocyst, 
proliferates to form the trophoblastic cell mass from which the cells infiltrate between the 
cells of the endometrial epithelium. These latter cells then degenerate and the trophoblast 
comes into direct contact with the endometrial stroma (Benirschke et al, 2005).   
The cells of the trophoblastic cell mass may differentiate along two main pathways: the 
villous and extravillous pathway. Villous trophoblast cells will ultimately cover the chorionic 
villi of the definitive placenta and have as a major concern the transport of oxygen and 
nutrients from the mother to the fetus (Benirschke et al, 2005; Loke & King, 1995). The villi 
are bathed in blood and contact is only achieved with maternal cells present in the circulation. 
In contrast, the extravillous trophoblast cells will migrate deep into the uterine mucosa as far 
as the myometrium and infiltrate through uterine tissues (Benirschke et al, 2005; Loke & 
King, 1995).  
1.1.1.1. Villous trophoblast cells 
The appearance of buds of cytotrophoblasts protruding into the primitive syncytium in the 
second week of gestation is the earliest sign of villous development. The primary villi are 
then converted into secondary villi by penetration of the solid cytotrophoblast buds by the 
underlying mesenchymal cells. Their conversion into tertiary villi occurs when the 
mesenchymal core is supplied by embryonic blood vessels which are proximally connected to 
the umbilical arteries. The embryonic blood vessels which are connected with blood vessels 
in the developing fetus establish by the fourth week of gestation the feto-placental circulation 
(Benirschke et al, 2005; Loke & King, 1995).  
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During the second and third months of pregnancy, the villous tree, a characteristic of the 
mature placenta is achieved by rapid extension and branching of the villi. At first, the villi are 
covered by primitive syncytium which subsequently becomes the villous syncytiotrophoblast. 
During the first trimester, the villi are composed of two trophoblast layers: the inner 
cytotrophoblast cells situated on the basement membrane and are covered by the outer 
syncytiotrophoblast layer. This syncytiotrophoblast layer outlines the intervillous space and 
comes into direct contact with maternal blood (Fig. 1.1). The core of the villus contains loose 
mesenchymal cells, embryonic blood vessels as well as fetal macrophages (Benirschke et al, 
2005; Loke & King, 1995). 
 
 
Figure 1.1: Development and structure of the placental chorionic villi. The primary chorionic 
villi are at the stage of outgrowths (columns) of cytotropoblast protruding into the 
syncytiotrophoblast. The secondary chorionic villi are formed as the extra embryonic 
mesenchyme invades the columns. The tertiary chorionic villi contain the embryonic blood 
vessels that develop from mesenchymal cells (Gest, 1999). 
 
Introduct ion Chapter  1   
 
4 
Through the progression of gestation the villi become smaller, whereas the cytotrophoblast 
layer becomes less prominent as the cells become extensively separated. During this time, the 
cells of the syncytiotrophoblast layer turn into more irregular and narrow cells with clustering 
of the nuclei. The fetal capillaries are outlined by a narrow rim of thinned syncytiotrophoblast 
layer. This is due to their transformation into vasculosyncytial membranes, the specialised 
layer responsible for gas transfer across the placenta (Loke & King, 1995). 
1.1.1.2. Extravillous trophoblast cells 
Following the second week of gestation, the budding cytotrophoblast cells which ultimately 
will form the villous tree, penetrate the primitive syncytium. At the tips of these newly 
formed villi the cytotrophoblast cells remain as a solid core known as the cytotrophoblast cell 
columns responsible for attaching the villi to the decidua. These cytotrophoblast columns are 
known as the anchoring villi (Loke & King, 1995). Once the penetration of the 
syncytiotrophoblast shell is completed, the proliferating cytotrophoblast from the proximal 
section of the cytotrophoblast cell columns of the anchoring villi differentiate into two 
distinctive subsets of extravillous cytotrophoblast. The phenotype that these cells pose 
enables them to invade, penetrate and remodel the maternal spiral arteries to redirect the 
maternal blood flow to the implantation site. This step is an important part of a successful 
pregnancy. 
Two routes for extravillous cytotrophoblast invasion exist (Pijnenborg et al., 2009) with 
different end point results: interstitial where the extravillous cytotrophoblast invades the 
decidua stroma reaching up to the inner third of the myometrium where they encircle the 
spiral arteries and replace the vascular media  with fibrinoid material converting the spiral 
arteries into large, dilated vessels of low resistance (Lyall, 2006) and endovascular where the 
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maternal blood vessels in the uterine decidua are penetrated by the extravillous trophoblasts 
in order to remodel the maternal blood arteries (Kaufmann et al., 2003).   
The cytotrophoblast cell columns extend across and fuse with neighbouring columns forming 
a cytotrophoblast shell which encircles the entire embryonic sac.  The invading trophoblast 
cells arise from the cytotrophoblast shell and once it has come into direct contact with the 
decidua, the isolated interstitial trophoblast cells penetrate the uterine mucosa. As the 
interstitial trophoblast cells lose contact with the cytotrophoblast shell their morphology 
changes where they appear as rounded uniform cohesive cells. Once the decidua has been 
invaded the interstitial trophoblast cells become isolated fusiform pleomorphic cells. The 
morphology of the nucleus changes from being a nucleus with prominent nucleoli in the 
columns to being a hyperchromatic pleomorphic nucleus with an irregular nuclear membrane 
(Loke & King, 1995).  
On the maternal side of the cytotrophoblast shell and specifically in the region of the original 
primitive syncytium, two irregular narrow strips of fibrinoid necrosis appear and are known 
as the Rohr’s layer and the Nitabuch’s layer. Apart from these small foci of necrosis at the 
placental decidual junction, the invasion of maternal tissues by trophoblast cells lacks any 
further tissue destruction or inflammatory response. The movement of the invading interstitial 
trophoblast cells towards the decidual spiral arteries is a focused process as trophoblasts are 
located in the region of the arteries and a much less number of invading cells is found in the 
intervening areas. The arteries in the decidua basalis which are surrounded by trophoblasts 
exhibit endothelial swelling and a characteristic destruction of the muscular media which is 
replaced with “fibrinoid” material. This disruption of the walls of the vessels is only seen in 
decidual vessels in the proximity of the implantation site (Loke & King, 1995).  
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During the beginning of the second trimester of pregnancy, the interstitial trophoblast cells 
have colonised the full thickness of the uterine mucosa in an effort to reach the decidua-
myometrial border (Fig.1.2). As the cells penetrate deeper layers, the trophoblast cells 
become multinucleated and more rounded and are known as placental bed giant cells. These 
cells can be regarded as the terminally differentiated end point of the extravillous pathway.  
During the second trimester there is further invasion into the inner myometrium. Destruction 
of the musculo-elastic tissues of the intra-myometrial segments of the spiral arteries occurs 
with a similar fibrinoid change of the existing vessel media (Loke & King, 1995).  
 
 
Figure 1.2: The placenta and the developing embryo, taken from: Brown, H.L. (2007); the 
merck manuals, stages of development of the fetus. 
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Endovascular extravillous cytotrophoblasts, being a separate pathway to the interstitial 
extravillous cytotrophoblasts, invade the lumen of the maternal spiral arteries were they form 
an “endovascular plug” to prevent the maternal blood from entering the intervillous space. 
Endovascular plugging helps to maintain a hypoxic environment in relation to that of the 
maternal tissues (Burton & Jauniaux, 2001)  which is crucial for fetoplacental angiogenesis of 
the early formed tertiary villi, also for the regulation of important cellular events taking place 
during trophoblast differentiation and for the in-utero fetal organogenesis (Burton & 
Jauniaux, 2001; Caniggia et al., 2000). The endovascular plug eventually regresses to 
establish the maternal-fetal circulation, this take place around the 10th week of gestation 
(Chaddha et al., 2004).  
To conclude the remodelling of the maternal spiral arteries, further differentiation of the 
extravillous cytotrophoblasts occurs where intramural extravillous cytotrophoblast infiltrate 
the walls of the spiral arteries thus transforming them into uteroplacental arteries. The 
endothelium is being replaced by intra-arterial extravillous cytotrophoblasts where they have 
adopted a vascular endothelial phenotype (Lyall, 2002). The vessels transform from being 
elastic, muscular, narrow and highly coiled to being widened exhibiting high flow, low- 
resistance and lacking vasomotor control thus allowing maximal maternal flow to reach the 
fetoplacental unit (Harris & Aplin, 2007). 
1.1.2. Proliferation, differentiation and fusion of villous trophoblast. 
There are two layers from which the villous trophoblast is composed of: the cytotrophoblast 
and the syncytiotrophoblast. The distinctive differences between the two define their function 
within the human placenta. The main characteristic of the cytotrophoblast layer is that the 
cells comprising it display high proliferative capacities. In contrast, the syncytiotrophoblasts 
have lost their generative ability and are unable to proliferate. The syncytiotrophoblast is a 
multinucleated layer also known as syncytium where it frames the outer surface of the 
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chorionic villi and it comes into direct contact with maternal blood (Huppertz & Borges, 
2008). The syncytium  serves many of the important functions of the placenta including the 
transport of oxygen, nutrients and waste products, production and secretion of steroid 
hormones such as progesterone and oestrogen, peptide hormones such as human chorionic 
gonadotrophin, human chorionic prolactin and also provide immune tolerance (Huppertz & 
Borges, 2008 ; Lunghi et al., 2007; Benirschke et al., 2005).  
By having the ability to expand its surface area the syncytium meets successfully the 
increasing demands of the growing fetus. An important contributor of this is the process of 
trophoblast turnover which involves the proliferation, differentiation and fusion of the 
mononucleated cytotrophoblasts with the overlying syncytiotrophoblast (Gauster et al., 
2009).  
Cytotrophoblast proliferation is a continuous process that begins from the first trimester of 
gestation and continues to a lesser degree up to the end of the gestation period (Huppertz et 
al., 1998). Throughout gestation, the growth and integrity of the placental villous trees is 
fully dependent on the continuous proliferation and fusion of villous trophoblast cells 
(Mayhew et al., 1994) as these progenitor cells are needed for the continual growth and 
regeneration of the overlying syncytium. The process of fusion is also very important as it 
maintains the post-mitotic syncytium alive as the cytotrophoblastic material provides 
organelles, enzymes and nucleic acid. If the input of cytotrophoblastic material is diminished 
the syncytium will become necrotic within a short period of time (Arnholdt et al., 1991). 
As seen in Fig. 1.3, the process of trophoblast turnover takes place on two levels: on the 
mononucleated cell level and on the multinucleated cell level. On the first level, the 
cytotrophoblasts undergo proliferation from which daughter cells are produced. These cells 
then exit the cell cycle and start differentiating. The cells undergoing differentiation start to 
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accumulate high amounts of RNA, proteins and organelles. Once this is achieved the last 
differentiation step occurs which is the syncytial fusion with the syncytiotrophoblast layer 
(Benirschke et al., 2005; Tanaka et al., 1998). Evidence of the fusion includes localised 
confluence of cytotrophoblast and syncytiotrophoblast cytoplasms and intrasyncytial plasma 
membrane (Mayhew, 2001). On the second level, the incorporated materials integrate fully 
with the syncytiotrophoblast layer (Benirschke et al., 2005). Further differentiation leads to 
the production of hormones, transporters and other proteins which are important for 
maintaining the pregnancy (Huppertz, 2006).  
 
 
Figure 1.3 : Turnover of villous trophoblast. The cytotrophoblast cells in the stem cell layer 
proliferate, then undergo differentiation and finally fuse forming the syncytiotrophoblast layer.  The 
cellular contents of the fused cells are incorporated into the syncytial layer and remain for 3-4 weeks. 
Following the differentiation and maturation of the cytotrophoblast cells within the 
syncytiotrophoblast layer the aged nuclei are extruded from the syncytial layer by apoptitic and to a 
lesser extent, by necrotic shedding of syncytial knots which are released into the maternal circulation. 
This process is performed in a continuous cycle which is tightly regulated through out gestation 
(Huppertz et al., 2002). 
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Finally, nuclei that demonstrate signs of ageing and late apoptosis (Huppertz et al., 1998) are 
packed into protrusions of the apical plasma membrane of the syncytiotrophoblast layer, 
known as syncytial knots. The syncytial knots are released from the layer and enter the 
maternal circulation (Johansen et al., 1999) where they are engulfed and cleared in the lungs 
of the mother protecting her from an imminent inflammatory response (Delmis et al., 2000; 
Lee et al., 1986). The nuclei that have been discarded are then replaced by further fusion 
events (Fig. 1.3). Disruption in the homeostasis of trophoblast turnover can lead to potential 
increases or decreases in the material being incorporated or being removed from the 
syncytium layer. This will have a direct effect on the proper function of the villous 
membrane, where dysfunctions of the syncytium layer will result in compromised fetal 
growth and development seen in pathophysiological conditions including pre-eclampsia 
(Leung et al., 2001) and intra-uterine growth restriction  (IUGR) (Smith et al., 1997). 
 
1.1.3. Molecular basis of cytotrophoblast differentiation 
1.1.3.1.  Fusigenic proteins involved in cytotrophoblast differentiation 
The exhaustion of the syncytial layer following limited fusion or depletion of fresh cellular 
components being provided within the syncytiotrophoblast must be avoided and the process 
of trophoblast turnover must be strictly regulated to avoid excess or restricted cytotrophoblast 
–syncytiotrophoblast fusion (Gauster et al., 2009). To ensure the orderly progression of the 
differentiation process a number of different factors have been identified for regulating this 
process.  
The regulation of the syncytialisation process remained a mystery for several years until 
recently where studies identified that envelope (Env)  proteins derived from human 
endogenous retroviruses (HERVs) as key regulators of this important process (Rote et al., 
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2004; Mi et al., 2000). A protein called syncytin-1 plays an essential role in the cellular 
fusion events in the placenta. It was shown that decreased expression of syncytin-1 was 
associated with the presence of pregnancy anomalies such as pre-eclampsia and hemolysis 
elevated liver enzymes (Wilson et al., 2003). However, unanswered questions remained as to 
the exact role played by syncytin-1 in trophoblast cell fusion and it was suggested that other 
HERV Env proteins might be involved in this event (Potgens et al., 2004; Potgens et al., 
2002). The most attractive candidate was syncytin-2 (Malassine et al., 2006; Renard et al., 
2005; Blaise et al., 2004; Blaise et al., 2003; de Parseval et al., 2003). It has been shown that 
the expression of syncytin-2 is exclusive in placental cells. Also the receptor binding to this 
protein has been shown to be placenta-specific opposing the findings for the receptor binding 
to syncytin-1 (Lavillette et al., 2002; Blond et al., 2000) thus making it a most suitable fusion 
candidate.  
The hypothesis that syncytin-2 demonstrates a better correlation with cell fusion events and 
therefore might be more relevant was corroborated by recent experimental studies where it 
was shown that in primary trophoblast cells both were showed to be expressed at the onset of 
cell culturing, with a significant drop in the expression levels of syncytin-1 was observed 
compared to a significant increase in expression levels of syncytin-2 with time (Vargas et al., 
2009). BeWo cells were used to perform similar experiments where cells were incubated with 
cell-fusion-inducing agents and a parallel increase in the level of mRNA of both syncytin-1 
and syncytin-2 was detected. Notably, syncytin-2 was very poorly expressed in nonstimulated 
cells and presented a more drastic increase in its expression upon stimulation (Vargas et al., 
2009).  
Further studies have been conducted to expose any differences in the localisation of these two 
proteins in primary trophoblast cultures and in BeWo cells. In villous trophoblasts it was 
shown that syncytin-2 is expressed in the membrane and in the cytoplasm. In the membrane 
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the signals obtained where in regions of cell to cell contact showing specific localisation as 
being expected from its potential function in trophoblast cell fusion (Vargas et al., 2009). In 
second trimester placenta expression of syncytin-2 was more frequently seen in 
cytotrophoblastic cells at the level of the cell membrane and this staining occurred at the sites 
of contact with the overlying syncytiotrophoblast (Malassiné et al., 2006). 
However, syncytin-1 appeared close to the region of cell to cell contact (Vargas et al., 2009). 
Also the expression was not affected by the differentiation stage of which the cells were in 
and an equal expression was observed in all trophoblastic cells, villous and extravillous 
trophoblast, independently of their differentiation stage (Muir et al., 2006; Malassine et al., 
2005). Based on the localisation, an involvement in cell fusion might be speculated but the 
expression was equally presented in stimulated and unstimulated BeWo cells (Vargas et al., 
2009). 
The fusigenic activities of syncytin-2 are mediated trough the major facilitator superfamily 
domain containing 2A (MFSD2A) which is the receptor for syncytin-2 mediated cell-cell 
fusion. In the human placenta, both syncytin-2 and MFSD2A have been shown to be 
expressed (Esnault et al., 2008).  
Esnault et al., have proposed an “in-fusion” cytotrophoblast model (Fig. 1.4) where the two 
partners involved in the cell fusion process – Env protein and concomitant receptor are finely 
regulated and not being expressed in parallel on the same cell type therefore allowing for the 
specific fusion between cytotrophoblast and syncytiotrophoblast to take place. This ability 
restricts fusion of mononucleated cytotrophoblast cells to “in-fusion” into the 
syncytiotrophoblast thus allowing the growth and maintenance of the syncytium layer and 
promoting an orderly organization of the syncytiotrophoblas (Esnault et al., 2008).  
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Figure 1.4: ‘‘In-fusion’’ model of the cytotrophoblasts (CT) into the syncytiotrophoblast (ST) layer. 
This modes proposes that syncytin-2 protein is expressed on a fraction of the cytotrophoblasts cells 
and major facilitator superfamily domain containing 2 (MFSD2) is expressed on the 
syncytiotrophoblast cells thus allowing for a controlled fusion and subsequently maintenance of the 
syncytiotrophoblast layer (Adapted from Esnault et al., 2008).  
Recent studies devoted to understanding how the expression of syncytion-2 and MFSD2A are 
regulated in the placenta have shown that the expression of these genes is regulated by the 
glial cell missing-1 (GCM1) placental transcription factor (Liang et al., 2010). The functional 
importance of this transcription factor is stressed in studies performed in mice, where both 
syncytiotrophoblast differentiation and formation of the chorionic villi are regulated by 
GCM1. Mouse embryos that lack GCM1 die in utero mid-gestation as the 
syncytiotrophoblast fails to differentiate (Baczyk et al., 2004). Up- regulation of GCM1 
results in less cytotrophoblast proliferation, induction of syncytial fusion and the subsequent 
formation of syncytiotrophoblast (Baczyk et al., 2009). The expression of GCM1 was 
confirmed on clustered trophoblast where each contained 3-4 cells that were uniformly 
distributed on the basal surface of the chorion. The majority of the chorionic trophoblast cells 
do not express GCM1 suggesting that the chorion does not consist of a uniform cell 
population (Anson-Cartwright et al., 2000). 
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Other fusogenic proteins that have been shown to be involved in the  process of syncytial 
fusion in the human placenta include the ADAM proteins (disintegrin and metalloprotease) 
which belong to the family of integral membrane or secreted glycoproteins (Huppertz et al., 
2006). A study performed by Ito et al., reported the presence of ADAM12 on the apical part 
of syncytiotrophoblasts in term placentae (Ito et al., 2004). Even though the localisation of 
this protein does not provide evidence of an involvement in syncytial fusion it may well 
provide a proteolytic activity needed for the cleavage of certain proteins thus preparing the 
process of fusion (Huppertz et al., 2006). 
1.1.3.2. Signalling pathways involved in trophoblast fusion -MAPK  
Apart from the fusogenic proteins discussed above that regulate the fusion of the trophoblast 
cells, the trophoblastic fusogenic machinery is also finely tuned by a number of other 
signalling molecules (Delidaki et al., 2010). The mitogen activated protein kinases (MAPKs) 
are a family of protein kinases responsible for converting extracellular stimuli into specific 
cellular responses; among them are the control of cell proliferation, differentiation, apoptosis, 
embryogenesis, regulation of inflammatory and stress responses (Kyriakis & Avruch, 2001 ; 
Pearson et al., 2001). 
The extracellular-signal-regulated kinases (ERK) pathway (Fig.1.5) was the first MAPK 
pathway to be described in mammals. ERK1 and ERK2 (ERK1/2) can be strongly activated in 
mammalian cells by growth factors, serum and phorbol esters. Ligands of heterotrimeric G 
protein-coupled receptors (GPCRs) such as hormones and neurotransmitters can activate to a 
lesser extent the ERK1/2 along with cytokines and osmotic stress (Daoud et al., 2005). The 
p38 pathway, another member of the MAPK, in mammalian cells is strongly activated by 
environmental stress and by pro-inflammatory cytokines such as intereukin 1 (IL-1) and 
tumour necrosis factor α (TNFα) (Daoud et al., 2005).  
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Figure 1.5: Schematic representation of the ERK pathway.  The ERK pathway is activated through 
the binding of the adaptor proteins Growth factor receptor-bound protein 2 (Grb2) or Shc to the 
phosphorylated, which results in the recruitment of the son of sevenless (SOS) to the activated 
receptor SOS activates RAS thus leading to the activation of RAF. RAF subsequently phosphorylates 
MEK1 and MEK2 which activate ERK1 and ERK2 respectively. 
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Studies using choriocarcinoma cell models and primary villous trophoblasts have proven the 
important role of the MAPK cascade in the process of trophoblast differentiation (Delidaki et 
al., 2010). ERK1/2 activation was shown to be essential in the initial stage of epithelial tubule 
development, the stage where the cells migrate and depolarize (O’Brien et al., 2004). Also 
the importance of ERK1/2 was demonstrated in the sea urchin embryo where ERK1/2 was 
essential in the stage where the cells repolarise and differentiate (Fernandez-Serra et al. 
2004). However, the molecular actions adopted by ERK1/2 and by p38 by which their activity 
in trophoblast fusion is coordinated, are not fully understood yet (Delidaki et al., 2010). 
Apart from the involvement of the MAPK family in trophoblast fusion, the formation of the 
syncytiotrophoblast cell layer in humans had been shown to be regulated by the cAMP/PKA 
signalling cascade (Keryer et al., 1998), demonstrating an initial understanding of the 
signalling pathways involved in this process. Extending these first observations, studies 
performed in BeWo cells showed that the activation of the syncytin-1 gene is controlled by 
the cAMP pathway through regulation of glial cell missing (GCMa) (Chang et al., 2005; 
Knerr et al., 2005). Forskolin and PKA are able to stimulate GCMa mediated transcriptional 
activation while CREB-binding protein (CBP) directly interacts with GCMa. PKA is 
responsible for facilitating the interaction between CBP and GCMa promoting the acetylation 
of GCMa thus increasing the stability of the protein and enhancing the transcriptional 
activation mediated by GCMa (Chang et al., 2005).  Thus the GCMa/ syncytin signalling 
cascade which directly regulated the fusion of trohoblast cells is contolled by the cAMP/ 
PKA signalling cascade (Knerr et al., 2005).  
A potential signalling cross-talk between the cAMP/PKA and MAPK pathways was recently 
introduced by Delidaki and co workers where they demonstrate that ERK1/2 and p38 
pathways are activated downstream of adenylyl cyclase and play an essential role in the 
upregulation of specific fusogenic genes regulating the trophoblast differentiation process.  
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The cAMP – dependent PKA in trophoblasts is responsible for mediating the biological 
effects of cAMP influencing cell differentiation. ERK1/2 and p38 MAPK activation induced 
by forskolin has also been shown to be mediated by PKA (Delidaki et al., 2010).  
1.1.4. Models of human placental function 
Understanding the development and the physiological processes of the human placenta has 
been pursued by scientists for many years. However, numerous difficulties arise in obtaining 
human placental samples and impede the research performed on human level. Overcoming 
the ethical issues and obtaining placental samples from vaginal deliveries or elective 
caesarean sections performed at term or pre-term is still not optimun as maintaining explants 
in culture is a restrictive step due to the limited viability of only 7 to 24 hours (Di Santo et al., 
2003). Performing studies using placental tissue can be limited also by the fact that this tissue 
has been exposed to stress at birth and to ischaemia prior to reaching the researcher, therefore 
its normal physiological state has been compromised and barely reflect an in vivo situation 
(Di Santo et al., 2003). 
In response to these difficulties, cell lines established from normal cells or cells from 
trophoblastic tumors of the human placenta have been widely used to study and understand 
key functions of the human placenta such as development, endocrine and immune function as 
well as signal transduction mechanisms of trophoblast cells (King et al., 2000). 
1.1.4.1. BeWo cell line 
The most popular and extensively used in vitro mode is the BeWo cell line which is derived 
from trophoblastic cells originated from human choriocarcinoma. Choriocarcinomas are 
defined as highly malignant tumours that arise from the trophoblast cells (Berkowitz & 
Goldstein, 1996). It has been documented that around 50% of choriocarcinomas follow a 
molar pregnancy where a mass is grown inside the uterus, 30% occur after a miscarriage and 
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20% after an apparently normal pregnancy (Fox, 1997). The hormonal and cellular metabolic 
functions exhibited by this tumor resemble the functions of the normal placenta.  
In 1959, Hertz isolated the original choriocarcinoma specimen which was then successfully 
established by serial transplantations in the hamster cheek pouch (Hertz, 1959). Following 
this and using the same original specimen, Pattillo and Gey established the first continuous 
human hormone-synthesizing tissue in cell culture (Pattillo & Gey, 1968). This tissue has 
been reported to have maintained stable growth characteristics,  with production of the 
multiple placental hormones secreted during pregnancy and are hallmarks of a normal 
pregnancy specifically, it exhibites a high degree of synthesis of the functional hormone hCG 
(human chorionic gonadotrophin). In addition, many aspects of placental-cell metabolism, 
growth, and differentiation are seen in this unique multipotential cell line (Pattillo et al., 
1971; Patillo et al., 1968). 
 
Wice et al., were the first to define the in vitro differentiation system where single 
cytotrophoblast cells of the human choriocarcinoma (BeWo) cell line underwent fusion and 
extensive morphological differentiation following stimulation with forskolin (Wice et al., 
1990). Forskolin is produced by the plant coleus forskohlii which is the only known plant 
containing the diterpenoid forskolin. Once in the cell, forskolin activates adenylate cyclase, 
which subsequenlty activates cyclic adenosine monophoshate (cAMP), an intracellular 
second messenger which is responsible for inducing the cellular responses in response to 
hormonal activation (Bhat, 1983). 
Incubation of cells with forskolin demonstrated a dose-dependent increase in intracellular and 
secreted cyclic AMP and a coordinated fusion of cells which yielded syncytia containing 
hundreds of nuclei per cytoplasm. Also these fused cells synthesized and secreted large 
amounts of human chorionic gonadotropin (Wice et al., 1990).  A different inducer of cell 
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differentiation that can be used to promote differentiation is the  8- Bromoadenosine- 3', 5'- 
cyclic monophosphate (8-Br-cAMP) an exogenous cAMP analogue where the hydrogen in 
position 8 of the heterocyclic nucleobase is replaced by bromine making the compound more 
lipophilic able to readily diffuse through the plasma membrane (Chen et al., 2011).  
As mentioned, the BeWo cell line has been extensively used for a variety of in vitro studies 
(Burleigh et al., 2007), including preventive and therapeutic agents for preeclampsia (Orendi 
et al., 2011; Gould et al., 2010), and placental transport of compounds and molecules 
(Sønnegaard Poulsen et al., 2009 ; Jones et al., 2007; Schmid et al., 2003).These studies have 
established BeWo cells as a good  in vitro model for studying placental functions, and the 
fusigenic ability of these cells enabling them to undergo fusion in vitro has further facilitated 
an increased scientific understanding of many aspects of the placental physiology and 
function. 
1.1.4.2. JEG-3 cell line 
The JEG-3 cell line was established by Kohler in 1971 and was a part of six clonal lines of 
human choriocarcinoma origin that were previously adapted to passage in the hamster cheek 
pouch by Hertz in 1959 (Kohler & Bridson, 1971). The morphology of JEG clones has been 
reported to vary among clones, but all clones including JEG-3 grew as individual cells but 
syncytia were not visible. All JEG clones were found to be active in an endocrine sense 
(Kohler & Bridson, 1971; Kohler et al., 1971). 
It is well accepted that JEG-3 cells are unable to fuse upon stimulation with a cAMP analog 
(8-bromocyclic AMP) unlike BeWo cells (Coutifaris et al., 1991). More specifically, in a 
study where the Ca
2+-
dependent cell adhesion molecule, E-cadherin, was examined during the 
morphological differentiation in trophoblastic cells including cells from JEG-3 and BeWo 
choriocarcinoma cell lines and cytotrophoblast cells isolated from human chorionic villi, it 
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was shown that JEG-3 cells are unable to fuse and form multinucleated syncytia (Coutifaris et 
al., 1991).  
The JEG-3 cell line has been widely used as a model for different placental actions such as 
placental metabolism of retinol (Blanchon et al., 2002), the effects of cytokine on steroid 
production (Pongcharoen & Supalap, 2009), and the transport of substances across the human 
placenta (Hardman et al., 2006; Müller et al., 2004). 
 
1.1.4.3. Other trophoblast cell lines 
Another trophoblastic cell line that is been used as a placental model is the JAR cell line. The 
JAR cell line was established by Pattillo and colleagues in 1971 and was established directly 
from a biopsy specimen of a trophoblastic tumor of the placenta. It has been shown to have 
secretory capabilities of various hormones including the steroid hormones estrogen and 
progesterone, the lactogen hormone hPL and the gonadotrophic hormone hCG. JAR cells 
were used in placental immunology studies (Apps et al., 2009 ; Jianga et al., 2006), apoptosis 
studies (Hallmann et al., 2004), and signalling studies (Boileau et al., 2001). 
In our study we chose to use the BeWo and JEG-3 cell lines as their inherent difference in 
their fusigenic capacity were ultimate for the aims of this study.These being to evaluate the 
expression and signalling characteristics of progesterone receptors in first trimester and third 
trimester placental cells. This opportunity is provided by using BeWo cells in their 
unstimulated (first trimsester) and stimulated (third trimester). JEG-3 cells being unable to 
syncytialise provide an excellent comparison between the first trimester placental cells 
(unstimulated BeWo cells) and also provide an independent      
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Figure 1.6: Summary figure of the choriocarcinoma cell lines used as models along with the 
hormone secretion and characteristics of each cell line.  
 
1.2. Steroid hormone Progesterone and its actions 
1.2.1. Physiological actions of progesterone during pregnancy  
Progesterone (P4) is a steroid hormone critical for the establishment and maintainance of 
pregnancy (Niswender et al., 2000). In the uterus, progesterone exerts its effects on the 
endometrium as a differentiation factor where it induces differentiation of the stromal cells of 
the endometrium; it stimulates glandular secretions along with the accumulation of basal 
vacuoles in the glandular epithelium (Maslar et al., 1986) and alters the secretion pattern of 
proteins by endometrial cells (Maslar et al., 1986; Strinden & Shapiro, 1983). These changes 
enforced on the uterus by progesterone are essential to provide a supportive environment for 
early embryonic development (Niswender et al., 2000). Progesterone is also responsible for 
preventing preterm labour by maintaining the myometrium in a quiescent state (Larsen, 2001; 
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Niswender et al., 2000). Electrical coupling is prevented and increased resting potential is 
provoked by progesterone in the myometrial cells to assure the myometreium remains in a 
non-contractile state (Parkington, 1983). Additionally, progesterone decreases the uptake of 
extracellular calcium that is necessary for myometrial cell contractions (Batra, 1986) through 
downregulation of genes encoding subunits of voltage-dependent calcium channels which are 
the entering points of extracellular calcium into the cell (Tezuka et al., 1995). Apart from its 
effects on the uterus, progesterone is responsible for mediating interactions between the 
endocrine and immune system to establish a friendly immunological environment for the 
developing fetus (Beagley & Gockel, 2003). This is achieved by progesterone induced 
blocking of mitogen stimulated lymphocyte proliferation, prolonging the survival of the 
allograft. Furthermore, progesterone exerts pluripotent effects during human gestation such as 
modulating the production of antibodies, reducing the production of macrophage induced 
secretion of proinflammatory cytokines and adapting the cytokine pattern during pregnancy 
(Beagley & Gockel, 2003). 
 
1.2.2. Synthesis and secretion of progesterone by the human placenta 
An essential role of the human placenta is to synthesise and secrete progesterone to maintain 
the pregnancy, where its secretion increases throughout pregnancy (Fig 1.7 Panel B) (Tuckey, 
2005). After the 8
th
 week of gestation the placenta becomes the primary source of 
progesterone production by expressing cholesterol side chain cleavage activity (Brook & 
Marshall, 2001).The cholesterol side-chain cleavage reaction involves the conversion of 
cholesterol to pregnenolone by cytochrome P450scc (CYP11A1). This reaction takes place in 
the inner membrane of the placental mitochondria (Tuckey, 2005).  The newly synthesised 
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pregnenolone is converted to progesterone by the action of type 1 3β-hydroxysteroid 
dehydrogenase (3β-HSD) (Fig.1.7 Panel A) (Beaudoin et al., 1997; Morel et al., 1997). 
 
 
 
 
Figure 1.7: Panel A: Steroidogenesis – Progesterone is synthesised from pregnenolone, which is 
derived from cholesterol (The Hormones : Progestins, 1996), Panel B: Levels of Progesterone during 
pregnancy (Pope Paul VI Institute, National Reproductive Hormone Laboratory).  
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The synthesis of progesterone by the placenta shows some differences in comparison to other 
steroidogenic tissues such as the adrenal glands and the corpus luteum (Tuckey, 2005).  A 
main difference is that the placenta does not express the steroidogenic acute regulatory 
(StAR) protein (Tuckey, 2005).  This StAR protein regulates the binding and transport of 
cholesterol to the inner mitochondrial membrane where it can be taken up by P450scc, and 
subsequently converted to pregnenolone (Miller, 2006 ; Tuckey, 2005).  Although the 
placenta does not express StAR, a successful pregnancy is not prevented (Miller, 1998), and 
metastatic lymph node 64 protein (MLN64),  a protein closely related to the StAR protein, is 
expressed constitutively in the placenta and is involved in the transport of cholesterol in the 
mitochondria (Strauss et al., 2000). Even though research is in its infancy regarding this 
protein and its mode of action, MLN64 in the placenta is a key player in maintaining an 
unrestrictive supply of cholesterol to the inner mitochondrial membrane for placental 
progesterone synthesis (Tuckey, 2005).  
 
Whilst in steroidogenic tissues the rate-limiting step to the production of steroid hormones is 
the delivery of cholesterol to the P450scc site in the mitochondria, in the placenta the rate-
limiting step for P450scc catalysis is the reduction of adrenodoxin (Adx) by adrenodoxin 
reductase (AR). Therefore the reduced concentration of AR in the matrix of the mitochondria 
is insufficient to maintain the Adx pool in a fully reduced state and deliver the electron 
supply that is required to P450scc (Tuckey, 2005). Adrenodoxin reductase (AR) and its redox 
partner, adrenodoxin (Adx), are responsible for providing a short electron transport chain for 
the delivery of six electrons from three molecules of NADPH to P450scc which are required 
for the side chain cleavage of cholesterol. AR and Adx are located in the mitochondrial 
matrix whereas P450scc is attached to the matrix of the inner mitochondrial membrane 
(Tuckey et al., 1997). 
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The regulation of placental progesterone synthesis is not acutely regulated as it is in other 
steroid-producing organs, and this is evident from the absence of short term fluctuations in 
maternal progesterone during pregnancy (Tuckey, 2005). The progesterone production and 
secretion from the syncytiotrophoblasts during the first weeks of pregnancy is insufficient to 
maintain the healthy progression of gestation as luteal failure results in abortion (Miller, 
1998). The transition from low blood supply and a hypoxic environment to a high blood and 
sufficient oxygen supply in the placenta stimulates the production of progesterone as oxygen 
is an essential substrate for the cholesterol side-chain cleavage reaction (Cannigia et al., 
2000; Schneider, 2000). 
1.2.3. Progesterone Receptors 
Progesterone is a steroid hormone which plays a central role in the establishment and the 
maintenance of human pregnancy by regulating a number of reproductive effects. Besides 
from the placenta, progesterone has been proven to affect the uterus, ovaries, mammary 
glands and brain, but it also plays an important role in non-reproductive tissues such as the 
cardiovascular system, bone and the central nervous system, thus highlighting the extensive 
role of this hormone in humans (Li et al., 2004; Graham & Clarke, 2002; Conneely & Lydon, 
2000; Graham & Clarke, 1997). Numerous physiological effects that progesterone exerts are 
mediated via interactions of the hormone with specific intracellular progesterone receptors 
(PRs) (Conneely et al., 2002). 
1.2.3.1. Nuclear Progesterone Receptors 
Nuclear progesterone receptor (PR) belongs to the super-family of nuclear receptors 
(Bramley, 2003; Aranda &Pascual, 2001) which are believed to be evolutionary maintained 
and derived from a common ancestor (Aranda & Pascual, 2001). The nuclear receptor 
superfamily is subdivided in six different subfamilies (Laudet, 1997). In the first subfamily 
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thyroid hormone receptors, retinoic acid receptors, vitamin D receptors and peroxisome 
proliferator-activated receptors are members. The second subfamily includes the retinoid X 
receptors, hepatocyte nuclear factor 4, testis receptors and the receptors involved in the eye 
development (TLX and PNR). The members of third subfamily (Fig.1.8) include the steroid 
receptors and the highly related orphan estrogen-related receptors (Aranda & Pascual, 2001). 
The fourth, fifth, and sixth subfamilies contain the orphan receptors NGFI-B, FTZ-1/SF-1, 
and GCNF, respectively (Aranda & Pascual, 2001; Giguere, 1999).  
 
 
 
 
 
 
 
 
Figure 1.8: Primary structure of the human nuclear receptors and the major representatives of each 
subfamily (Adapted from Wahli & Martinez, 1991). 
 
The nuclear receptors and hence the PR as shown in Fig 1.9, consist of a variable N-terminal 
domain (A/B domain), a conserved domain that binds DNA (DBD or domain C), a hinge 
domain (D domain), a ligand –binding domain (LBD) also known as domain E which is 
conserved among the nuclear receptors (Fig. 1.9) (Hirata et al, 2002; Aranda & Pascual, 
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2001). The N-terminus contains an activation-function-1 (AF-1) which contributes to the 
integral ligand- independent activation by the receptor. A second activation domain, known 
as AF-2 is situated on the C-terminus of the LBD but in contrast to the AF-1 domain, AF-2 is 
dependent upon the ligand and it is found to be conserved among all the members of the 
nuclear receptor superfamily (Fig.1.9 ) (Aranda & Pascual, 2001). AF-3, a third activation 
function is found within the N-terminus domain and it is specific to PR-B isoform (Fig. 1.10) 
(Li & O’Malley, 2003). 
 
 
 
 
Figure 1.9: Schematic representation of a nuclear receptor. A typical nuclear receptor is composed 
of several functional domains. The variable NH2-terminal region (A/B) contains the ligand-
independent AF-1transactivation domain. The conserved DNA-binding domain (DBD), or region C, 
is responsible for the recognition of specific DNA sequences. A variable linker region D connects the 
DBD to the conserved E/F region that contains the ligand-binding domain (LBD) as well as the 
dimerization surface. The ligand-independent transcriptional activation domains contained within the 
A/B region, and the ligand-dependent AF-2 core transactivation domain within the COOH-terminal 
portion of the LBD (Adapted from Aranda & Pascual, 2001). 
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Progesterone mediates its biological effects through two PR isoforms, PR-A and PR-B. In 
humans, a single gene consisting of eight exons (Misrahi et al., 1993) generates both mRNA 
transcripts through two alternative promoters and translational initiation at two different 
AUG codons (Kastner et al., 1990; Conneely & Lydon, 2000).  The structural difference 
between PR-B from PR-A is the additional extension of 164 amino acids residing in the N-
terminus of the protein (Li & O’Malley, 2003).  
 
 
 
 
 
 
 
 
Figure 1.10: A schematic representation of the domain organization of the PR variants PR-A, PR-B 
& PR-C; h: hinge region; LDB: ligand binding domain; DBD: DNA binding domain. The numbers 
denote the positions of amino acids for each isoform proteins. AF-1, -2, and -3 are transcription 
activation domains (Li & O’Malley, 2003).  
 
 
 
 
The two PR isoforms are able to elicit distinct physiological responses to progesterone as this 
has been demonstrated by selective ablation of these proteins in mice (Conneely et al., 2002) 
where pleiotropic reproductive abnormalities were observed (Lydon et al., 1995). The 
phenotypic mutations seen on the function of the female reproductive system proved the idea 
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that each PR isoform had an individual contribution, as distinct transcriptional responses to 
PR-A and PR-B were seen in cell-based transactivation assays (Conneely et al., 2002). 
It was shown in mice lacking both nuclear PR isoforms that ovulation had failed to occur 
despite the presence of normally developed follicles that possess mature oocytes (Lydon et 
al., 1995). In the endometrium, selective knockout of nuclear PR, revealed that progesterone 
drives the differentiation of stromal cells upon activation of the PR-A isoform. Female mice 
that lack PR-A isoform were shown to be sterile due to defective ovulation, implantation and 
decidualisation (Mulac- Jericevic & Conneely, 2004). 
Progesterone also exerts its actions on the myometrium, and using anti-progestins (RU486) to 
induce parturition, it has been shown that nuclear PRs contribute to the relaxation of the 
myometrium during pregnancy (Avrech et al., 1991). The onset of labour is been regarded as 
the result of decreased myometrial progesterone responsiveness, also known as ‘functional 
progesterone withdrawal’ (Mesiano, 2007; Brown et al., 2004; Astle et al., 2003). In humans, 
the PR-B isoform is important for maintaining the myometrium in a relaxed state, whereas 
PR-A isoform upregulation at term can contribute towards adopting the contractile phenotype 
(Merlino et al., 2007). In the breast the role of the nuclear PR mediating the progesterone 
actions are strongly supported by studies performed in PR knockout (PRKO) mice. Impaired 
mammary gland development which was characterized by decreased pregnancy-associated 
side branching of the ductal epithelium was the results of a null mutation for both nuclear PR 
isoforms (Lydon et al., 1995). In PR-A knockout mice, progesterone is able to elicit side-
branching and lobular–alveolar development, but this is not evident in mice with a PR-B 
ablation. In contrast, to the lower female reproductive tract, the expression of PR-B is 
sufficient for mediating the proliferation and differentiation actions of progesterone on the 
mammary gland (Mulac-Jericevic & Conneely, 2004; Mulac-Jericevic et al., 2003; Mulac-
Jericevic et al., 2000). 
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Further to the two well characterised PR isoforms, a third isoform PR-C has also been 
described (Wei & Miner, 1994). The expression of this third isoform is regulated from 
alternate initiation sites of translation on PR mRNA in target tissues in humans. The 
functional role of PR-C is less well explored (Ogle, 2002). The first description of the 
presence of PR-C was received by studies using the human breast cancer cell line T47D (Wei 
& Miner, 1994).   Since, it has been translated from a partial PR cDNA and it has been shown 
to be an N-terminally truncated form of PR-A and PR-B with a molecular mass of 60 kDa 
(Fig 1.10) (Samalecos & Gellersen, 2008; Wei et al., 1996). PR-C contains the PR domains 
found upstream of the second zinc finger motif of the DND-binding domain, including 
sequences necessary for dimerazitaion and for ligand binding. Although it is transcriptionally 
silent it can modulate the transcriptional activity of the other two PR isoforms (PR-A and PR-
B) proposing an ability to form heterodimers (Wei et al., 1996).  
The progesterone receptor is activated upon progesterone binding to the ligand binding 
domain. A conformational change in the structure of the receptor facilitates the dissociation 
of the receptor from the multiprotein sequestering complex that consists of protein 
chaperones including heat shock proteins (hsp 70 & hsp 90) and immunophilins (Li & 
O’Malley, 2003). Receptors then homodimerize and bind to progesterone – responsive 
elements (PRE) (Li & O’Malley, 2003; Allan et al., 1992) located in the promoter regions of 
target genes (Conneely & Lydon, 2000).  Target gene transcription rates can be increased 
through additional interactions of the DNA-bound receptors with steroid coactivators and the 
transcription machinery, where the assembly of the preinitiation complex at the promoter is 
facilitated (Li & O’Malley, 2003).  
The coactivators for the progesterone receptor steroid receptor coactivator-1 (SRC-1), steroid 
receptor coactivator-2 (SRC-2), steroid receptor coactivator-3 (SRC-3), CREB-binding 
protein (CBP) and the related protein p300 are the most important coregulators involved in 
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enhancing the effect on target gene transcription. This is achieved through multiple 
mechanisms, including stabilization of nuclear receptors and the basal transcription 
machinery at the promoter; covalent modification of histones, activators, other coregulators; 
and possibly turnover of activators and other proteins (Rowan & O’Malley, 2000). 
SRC-1 interacts with the PR through the AF-2 containing LBD and also it interacts with the 
AF-1 domain through multiple regions of SRC-1 (Onate et al., 1998) thus bringing together 
both activation functions of the receptor in order to achieve maximal transcription at the 
target genes.   The function of SRC-1 is mediated by the two activation domains which are 
important for the interactions with other activators or the basal transcription machinery 
(Onate et al., 1998), by the binding domains for CREB binding protein (CBP) and the histone 
acetyltransderase (HAT) p/CAF and an intrinsic HAT activity which gives SRC-1 a role in 
the remodelling of chromatin (Spencer et al., 1997). The biological importance of SRC-1 for 
the actions of progesterone has been documented in SRC-1 null mice which exhibited partial 
hormone resistance in the main target tissues of progesterone the mammary gland and uterus 
(Xu et al., 1998). Similarly to SRC-1, SRC-2 and SRC-3 are able to interact with the PR in a 
hormone-dependent manner and to coactivate it (Rowan & O’Malley, 2000; Li et al., 1997). 
CREB-binding protein and the related protein p300 function as coactivators for a diverse 
group of transcription factors, including the PR (Rowan & O’Malley, 2000). CBP possesses 
an intrinsic HAT activity and recruits the HAT, p/CAF (Yang et al., 1996). CBP functionally 
interacts with all three SRC family members (Voegel et al., 1998; Torchia et al., 1997; 
Kamei et al., 1996) and acts synergistically with the SRC-1 to coactivate the PR (Smith et al., 
1996). However, interaction between the CBP and either the SRC-1 or the PR was shown to 
be weak when compared to the interaction between the SRC-1 and the PR (McKenna et al., 
1998). Collectively, these studies point to a model where an initial complex is formed 
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between the liganded PR and the SRC-1 prior to recruiting the CBP on site (Fig. 1.11) 
(McKenna et al., 1998).  
 
 
 
Figure 1.11 : Activation of progesterone receptor (PR). PR is an inactive complex with heat shock 
proteins when in the unbound state. Upon binding of progesterone, heat shock proteins dissociate, and 
the PR adopts a conformation that will first recruit the SRC family of coactivators, and subsequenlty 
other cofactors to the promoter which will open up local chromatin structure through histone 
acetyltransferase (HAT) activity and contribute to the stabilization of the preinitiation complex 
(Rowan & O’Malley, 2000). 
 
 
 
 
1.2.3.2.  Membrane Progesterone Receptors  
Many of the physiological effects exerted by steroid hormones are too rapid to be mediated 
via the classical genomic mechanism, involving activation of the nuclear steroid receptors 
(Gu et al., 1999; Yang et al., 1994). Thomas’ lab in a series of elegant experiments 
discovered a putative membrane receptor as a steroid membrane receptor able to bind and 
respond to progestins. Seven important criteria were fulfilled to establish this designation: 
plausibility of its structure, tissue specificity, plasma membrane localization, steroidal 
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binding characteristics, ability to activate signal transduction pathways, hormonal regulation, 
and biological relevance (Zhu, et al., 2003
A
).  
A cDNA clone was isolated from the ovaries of a spotted seatrout (Cynoscion nebulosus). 
The 1.7kb cDNA sequence comprised an open reading frame (ORF) of 1,059 base pairs and 
coded for a 352 amino acid protein (Fig.1.12) with an estimated molecular mass of 40,585Da. 
With the use of computational analysis based on the deduced amino acid sequence the 
prediction was that the protein locates in the plasma membrane and had seven transmembrane 
domains, a known characteristic of G-protein-coupled membrane receptors (Zhu, et al., 
2003
A
).   
 
 
 
Figure 1.12: A schematic diagram of the encoded protein showing extracellular (gray), seven-
transmembrane (solid black), and cytoplasmic (clear) domains predicted by several programs. 
Numbers indicate the amino acid number in each domain (Zhu, et al., 2003
A
). 
 
Saturable and specific progesterone binding was reported with the use of a recombinant 
protein whereas no specific progesterone binding was observed with control proteins 
containing an empty vector. Also high affinity binding sites were confirmed (Kd 30 nM).  
Steroid competition studies showed that the binding was highly specific for progesterone and 
17-hydroxyprogesterone and no displacement of [
3
H] progesterone was observed with 
estradiol-17β, cortisol, or 17, 20β, 21-trihydroxy-4-pregnen-3-one (20β-S, a maturation 
inducing steroid) (Zhu, et al., 2003
A
).    
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The receptor was able to cause the rapid activation of intracellular signalling pathways, with 
ERK1/2 activated within 5 min following stimulation with progesterone and 20β-S. No 
activation of ERK1/2 was observed in control MDA-MB-231 cells transfected with an empty 
carrier vector. Following incubation with 20β-S both the mRNA of the membrane receptor 
and protein levels were shown to be up-regulated in reproductive tissue, specifically in the 
ovaries (Zhu et al., 2003
B
). 
After the first set of experiments that introduced the membrane progesterone receptor (mPR), 
thirteen cDNAs similar to the mPR were identified in other vertebrate species, including 
human. By using computer - based structural analyses it was consistently predicted that all of 
these cDNAs encoded for plasma membrane proteins with seven, or six, transmembrane 
domains. The phylogenetic analysis showed that three major clades of mPRs existed, mPRα, 
mPRβ, mPRγ in mammals. These membrane progesterone receptors (mPRs) are structurally 
unrelated to the nuclear steroid receptor and pose characteristics similar to G-protein-coupled 
receptors (GPCRs), however they are phylogenetically distinct from the GPCR superfamily 
(Fig. 1.13) (Zhu, et al., 2003
A
). 
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Figure 1.13: A proposed model for insertion of the seatrout mPR in the plasma membrane. Each 
circle represents one amino acid residue (Zhu, et al., 2003
B
).  
 
There are 8, 16, and 38 amino acid substitutions that characterize and distinguish the three 
mPR clades, respectively. The amino acids unique to mPRα are found mainly in the 
extracellular loops, where those amino acids that are unique to mPRβ are found among the N-
terminal, transmembrane domain, external loops and internal loops, those unique to mPRγ are 
in the transmembrane domain (Zhu, et al., 2003
B
). 
Preliminary evidence obtained from array analysis revealed distinct tissue localization of the 
three mPR.  mPRα was localized in reproductive tissues, particularly in the placenta, testis, 
and ovary and also in the kidney, suggesting it is the predominant subtype mediating the 
rapid non- genomic actions of progesterone in major reproductive tissues (Zhu et al, 2003
A
). 
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Early studies indicated that mPRβ was found to be exclusively localized in neural tissues and 
was detected throughout the brain and in the spinal cord whereas the –γ subtype was found to 
be present in the kidney, fetal kidney, colon, a lung carcinoma, and in HeLa 53 cells. The 
authors proposed that, non - overlapping tissue distribution of the human mPRα and mPRβ 
subtype mRNA is an indication that the two subtypes are responsible for regulating different 
physiological functions of progesterone (Zhu, et al., 2003
B
). Recent studies though have 
identified mPRβ in human fallopian tubes and mPRγ was identified also in the human ovary 
(Nutu et al., 2007). 
Experiments to establish the steroid binding characteristics of these receptors where 
performed by using recombinant proteins produced in E. Coli for each of the three subtypes. 
The results indicated high affinity and saturable progesterone binding to [
3
H] progesterone. 
Additionally, the kinetics of association and dissociation where shown to be rapid, occurring 
within a few minutes, a typical characteristic of membrane receptors. Also, several synthetic 
progestins and antiprogestins, which have relatively high binding affinities for nuclear 
progesterone receptors, displayed no binding affinity for the recombinant human mPRγ 
protein (Zhu, et al., 2003
B
).  
Five years after the first reports another study from the Lyons lab presented data confirming 
that the human mPRα, mPRβ, mPRγ are capable of detecting and responding to progesterone 
when expressed in a yeast experimental model. This was carried out by expressing mPRs in 
the eukaryotic model organism Saccharomyces cerevisiae. Reasons for choosing this model 
as stated by the authors take account of the fact that progesterone has a very low biological 
activity in this model organism (Banerjee et al, 2004) and also proteins encoding the nuclear 
receptor family are not present in its genome (Phelps et al, 2006).  Based solidly on their 
ability to sense and respond to progesterone, these groups presented two more types of mPRs 
which were renamed mPRδ and mPRε respectively (Smith et al, 2008). 
Introduct ion Chapter  1   
 
37 
Whilst the early studies on mPRs concentrated on oocyte maturation in fishes (Josefsberg et 
al., 2007; Zhu et al., 2003
A
; Thomas et al., 2002) establishing the progesterone induced 
oocyte maturation as the classic example of the rapid, non genomic effects that are mediated 
via steroid receptors present on the cell membrane (Josefsberg et al., 2007), more recent 
studies have attempted to establish the significance of the role of mPRs in human 
reproductive tissues. 
Up to now it has been shown that mPRs, are involved in the progesterone regulated gamete 
transport in women. In particular, mPRβ and mPRγ are present in the ciliated cells of the 
fallopian tube whose main function is to facilitate gamete transport and fertilization in 
women. These receptors have been shown to be regulated by progesterone thus further 
strengthening the role of the ciliated cells of the fallopian tube as physiological targets of the 
action of progesterone (Nutu et al., 2009). mPRs have been shown to be expressed and able 
to activate G-protein signalling in the endometrium, the myometrium and in fetal tissues 
(Fernandes et al., 2005). Two individual studies have suggested that mPRs are regulated in 
uterine tissues throughout the estrous cycle and also may be involved in term and preterm 
labor. In the human endometrium, mPRα, mPRβ and mPRγ are regulated throughout estrous 
with the levels of mPRα and mPRβ increasing midway through the cycle while mPRγ levels 
decrease (Fernandes et al., 2005). 
During labour, the expression levels of mPRs present in the myometrium change. In term and 
preterm labour it has been shown that mPRα levels decrease while the levels of mPRβ 
decrease only during term labour whereas mPRγ levels appear unregulated (Fernandes et al., 
2005). Yet another study showed that only mPRα and mPRβ were expressed in human 
pregnant myometrium, with mPRα being the predominant isoform. In the same study 
performed by Karteris, an alternative model was proposed that implicated mPRs in the onset 
of parturition: mPRs binding to petrusis toxin sensitive G protein alpha subunits and inhibite 
Introduct ion Chapter  1   
 
38 
adenyl cyclise and increase the myosin light chain phosphorylation. These mPR mediated 
events promote a shift from the quiescent phase in which the myometrium is in and sensitize 
it towards a contractile state at term (Karteris et al., 2006).  
 The importance of the physiological actions of the multiple mPR isoforms throughout the 
female reproductive cycle have been acknowledged, including oocyte growth (Qiu et al., 
2008) transport of the oocyte from the ovary to the uterus (Nutu et al., 2009), preparation of 
the uterus for implantation (Ashley et al., 2009; Ashley et al., 2006), gestation and fetal 
development (Fernandes et al., 2005), and parturition (Karteris et al., 2006).  
From the research progress achieved in the field up to now, it is seen that in the reproductive 
tissues the expression of both PRs and mPRs is responsible for functional redundancy 
ensuring reproductive success via progesterone mediated actions. 
1.2.3.3. Progesterone Receptor Membrane Component-1 
Another protein able of mediating rapid non-genomic actions of progesterone is the 
progesterone receptor membrane component-1 (PGRMC-1). A cDNA encoding a 
progesterone membrane binding protein was isolated from a porcine vascular smooth muscle 
cell cDNA library (Falkenstein et al., 1996). This small progesterone binding protein consists 
of 194 amino acids (Falkenstein et al, 1996) and has a molecular weight of 28 kDa (Peluso et 
al, 2006). It comprises of a short N-terminal extracellular domain, single transmembrane 
domain and a cytoplasmic domain (Min et al., 2004) where the cytoplasmic domain contains 
three Src homology domains that may be involved in the ligand – dependent signal 
transduction (Peluso, 2006). It has been reported as being detected as a 56 kDa dimer or as a 
28 kDa monomer by two different groups (Selmin et al., 1996; Meyer et al., 1996). PGRMC-
1 molecule has been found to interact with plasminogen activator inhibitor mRNA binding 
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protein 1 (PAIRBP1) (Peluso et al., 2005), which localizes on the cell membrane and is 
involved in transducing progesterone membrane-initiated actions (Peluso et al., 2004), 
PGRMC-1 has been reported to be present in the mouse granulosa cells (McRae et al., 2005), 
in luteal cells (Cai & Stocco, 2005), and spontaneously immortalized granulosa cells (SIGCs) 
(Peluso et al., 2005). Additionally, it is found on the plasma membrane (Peluso et al., 2009; 
Peluso et al., 2006; Krebs et al., 2000) as well as in  several intracellular locations such as the 
endoplasmic reticulum, Golgi apparatus (Wu et al., 2011), inner acrosomal membrane (Losel 
et al., 2004).  
A wide range of physiological roles have been attributed to this protein including steroid 
synthesis and metabolism (Raza et al., 2001), regulation of cholesterol uptake (Runko et al., 
2002), endocytosis, alteration of reproductive behaviors (Krebs et al., 2000), by functioning 
as an adapter protein and also an ability to form complexes with other proteins that are 
involved in the cholesterol system (SCAP and Insig1) (Suchanek et al., 2005). 
A recent study performed by Wu identified PGRMC-1 as the mediator of progesterone action 
on myometrial contractility (Wu et al., 2011). The antiapoptotic effects of progesterone in 
granulose and luteal cells demonstrated by Peluso in 2005 were shown to be rapid (within 
minutes) and initiated at the plasma membrane. These findings were extended by the same 
group where it was demonstrated that PGRMC-1 is an essential component of progesterone’s 
membrane-initiated antiapoptotic action (Peluso et al., 2006).  
1.2.4.  Genomic vs. Non-genomic actions of progesterone.  
As the actions of progesterone are essential for the orderly reproductive functions to occur, 
the mechanisms by which this steroid hormone mediates its actions has been an area of 
intense study for the last 20-30 years. It appears that there is an expanding PR repertoire 
involving multiple classes of receptors cpable of binding to progesterone (Fig.1.14). 
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Figure 1.14: Diagram of the receptors involved in progesterone (P4) signalling. Receptors present 
on the membrane, mPRs and PGRMC-1 able to bind progesterone and mediate their rapid signalling 
through signalling cascades which are still under investigation. The intracellular nuclear PR mediates 
its actions through transcription and translation.  
In accordance with the cnonical theory of steroid hormone action, steroids and thus 
progesterone affect the transcription of mRNA and subsequently protein synthesis (Revelii et 
al., 1998; Wehling, 1997). This is accomplished by the ability of nuclear receptors to interact 
with DNA responding to hormone binding and recruiting multiprotein complexes controlling 
gene expression (Gellersen et al., 2009). Gene transcription and translation occurs in the 
order of hours to days.  
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In the recent years, non-classical effects of steroid hormones have been examined that do not 
depend on gene transcription for protein synthesis and are too rapid to be mediated by gene 
transcription (Table 1.1). Terms like non-genomic or non-nuclear are used to describe these 
effects so as to underline that DNA binding of the receptors and subsequently RNA synthesis 
are not a necessity (Simoncini & Genazzani, 2003).  Non - genomic steroidal effects are 
characterized by two properties; their insensitivity to transcriptional and protein synthesis 
inhibitors, and by their rapid onset of action which is within seconds to minutes (Norman et 
al., 2004 ; Losel & Wehling, 2003; Bramley, 2003 ; Falkenstein et al., 2000).  These rapid 
effects can be replicated in cells that do not express genomic receptors such as spermatozoa 
and can be imitated by binding to receptors unable of activating transcriptional actions due to 
mutations (Simoncini & Genazzani, 2003). 
Mechanisms of Genomic Vs. Nongenomic signalling 
Genomic Nongenomic 
Gene expression & new protein 
synthesis 
Activation/ repression of pre-existing 
proteins 
Relatively long latency of onset Rapid onset of action 
Medium and long term cell programme Rapid adaptation to changes in the milieu 
Organisation of cell networks for 
complex functions 
Dynamic modifications of long term cell 
programme 
 
Table 1.1: Genomic and non-genomic actions of steroid hormones: a tentative interpretation. 
(Adapted from Simocini & Genazzani, 2003). 
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There have been several studies performed in mammals that show the ability of nuclear PR to 
signal non - genomically by initiating rapid signalling both from the cytoplasm and the cell 
membrane. Studies with breast cancer cells have shown that the nuclear PR in both states – 
liganded and unliganded – can initiate and respond to growth factor signalling pathways. 
MAP kinase activation by nuclear PR is initiated by the interaction between a proline-rich 
motif on the nuclear PR and SH3 domains on the upstream kinase c-Src 
(Boonyaratanakornkit et al., 2007; Carnevale et al., 2007; Faivre et al., 2005; Skildum et al., 
2005). Studies suggest that progesterone acts via interactions with signalling pathways 
mediated by growth factors to regulate the proliferation of breast cancer cells 
(Boonyaratanakornkit et al., 2007; Carnevale et al., 2007). Other studies have indicated the 
interactions of nPR with the nuclear estrogen receptor (ER) to indirectly activate MAP kinase 
(Migliaccio et al., 1998). These interactions were facilitated by two domains of the nPR that 
through interaction with the ER the c-Src and MAP kinase are activated (Ballare et al., 2003). 
These interactions between nPR and ER have been shown to mediate the progesterone 
induced proliferation of endometrial cells (Vallejo et al., 2005). 
Except from the rapid non-genomic nPR mediated signalling initiated in the cytoplasm, nPR 
also contains highly conserved motif in the ligand binding domain which induces its 
membrane localization (Pedram et al., 2007). 
The actions of progesterone mediated via the “classical” genomic pathway in the female 
reproductive tract received unequivocal attention through the years.  Researchers have 
embarked on understanding the actions which are mediated non genomically via the nPR and 
the mPRs in order to further understand the multiple actions of progesterone (Hammes, 
2003). 
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1.3. Research aims and objectives 
To this day the knowledge of the receptors by which progesterone exerts its effects in the 
human placenta, are very limited. This study focuses on understanding the expression of 
progesterone receptors in the human placenta along with achieving an understanding on the 
mechanism of PR signalling and to assess the functionality of mPRs in this organ.  
Objectives: 
1. Validation of the synsytialization model of BeWo cells.  
2. Elucidating the expression and cellular distribution of progesterone receptors (mPRs, 
PGRMC-1 and PR-A/B) in two human placental cell lines (BeWo and JEG-3) as well 
as in human placental tissues. Also examining the effect of syncytialization on the 
expression of these receptors. 
3. Examine the progesterone-receptor mediated signalling in the human placental cell 
lines.  
4. Investigating the involvement of progesterone-receptor signalling in vitro during an 
inflammation response. 
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CHAPTER 2 
2. MATERIALS AND METHODS 
 
2.1. Solutions 
Chemicals and Reagents  
 Elution buffer: Molecular grade H2O. 
 Wash buffer 1: 1 M Tris (pH 7). 
 DNase I containing buffer: Amplification Grade DNase I - 10mM Tris-HCl (pH 7.5), 
10mM CaCl2, 10mM MgCl2 and 10X Reaction Buffer- 200mM Tris-HCl (pH 8.3), 
20mM MgCl2 per 1ml. 
 
 Stop buffer: 50mM EDTA per 1ml. 
 1x TBE buffer: 90mM Tris, 90mM Boric acid, 2 mM EDTA. 
 10x loading buffer : 20% Ficoll 400 (Fisher Scientific, Cat.No 26873-85-8), 0.1 M 
Na2EDTA (pH 8), 1% SDS, 0.25% Bromophenol blue,  0.25% xylene cyanol. 
 5X first-strand buffer : 250mM Tris-HCl (pH 8.3), 375mM KCl, 15mM MgCl2. 
 2x Laemmli buffer: 4% SDS (w/v), 20% glycerol, 10% 2-mercaptoethanol (v/v), 
0.004% bromphenol blue (w/v),  0.125 M Tris HCl (pH 6.8) (w/v). 
Western Blot analysis: 
 12.5% SDS-PAGE Gels 
2 
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o Resolving gel: 30% acrylamide/ bisacrylamide (v/v), 1.5M Tris base (pH 8.8), 
10% SDS (w/v), 10% ammonium persulphate (w/v), TEMED.  
o Stacking gel: 30% acrylamide/ bisacrylamide (v/v), 1M Tris base (pH 6.8), 
10% SDS (w/v), 10% ammonium persulphate (w/v), TEMED. 
 Blocking solution (5% w/v) dried milk powder in 1X TBS- Tween 20 (20mM Tris 
base, 140mM NaCl, 0.1% Tween 20 (v/v) (pH 7.6). 
 1x PBS 0.1% Tween 20 
2.2. Cell lines 
BeWo : Human trophoblastic cell line with endocrine properties and able to cellularly 
differentiate in vitro. This cell line was initiated from a malignant gestational 
choriocarcinoma of the fetal placenta (ECACC European Collection of Cell Culture; Liu et 
al., 1997; Rama Sastry 1999). 
JEG-3: Human placental choriocarcinoma cell line with endocrine activity (Health Protection 
Agency, Salisbury, UK;  Pattillo & Gey, 1968) 
2.3. Cell culture 
A Holten LaminAir Class II Haeraus Instruments hood was used for the routine culture of the 
cell lines. BeWo cells were cultured in Ham F12 Medium (Gibco) supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (FBS) (Gibco) and 100 μg/ml of Penicillin and 100 
μg/ml of Streptomycin (Gibco). The cells were maintained in 75cm2 non treated culture 
flasks (Nunc) under standard culture conditions in humidified atmosphere containing 5% CO2 
at 37˚C. The cells were confluent after 48 to 72 hours where subculturing of BeWo cells 
consisted in splitting the cells 1:3 into 19ml of complete Ham F12 medium per culture flask. 
The cells were firstly washed with 2.5 ml of 1x Phosphate- Buffered Saline (PBS) (Gibco) to 
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then detach the cells by incubating in 2.5 ml of 0.25 % Trypsin (Gibco) for a few minutes and 
by tapping the culture flask gently. The cell suspension was placed in a 50 ml tube and after 
adding 2.5 ml of Ham F12 medium to neutralise the activity of trypsin the cells were 
centrifuged for 5 minutes at 1500 RPM using a megafuge (Heraeus 1.0, Heraeus 
Instruments). The supernatant was then removed and the cells were resuspended in a known 
volume of fresh medium. BeWo cells were supplied with fresh media every 48 hours 
maximum according to supplier’s instructions to prevent glucose exhaustion in the culture.  
JEG-3 cells were maintained in Minimum Essential Medium (MEM) (Sigma Aldrich) 
supplemented with 2mM Glutamine (Gibco), 1% (v/v) Non Essential Amino Acids (Gibco), 
1mM Sodium Pyruvate (Gibco), 100 μg/ml of Penicillin, 100 μg/ml of Streptomycin (Gibco) 
and  10% (v/v) heat-inactivated fetal bovine serum (FBS) (Gibco). The procedure followed 
for subculturing JEG-3 cells was the same as for BeWo cells. 
2.4. Placental Tissue Acquisition  
Placental tissues were obtained from women at both at term (> 37 weeks) and preterm (<37 
weeks) undergoing either normal vaginal delivery or elective caesarean section. All samples 
were collected from pregnancies without any known pathological problems.  Immediately 
after delivery, the maternal and fetal surfaces were dissected off and the fetal membranes 
were peeled gently away from the placenta. Placental tissues were obtained from the maternal 
side of the placentas. The tissue samples taken were approximately 0.2-0.5cm
3
 in size and 
were taken from the centre of the cotyledons evenly across the placenta. The tissues were 
dissected to remove any visible connective tissue and calcium deposits. Depending on the 
experimental analysis, some of the tissues were transferred to 10 volumes of RNAlater 
solution (Invitrogen). Others were homogenisated directly and RNA was obtained from them. 
Placenta samples were then washed five times with PBS and were snap frozen in liquid 
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nitrogen. Placental tissue sections were embedded in paraffin by the histology services of the 
University Hospital of Crete were the samples were obtained from. Ethical approval was 
obtained from the local ethical committees and also informed consent was obtained from all 
the patients.  
2.5. Syncytialisation of BeWo cells 
BeWo cytotrophoblast (CT) cells were induced to fuse forming multinuclear syncytia also 
known as syncytiotrophoblast (ST) cells. The syncytialisation process was performed using 
the chemical Forskolin (Sigma, Cat. No. F3917). Forskolin was dissolved in DMSO at a 
concentration of 0.1M. To assess the syncytialisation process, BeWo cells were treated with 
50μM and 100μM over a total period of 72 hours. Forskolin treatment was renewed every 24 
hours. The cells were maintained in 75cm
2
 non treated culture flasks (Nunc) under standard 
culture conditions in humidified atmosphere containing 5% CO2 at 37˚C. 
2.6. RNA Extraction 
RNA extraction was performed using GenElute
TM
 Mammalian Total RNA miniprep kit 
(Sigma-Aldrich, Cat. No. RTN70) which isolates total RNA from mammalian cells and 
tissues. The protocols followed for RNA extraction from mammalian cells and tissue samples 
differ as different cell lysis and disruption conditions apply. 
2.7. RNA Extraction from cells 
The cells of interest were cultured in 75cm
2 
non treated culture flasks
  
 or in 6-well non 
treated multidishes (Nunc). The cells were maintained in culture to achieve 70% confluence, 
after which the cells were washed with sterile 1xPBS (Gibco) prior to starting the RNA 
extraction.  
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Since the cells were attached on the culture vessel the lysis/ RNase inactivation step was 
performed directly in the culture vessel. The mixture containing lysis buffer and 2-
mercaptoethanol (10μl 2-mercaptoethanol added for each 1 ml) was left in the culture vessel 
for 2 minutes with repetitive shaking. The lysate was filtered by centrifugation using 
GenElute filtration columns for 2 minutes at 16,000 RPM. RNA was isolated by binding in 
the presence of 70% ethanol solution in a GenElute binding column. The isolated RNA was 
collected in the collection tubes and was washed three times with the provided wash buffers 
in order to obtain ethanol-free RNA and remove contaminants. The columns were further 
centrifuged to ensure that were completely dry before eluting the RNA using 40μl of elution 
buffer in RNase free tubes. RNA was maintained on ice at all times.  
For removal of any residual DNA the extracted RNA preparations were further treated with 
DNase I (Sigma-Aldrich, Cat. No. AMPD1), whereby RNA was incubated with DNase I 
containing buffer for 15 minutes at room temperature. The action of DNase I was stopped by 
adding the stop buffer and denaturing the enzyme by incubating at 70ºC for 10 minutes.  
2.8. RNA Extraction from placental tissue 
Prior to extracting RNA form the samples, the placental tissues were homogenised using 
TissueLyser II (Qiagen). The snap-frozen placental samples stored in RNAlater were left to 
thaw on ice. Once thawed, the placental tissues were transferred to sterile eppendorf tubes 
containing the lysis mixture. A stainless steel bead was added to each tube to facilitate cell 
disruption. Proteinase K (Sigma-Aldrich, Cat. No. P4850) was added directly to each sample 
after homogenization to ensure efficient cell disruption and incubated at 55°C for 10 minutes. 
Next, the lysate was filtered and the same steps as above (section 2.6) were followed.  
The quantity and quality of the extracted RNA was measured by analyzing 1μl of RNA 
sample on a Nanodrop-1000 Spectrophotometer (Fisher Scientific). As a blank reading, 1μl 
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of elution solution was used. Further, to ensure no RNA degradation, 2μl of 10x loading 
buffer were added to 5μl of RNA sample and run on a 1% agarose gel at 80V for 45 minutes 
and subsequently visually examines under UV conditions. Purified RNA was stored at -70 ºC 
until further use. 
2.9. cDNA synthesis 
SuperScriptTM II reverse transcriptase kit (Invitrogen, Cat.No. 18064-022) was used to 
generate complimentary DNA. In a nuclease-free 0.6ml microcentrifuge tube, 500ng of RNA 
sample, 100ng of random hexamers and 10mM deoxyribonucleotide triphosphate (dNTP) 
mix were added together. The mixture was centrifuged briefly before incubating at 65 ºC for 
5 minutes and then placed on ice for 1 minute. Following, 5X first-strand buffer and 0.1M 
DTT were added to the above mixture and incubated for 2 minutes at room temperature. In 
each sample 200 units of SuperScript
TM
 II reverse transcriptase enzyme were added and the 
mixture was incubated at 42ºC for 50 minutes. The activity of the enzyme was stopped by 
incubating the samples at 70ºC for 15 minutes. The newly synthesised cDNA was stored at -
20ºC until further use. 
2.10. Primer design  
The design of the primers of interest began at: www.ncbi.nlm.nih.gov where the gene sequences 
were searched for the genes of our interest  by reference number available from publishing. This 
target sequence was then inserted into Invitrogen’s own primer design tool, OligoPerfectTM 
Designer at: www.invitrogen.com/content.cfm?pageid=9716, synthesizing a primer set of sense 
and antisense primer. The maximum primer size required was 25bp, the minimum product should 
be 200-500bp, and as extremes were preferably avoided, the percentage of GC (around 50%) 
content and temperature of the primer (around 60 oC) was required to be the same for each one in 
the pair to prevented problems with annealing during PCR. 
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2.11. Reverse Transcriptase Polymerase chain reaction (RT-PCR) 
PCR procedure along with the enzyme Taq DNA polymerase (Sigma-Aldrich, Cat. No. 
D4545) was used to amplify the genes of interest. The reaction mixture consisted of 1 μl of 
cDNA synthesised as described above,  5 μl of 10x PCR Buffer, 1 μl dNTP mix (10 mM), 1.5 
μl MgCl2 (25 mM), 1 μl of each specific forward and reverse primers (0.1 μg/μl; Table 2.1) 
,0.5 μl of Taq DNA polymerase (5 U/ μl) and 39μl of ddH2O.  The constituents were mixed 
thoroughly before being subjected to PCR amplification procedure. Initially they were 
denatured at 94ºC for 4 minutes followed by 30 cycles at 94ºC for 30 seconds, primer specific 
annealing temperature  for 30 seconds and 72ºC for 1 minute, the final cycle was followed by 
72ºC extension for 1 minute.  
Gene of 
Interest 
Forward Primer Reverse Primer Product 
size (bp) 
β-actin AAGAGAGGCATCCTCACCCT TACATGGCTGGGGTGTTGAA 216 
mPRα GCTGTTCACTCACATCCC TGGTGCAACCCCCAGA 289 
mPRβ GCGGCCCTGGTACTGCTGC CACGGCCACCCCCACA 200 
mPRγ ACTATGGTGCCGTCAACCTC GTGGTACGAGGTGGCTTCAT 305 
mPRδ CCCCAACTTCTTCAAGTCCA CTGGAAGGAGCTGAGGACAC 114 
mPRε CGCCTTGGAGGAGACTACTG TTGGGATCCCTTTGTAGCAG 155 
 
 
PCNA GCCGAGATCTCAGCCATATT 
 
ATGTACTTAGAGGTACAAAT 
 
452 
 
Table 2.1: List of genes studied by reverse transcriptase PCR. Sequences of primers are shown 
with the expected product size in base pairs (bp). 
 
2.12. Real Time Polymerase chain reaction (Q-PCR) 
SYBR
® 
Green JumpStart
TM
 Taq ReadyMix
TM  
(Sigma-Aldrich, Cat. No. S4438) was used to 
perform the Q-PCR along with ABI PRISM
®
 7900HT Sequence Detection System (SDS 2.1) 
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software. A final reaction volume of 25 μl included 2x JumpStartTaq ReadyMix (1.25 units 
Taq DNA polymerase, 10 mM Tris-HCl, 50 mM KCl, 3.5 mM MgCl2, 0.2 mM dNTP, 
stabilizers), 1 μl of each specific forward and reverse primers (0.1 μg/μl; Table 2.1), 1x 
reference dye and cDNA. The reaction mixture was then thoroughly mixed and 24 μl were 
aliquoted in each of the 96 wells of the plate (MicroAmp™ Fast Optical 96-Wells Reaction 
Plate, Applied Biosystems, Cat.No. 4314320). 1 μl of cDNA was added soon after and the 
plate was sealed using an optical adhesive film (MicroAmp
®
 Optical Adhesive Film, Applied 
Biosystems, Cat.No. 4314320). The plate was then centrifuged for 1 minute at 1,000 RPM 
and loaded onto the Sequence Detection System. All reactions were performed in triplicates 
and control reactions where no cDNA was added in the wells, only dH2O were included in 
the study design. The conditions for the Q-PCR reaction the following: 
 
 
Figure 2.1: Real time PCR cycle conditions.  
 
Q- PCR quantification method can be either relative or absolute. In absolute quantification 
the exact copy number per cell is determined whereas in the relative quantification, a 
comparison is performed between the expressions of a gene of interest to that of a 
housekeeping gene. 
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The relative quantification step produces a graph known as the ‘amplification curve’. This is 
plotted by the machine and indicates the number of cycles versus the fluorescence intensity. 
As the number of cycles progress the amount of double-stranded DNA also increases and 
fluoresce as the SYBR Green molecule binds to the newly formed double-strand DNA. A 
threshold is set automatically depending on the range of detection of the amplification. At the 
cycle where the fluorescence signal crosses the set threshold, that value is named ‘cycle 
threshold’ (Ct). 
A limitation that occurs with relative Q-PCR is that SYBR Green also binds non-specifically 
to double stranded DNA and primer dimer complexes. A way to distinguish between specific 
and non-specific amplification was by performing a ‘dissociation-curve’ analysis. It is known 
that the melting temperature (Tm) of DNA depends upon the length of the strand as well as 
its GC’s content. These properties can be used to distinguish between the specific and non-
specific products formed during the relative Q-PCR. The ‘dissociation-curve’ is a graph that 
shows the temperature versus the fluorescence and as the temperature gradually increases the 
laser of the machine is able to detect the loss of fluorescence signal as SYBR Green detaches 
as DNA melts at high temperature. Non-specific products would be expected to have 
different sizes and GC content compared to the specific product thus being able to melt at 
different temperatures. Therefore, a comparison was made to ascertain whether the obtained 
peak is of desired product. A representative amplification plot (panel A) and a representative 
dissociation curve (panel B) are shown in Fig.2.2.  
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Figure 2.2: Representative amplification plot and dissociation curve.  
 
In this study, the relative quantification approach was used with a number of genes of interest 
and a calibrator gene (Table 2.2). 
 
Gene of 
Interest 
Forward Primer Reverse Primer Product 
size (bp) 
mPRα CGCTCTTCTGGAAGCCGTACATC
TATG 
 
CAGCAGGTGGGTCCAGACATTCAC 
 
100 
mPRβ AGCCTCCTACATAGATGCTGCCC 
 
 
GGTGCCTGGTTCACATGTTCTTCA 
 
194 
mPRγ CAGCTGTTTCACGTGTGTGTGAT
CCTG 
 
GCACAGAAGTATGGCTCCAGCTATC
TGAG 
 
120 
PGRMC-1 TCTGGACTGCACTGTTGTCCTTG 
 
GCAAACACCTGTTCCTATTCTG 
 
290 
PR-B AGCAGTCCGCTGTCCTTTTCT 
 
CCTGAAGTTTCGGCCATACCT 
 
176 
β-actin 
 
AAGAGAGGCATCCTCACCCT 
 
TACATGGCTGGGGTGTTGAA 
 
216 
Syncytin-2 
 
ACACCTTGCCTGAAGTTTCG 
 
 
CTGTCCTTTTCTGGGGGACT 
 
129 
 
Table 2.2: List of genes studied by real time. Sequences of primers are shown with the expected 
product size in base pairs (bp). 
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The following equations (User Bulletin #2, ABI PRISM 7700 Sequence Detection System) 
were used to analyse the results obtained from the Q-PCR: 
 
For cell samples:  ΔCt= Ct (gene of interest) – Ct (housekeeping gene) 
 ΔΔCt = ΔCt (samples) – ΔCt ( calibrator) 
 Relative Quantity (RQ) = 2
- ΔΔCt
 ± ( 2
-ΔΔSD
 (+)  -  2
-ΔΔSD
 (-) ) 
 
For placental samples: ΔCt= Ct (gene of interest) – Ct (housekeeping gene) 
 Arbitary Value : 2
- ΔCt 
 
2.13. Agarose Gel electrophoresis 
For DNA electrophoresis gels were prepared with agarose (Fisher, Cat.No. BP1356), the 
concentration of which was chosen based on the size of fragments to be resolved and it was 
dissolved in 1x TBE buffer containing 0.05% (w/v) ethidium bromide (Sigma, Cat. No. 
E1510). The PCR products were mixed with 10x loading buffer and an indicative sample of 
20 μl was loaded into the well of the gel. 1Kb DNA ladder (Invitrogen, Cat.No. 10787-018) 
was loaded once all of the samples had been loaded into the gel. Then, the gel was 
electrophoresed for a suitable length of time at 80 volts. The DNA was visualised by placing 
the gels on a short wave ultra-violet transluminator and an image was captured using an 
Alpha Imager 2200 (AlphaInnotech Corporation). 
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2.14. Indirect Immunofluorescence analysis 
2.14.1. Indirect Immunofluorescence on cells 
BeWo CT, BeWo ST and JEG-3 cells were grown on sterile 0.13mm-0.17mm glass 
coverslips in 6-well multidishes and grown to a sufficient confluence. Cells were rinsed with 
1x PBS, three times before fixing using 4% Paraformaldehyde (pfa) and incubating for 10 
minutes at room temperature. Three washes with 1x PBS followed. The cells were then 
permeabilised using 0.2% PBS Tween 20 solution, at room temperature for 20 minutes, 
followed by three washes in 1x PBS solution containing 100mM Glycine. Cells were then 
incubated with 10% specific species serum (Jackson ImmunoResearch) in 1x PBS for 1 hour 
at room temperature in order to minimize any non-specific binding of IgG. The blocking 
serum used for each primary antibody was chosen based on the species in which the 
secondary antibody was raised.  
Antibodies were diluted in 1.5% of specific serum in 1x PBS. Primary antibodies used in this 
study are listed in table 2.3 along with their dilution. The coverslips were incubated at 4°C 
overnight. Next, the coverslips were washed three times with 1x PBS and incubated with a 
respective secondary antibody (Table 2.3) for 1 hour at room temperature. Cells were then 
washed with 1x PBS and rinsed in distilled water before mounting in Vectashield
® 
Mounting 
Medium containing DAPI. Negative controls were prepared by omitting the primary 
antibody. All the other steps were exactly the same.  
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Table 2.3: List of primary and secondary antibodies used with their respective dilutions.  
 
2.14.2. Indirect Immunofluorescence on paraffin-embedded placental tissues.  
The specimens used were heated in an oven at 65
o
C for 1 hour. Following, the slides were 
dewaxed in Histo-Clear (Fisher Scientific, Cat.No. HIS-010-010S) a non-hazardous substitute 
of xylene. The sections were then dehydrated in 100% ethanol, twice for 5 minutes each time. 
The sections were rehydrated through a graded series of ethanol in normal distilled H2O over 
20 minutes (95%, 70%, 50%, and 30%). The slides were rinsed in distilled H2O once, and 
then in 1x TBS tween 20.   The endogenous peroxidase activity was blocked by incubating 
the sections with 3% hydrogen peroxide for 10 minutes at room temperature. Following from 
this step the previously stated methodology (section 2.12.) was followed starting from the 
blocking step and onwards. Primary and secondary antibodies are detailed in table 2.4. 
Primary Antibodies Secondary Antibodies 
Antibody Dilution Species/ Details Antibody Dilution 
mPRα 1:50 
Goat (Santa Cruz 
/sc-50111) 
Donkey anti-goat 
(Invitrogen/A11055) 1:400 
mPRβ 1:50 
Goat (Santa Cruz / 
sc-50109) 
Donkey  anti-goat 
( Invitrogen/A11055) 
1:400 
mPRγ 1:50 
Goat (Santa Cruz / 
sc-28019) 
Donkey  anti-goat 
( Invitrogen/A11055) 
1:400 
PGRMC-1 1:75 
Rabbit (Gift from 
Prof. P. Thomas 
Donkey  anti-rabbit 
(Invitrogen/A10042) 
1:400 
PR-B 1:50 
Mouse ( Santa Cruz / 
sc-811) 
Goat anti-mouse 
(Santa Cruz / sc-3796) 
1:75 
Pan-Cadherin 
1:200 
Mouse (Αbcam / 
ab22744) 
Goat anti-mouse 
(Santa Cruz / sc-3796) 1:200 
Anti-PCNA 1:1000 Mouse 
Rabbit anti-mouse 
(Zymed / 616520) 
1:200 
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Table 2.4: List of primary and secondary antibodies used with their respective dilutions.  
 
2.15. Microscopy 
The slides were examined and imaged on an using a Plan Apo Neofluor 63X NA 1.25 oil 
objective (Zeiss) on a Zeiss Axiovert 200M microscope and the images were viewed using 
the AxioVision software. Images were taken at a fixed exposure time.  The data was derived 
after examining three independently treated coverslips for each sample along with the 
negative control.  
2.16. Treatments of BeWo and JEG-3 cells 
BeWo and JEG-3 cells were maintained in cell culture as described above. Cells were seeded 
in 6-well multi dishes for treatment purposes. Some BeWo cells were synsytialised for the 
following treatments to take place. Once confluence (~70%) was achieved, the media was 
aseptically removed and the cells were rinsed with 1xPBS. A known volume of phenol red 
free media containing only 100 μg/ml of Penicillin and 100 μg/ml of Streptomycin (Gibco) 
Primary Antibodies Secondary Antibodies 
Antibody Dilution Species/ Details Antibody Dilution 
mPRα 1:50 
Goat (Santa Cruz 
/sc-50111) 
Donkey anti-goat 
(Invitrogen/A11055) 1:400 
mPRβ 1:50 
Goat (Santa Cruz / 
sc-50109) 
Donkey  anti-goat 
( Invitrogen/A11055) 
1:400 
mPRγ 1:50 
Goat (Santa Cruz / 
sc-28019) 
Donkey  anti-goat 
( Invitrogen/A11055) 
1:400 
PGRMC-1 1:75 
Rabbit (Gift from 
Prof. P. Thomas 
Donkey  anti-rabbit 
(Invitrogen/A10042) 
1:400 
PR-B 1:50 
Mouse ( Santa Cruz / 
sc-811) 
Goat anti-mouse 
(Santa Cruz / sc-3796) 
1:75 
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was added to the cells 24 hours prior starting the treatments. BeWo CT, BeWo ST and JEG-3 
cells were treated with the compounds shown below (Table 2.5). The time points were 
identical for all treatments and were the following: 1minute, 3 minutes, 5 minutes, 10 
minutes, 20 minutes, 30 minutes, and 60 minutes.  
 
Compound Stock Concentration Final concentration 
Progesterone (P4) 
(Sigma, P0130) 
10
-1 Μ  
100nM ± U0126 (1μM) 
 10-ethenyl-19-
norprogesterone 
(OD 02-0) (Gift from Prof. P. Thomas) 
10
-3 Μ 100nM 
 
Promegestone  (R5020) 
(PerkinElmer, NLP00400) 
10
-2
 M 30nM ± U0126 
U0126 (Sigma, U120) 10-3 M 1μM 
 
Table 2.5: Compounds used to treat cells, the final concentration used in the experiment is shown 
in the last column of the table. 
 
2.17. Electrophoresis and Western blotting 
Once the treatments were completed, BeWo CT, BeWo ST and JEG-3 cells where lysed in 2x 
Laemmli buffer and boiled at 100
o
C for 3 minutes. The samples were then stored at -70
o
C 
until further use.  12.5% SDS-PAGE gels were prepared. Firslty, the resolving 
polyacrylamide solution was poured between glass plates and was overlaid with isopropanol 
and allowed to polymerise for ~30minutes at room temperature. Once the gels had 
polymerised, the overlay was rinsed off with double distilled H2O and the top of the gel was 
dried briefly using filter paper. The stacking gel was poured on top and the 10 well combs 
were placed in it. The stacking gel was left to polymerise for ~30minutes at room 
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temperature. Once ready to be used, the protein samples were firstly defrosted, then heated 
for 3 minutes using a heat block at 100
o
C and then placed on ice. The samples were loaded 
onto the gel and were electrophoresed in 1X SDS-PAGE running buffer at 80V until the dye 
front reached the bottom of the gel. A ColorBurst
TM
 electrophoresis marker (Sigma-Aldrich, 
Cat.No. C1992) was used to monitor the progress of the electrophoretic run as well as to 
confirm that the protein transfer was completed. MagicMark™ XP Western Protein Standard 
was also used to detect protein size on film (Invitrogen, Cat. No. LC5602). 
Before transferring the proteins onto a Polyvinylidene fluoride (PVDF) membrane 
(Immobilon-P Membrane, Millipore), the membrane was activated by incubating for 15 
seconds in methanol, following by a 2 minute incubation in dH2O and finally incubating for 5 
minutes in wet-transfer buffer. Proteins were then electrophoretically transferred onto the 
activated PVDF membrane in wet-transfer buffer for 1 hour at 100V. The transblot sandwich 
was made up by placing a sponge pad on the upper and lower site of the apparatus, 2 pieces 
of Whatman paper on each site. The gel was placed on top of the paper on the lower site and 
a piece of membrane was placed on top of the paper. A note should be made that all 
components were soaked in wet-transfer buffer before making up the transblot sandwich. The 
transblot sandwich was positioned according to the manufacturer’s instructions in a Biorad 
Transblot apparatus. To help minimise non-specific binding of the antibody to the membrane 
matrix, the membranes were incubated in blocking solution (5% w/v) dried milk powder in 
1X TBS- Tween 20 for 3 hours at room temperature with gentle agitation.  
The primary antibodies used are described in table 2.6. The membranes were incubated with 
the antibody of interest which was diluted in 5% Bovine Serum Albumin (Sigma-Aldrich, 
Cat. No. A7906) 1X TBS-Tween 20 overnight at 4
o
C. Following three washes in 1X TBS-
Tween 20 the membranes were incubated in horseradish peroxidase (HRP) conjugated 
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secondary antibody for 1 hour at room temperature. The secondary antibodies were diluted in 
5% Bovine Serum Albumin in 1X TBS-Tween 20.  
 
Table 2.6: List of primary and secondary antibodies used with their respective dilutions.  
 
In order to detect the antibody complexes, the Enhanced Chemiluminescence (ECL) method 
was used. Solution A containing 100 mM Tris (pH 8.0) and 30% H2Ο2 was mixed with 
solution B containing 100 mM Tris (pH 8.0), 250 mM luminol and 90 mM coumaric acid and 
applied to the blots for 5 minutes under vigorous agitation. All the excess solution was 
drained and the blots were placed in a plastic case along with the x-ray film (Kodak, Biomax 
x-ray film). The x-ray film was developed using developer solution (Kodak, GBX developer 
& replinisher) and fixer solution (Kodak, GBX Fixer & Replenisher). 
Primary Antibodies Secondary Antibodies 
Antibody Dilution Species/ Details Antibody Dilution 
mPRα 1:200 
Goat (Santa Cruz 
/sc-50111) 
Rabbit anti-goat 
(Sigma/A5420) 1:2000 
mPRβ 1:200 
Goat (Santa Cruz / 
sc-50109) 
Rabbit anti-goat 
(Sigma/ A5420) 
1:2000 
Phospho-p44/42 
MAPK (Erk1/2) 
1:1000 
Rabbit (Cell 
Signalling / 197G2) 
Goat anti-rabbit 
(Sigma /A0545) 
1:2000 
p44/42 MAPK 
(Erk1/2) 
1:1000 
Rabbit (Cell 
Signalling / 9102) 
Goat anti-rabbit 
(Sigma /A0545) 
1:2000 
Pan-Cadherin 
1:1000 
Mouse (Αbcam / 
ab22744) 
Rabbit anti-mouse 
(Zymed / 616520) 
1:2000 
Anti-PCNA 1:1000 Mouse 
Rabbit anti-mouse 
(Zymed / 616520) 
1:2000 
GAPDH 1:2000 
Rabbit (Sigma / 
G9545) 
Goat anti-rabbit 
(Sigma /A0545) 
1:2000 
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2.18. Densitometric Analysis 
The Western blots were scanned and the digital images were uploaded using the 
AlphaEaseFC software.The band intensities were then normalised against the band intensity 
of GAPDH or in the case of phospho-ERK against, total ERK.  
  
2.19. ImageStreamx Analysis 
The ImageStream
X
 is an imaging flow cytometer providing scientists with the ability to 
visualise cells directly in flow, at rates exceeding 1,000 cells per second, and with the 
fluorescence sensitivity of the best conventional flow cytometers. The cellular morphology 
along with the intensity and location of fluorescent probes directed against antigens of 
interest can be quantitatively measured by using this instrument.  Through microscopy 
detailed cellular images and morphologic information are offered to scientists, a useful 
scientific tool for the study of cell function. The interpretation of microscopic imagery though 
can be subjective and limited to qualitative information. Flow cytometry offers quantitative 
phenotyping and has the ability to yield statistically robust results by interrogating large 
numbers of cells. Flow cytometry lacks the ability to image, therefore the ability to measure 
sub-cellular localization and cell function are compromised and are measured indirectly. By 
combining the phenotyping abilities of flow cytometry with the detailed imagery and 
functional capabilities of microscopy, we chose to use ImageStream
X
 technology which 
overcomes the limitations of both techniques. Specifically, this approach was considered to 
be the most appropriate to use, apart from the reasons stated previously, but also due to the 
limitations arising by the chosen progesterone receptor isoforms  to be studied as this are 
produced by a single gene.    
Cells were grown to confluence (~70%) prior to being treated with 0.25% trypsin. The effect 
of trypsin was neutralized by addition of an equal volume of specific medium as mentioned 
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in section 2.2. The cell suspension was centrifuged at 1500 RPM for 5minutes prior to 
removing the supernatant and resuspending the cells in a known volume of medium. The 
cells were incubated with Progesterone-BSA complex labelled with fluorescein 
isothiocyanate (P4-BSA-FITC) (Sigma, Cat. No. P8779) for 5 minutes at 37
o
C. Cells were 
then centrifuged for 5 minutes at 1500 RPM, the supernatant was removed and washed by 
gentle resuspension with 1x PBS 0.1% Tween 20. The cells were again centrifuged and 
removed the supernatant before fixing in 4% paraformaldehyde by incubation at room 
temperature for 10 minutes. Cells were centrifuged at 5000 RPM, the fixative was removed 
and washed by gentle resuspension with 1x PBS 0.1% Tween 20. Cells were centrifuged once 
more and fresh 1x PBS 0.1% Tween 20 was added. Counterstain DAPI (Vectashield
®
 
Mounting Medium) was added and the cells were placed at 4
o
C for ~ 30 minutes prior to 
loading onto ImageStream
x
. 
The following protocol was performed using a non-BSA complexed antibody to the PR-B 
this time. Once cells were confluent (~70%) 0.25% of trypsin was used to detach the cells. 
The effect of trypsin was neutralized by addition of an equal volume of specific medium as 
mentioned in section 2.2. The cell suspension was centrifuged at 1500 RPM for 5minutes and 
the supernatant was removed. The cells were then resuspended in 1ml 1xPBS solution and 
transferred to a 1.5ml Eppendorf tube. The cells were then fixed by adding 500μl of 4% 
paraformaldehyde per tube and incubated at room temperature for 10mins. The cells were 
then centrifuged at 5000 RPM for 5 minutes, the fixative was removed and fresh 1x PBS 
solution was added. Another centrifugation step was performed and the supernatant was 
removed from the cells. 500μl of 0.5%  Bovine Serum Albumin (Sigma Cat. No.A7906) in 
1x PBS 0.1 % Tween 20 solution was added to the cells and incubated at room temperature 
for 1 hour on a roller to ensure a homogenous blocking. The cells were then centrifuged at 
5000 RPM for 5 minutes and the supernatant was removed. Primary antibody, PR-B (Santa 
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Cruz, Cat.No sc-811) was added at a dilution of 1:100 made in 0.5% Bovine Serum Albumin 
in 1x PBS 0.1 % Tween 20 solution and incubated at room temperature for 1 hour. A 
centrifugation step followed where the supernatant was removed. Two washes with 1x PBS 
0.1 % Tween 20 solution were performed. Then the cells were incubated with anti-mouse 
TRITC (Santa Cruz, Cat. No. sc-3796) secondary antibody at a dilution of 1:50 made up in 
0.5% Bovine Serum Albumin in 1x PBS 0.1 % Tween 20 solution. The cells were incubated 
for 1 hour at room temperature. The cells were then centrifuged, the supernatant was removed 
and two washes with 1x PBS 0.1 % Tween 20 solution followed. Counterstain DAPI 
(Vectashield
®
 Mounting Medium) was added and the cells were placed at 4
o
C for ~ 30 
minutes prior to loading onto ImageStream
x
. 
2.20. Cell Proliferation assay (MTT assay) 
An MTT (Sigma, Cat.No.CGD-1) test was carried out in order to assess the viability of 
BeWo cells after exposing them to Forskolin treatments for set time points (48 hours and 72 
hours). The number of cells per well was set to 5x10
4
 and the cells were plated in 96 multi 
well dishes. It is important to note that media without phenol red was used for this assay. 
MTT solution (Provided: 5mg/ml MTT in RPMI-1640 without phenol red) equal to 10% of 
the culture volume was added to each well and incubated for 3.5 hours. Following, the 
resulting MTT formazan crystals were dissolved in MTT solvent (0.1 N HCl in anhydrous 
Isopropanol). Absorbance was read at 560nm and 620nm using a spectrophotometric 
microplate reader and the absolute absorbance was calculated. The experiments were 
performed in triplicate wells and repeated 3 times. 
2.21. Trypan Blue exlusion assay 
BeWo and JEG-3 cells were maintained in cell culture as described above (2.2). Cells were 
seeded in 6-well multi dishes for treatment purposes. Once confluence was achieved, the 
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media was aseptically removed and the cells were rinsed with 1xPBS. A known volume of 
phenol red free media containing only 100 μg/ml of Penicillin and 100 μg/ml of Streptomycin 
(Gibco) was added to the cells 24 hours prior starting the treatments. The cells were 
incubated for 24 hours with the specific compounds (Table 2.7) prior to starting the trypan 
blue exclusion assay. It should be noted that U0126 compound was used to pre-treat the cells 
for 30 minutes before continuing with any other treatments. 
 
Compound Final Concentration Combination treatments 
Progesterone (P4) 
(Sigma, P0130) 
1nM 
10nM 
100nM 
1000nM 
 ± IL-1β ± U0126 
 ± IL-1β ± U0126 
 ± IL-1β ± U0126 
 ± IL-1β ± U0126 
10-ethenyl-19-
norprogesterone 
(OD 02-0) (Gift from Prof. 
Thomas) 
1nM 
10nM 
100nM 
1000nM 
 ± IL-1β ± U0126 
 ± IL-1β ± U0126 
 ± IL-1β ± U0126 
 ± IL-1β ± U0126 
IL-1β (Sigma, I9401) 10ng/ μl  
Promegestone  (R5020) 
(PerkinElmer, NLP00400) 
30nM 
 ± IL-1β ± U0126 
U0126 (Sigma, U120) 1μM  
 
Table 2.7: Compounds used to treat cells. Final concentration used to treat cells is shown 
along with the combined treatments that were performed.  
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Once the incubation period was over, medium was removed and the cells were rinsed in 
1xPBS. Following a 0.25% trypsin solution was added to the cells for ~ 3 minutes. The effect 
of trypsin was then neutralised by addition of an equal volume of medium. The cell 
suspension was centrifuged at 1000 RPM for 5 minutes. The supernatant was aseptically 
removed and the cells were resuspended in a known volume of medium. In order to 
determine the cell numbers an aliquot was removed from the cell suspension and mixed with 
trypan blue stain (Gibco) in a 5:1 ratio, total volume 100 μl. 20μl were removed and placed 
on a hemocytometer (Neubauer) with a chamber depth of 0.1 mm. The number of cells was 
recorded in 4 large squares under a 10x lens on a phase contrast light microscope. The 
number of dead cells that had been stained blue was recorded along with the total number of 
cells which was estimated by following the equation: Average No. of cells x dilution factor x 
10
4
. 
2.22. Statistical Analysis 
Data were expressed as mean± SEM. For the quantitative PCR, the following equations were 
used: ΔCt=Ct (gene of interest)-Ct (house keeping gene), ΔΔCt=ΔCt (sample) - ΔCt 
(calibrator), Relative Quantity (RQ) =2
–ΔΔCt
. RQ value was set up as 1 for the untreated (no 
supplement) BeWo and JEG-3 cells. We have also calculated the gene expression levels as 
RQ values, using the untreated control for each cell line as a calibrator. We did so, since RQ 
values provide a more accurate comparison between the initial amounts of template in each 
sample, without requiring an exact copy number for analysis. Statistical analysis of the ΔCt 
and RQ value was performed using student’s t-test. For the correlation studies, a two-tailed 
test using SPSS (Version 18) was used. For the western blotting studies, each band was 
quantified using AlphaEaseFC software followed by student’s t-test. A p value of <0.05 was 
regarded as significant for all the above mentioned studies. 
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CHAPTER 3 
3. RESULTS 
 
3.1. Validation of BeWo syncytialisation model 
BeWo cells are fusigenic thus they have the ability to syncytialise in vitro. Once they are 
fully syncytialised they resemble a third trimester placental model, whereas in the non-
differentiated state their morphology is similar to that of primary trophoblast cultures (Pattillo 
& Gey, 1968; Hertz, 1959). This property of BeWo cells will be instrumental in providing a 
better insight of the 3
rd
 trimester human placenta by allowing examination of two distinct 
functional cell types which are vital for the functionality of the human placenta.  Prior to 
embarking on any further studies the syncytialisation model had to be validated, and in order 
to assess the incidence of syncytialisation in BeWo cells a number of different markers were 
used. 
3.1.1. Expression of Proliferating Cell Nuclear Antigen (PCNA) 
Proliferating Cell Nuclear Antigen (PCNA) was used as an indicator of cell proliferation as it 
is found in the nucleus of cells during the DNA synthesis phase. BeWo cells were treated 
with the chemical agent forskolin, an adenyl cyclase activator (Lyden et al., 1993), which 
was used to induce the syncytialisation process for 48 hours at a concentration of 50 μM and 
3 
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100 μM. Expression of PCNA at mRNA level was significantly down-regulated in BeWo 
cells that were treated with forskolin (50 and 100 μM) for 48 hours when compared to the 
untreated BeWo cells (Fig.3.1). The results obtained from semi- quantitative RT-PCR were 
used to quantify the amount of DNA amplified for PCNA and were normalised against β-
actin which was the housekeeping gene. The normalised signal intensities obtained are 
represented in Fig. 3.2. 
 
 
 
Figure 3.1: RT-PCR gel demonstrating the expression of PCNA and β-actin housekeeping 
gene in treated and untreated BeWo cells. Lane 1: DNA ladder; lane 2: cDNA from untreated 
BeWo cells (48 hours); lane 3: cDNA from stimulated BeWo cells (50 μM forskolin, 48 
hours); lane 4: cDNA from untreated BeWo cells (48 hours); lane 5: cDNA from stimulated 
BeWo cells (100 μM forskolin, 48 hours). 
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Figure 3.2: Densitometric analysis of PCNA in forskolin treated and untreated BeWo cells. 
Expression of PCNA was normalised against the expression of β-actin housekeeping gene. 
Each histogram represents the mean ± SEM of three individual experiments. Blue lines 
indicate significance, p<0.0001***. 
 
 
The expression of PCNA was also examined at the protein level, (Fig. 3.3) demonstrating 
down-regulation following treatment with 50 μM and 100 μM Forskolin for 72 hours (lane 1 
& 3) when compared with the untreated samples (lane 2 & 4). The membrane was reprobed 
with antibodies to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as shown in the 
lower panel of Fig.3.3. Densitometric analysis (Fig. 3.4) confirmed a significant reduction 
(p<0.001) in PCNA protein in the BeWo cells treated with 50 and 100 μM forskolin for 72 
hours compared to untreated cells.  
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Figure 3.3: Protein expression of PCNA and GAPDH . Lane 1: BeWo cells treated with 50 
μM forskolin for 72 hours; lane 2: control, unstimulated BeWo cells (72 hours), lane 3: 
BeWo cells treated with 100 μM forskolin for 72 hours; lane 4: control, unstimulated BeWo 
cells (72 hours). 
 
 
 
 
Figure 3.4: Densitometric analysis of PCNA in forskolin treated (50 and 100 μM) for 72 
hours and untreated BeWo cells. Each histogram represents the optical density units. PCNA 
expression was normalised against the expression of GAPDH. Blue lines indicate 
significance, p<0.001**. 
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In order for the mononuclear cytotrophoblast cells to fuse and form the multinuclear syncytia 
layer, the cells must stop proliferating (Benirschke et al., 2005; Tanaka et al., 1998).  As 
PCNA is only found in the nucleus of proliferating cells it is evident from the above results 
that BeWo cells undergoing chemical syncytialisation in vitro showed decreased levels of 
PCNA at both gene and protein level as a result of ceased proliferation. 
3.1.2. Expression of Pan-Cadherin in syncytialised BeWo cells 
During the process of syncytialisation the plasma membrane of the individual cytotrophoclast 
cells fuses in order to form the multinuclear syncytia layer. Therefore the decrease in plasma 
membrane content is an indication that the process of differentiation is in order. We have 
used a cell membrane marker, pan-Cadherin to examine the levels of the cadherin protein in 
treated and untreated cells to determine whether a decrease in total plasma membrane was 
achieved following treatment with forksolin.  Western blot analysis revealed down-regulation 
of cadherin protein levels in BeWo cells that were treated with forskolin over a total of 72 
hours at both concentrations (50 μM & 100 μM) when compared with the non-treated control 
BeWo cells (Fig.3.5). As shown in Fig. 3.6 the down regulation in the expression of cadherin 
in BeWo cell treated with 50μM forskolin for 72 hours was significant (p <0.001) when 
compared to the untreated BeWo cells. Cells that were treated with 100 μM of forskolin 
showed a significant (p <0.05) downregulation of cadherin when compared to the untreated 
BeWo cells (Fig.3.6).  
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Figure 3.5: Protein expression of Cadherin and GAPDH. Lane 1: BeWo cells treated with 50 
μM forskolin for 72 hours; lane 2: control, unstimulated BeWo cells (72 hours), lane 3: 
BeWo cells treated with 100 μM forskolin for 72 hours; lane 4: control, unstimulated BeWo 
cells. 
 
 
 
 
Figure 3.6: Densitometric analysis of Cahderin in forskolin treated (50 and 100 μM) and 
untreated BeWo cells. Each histogram represents the optical density units. Cadherin 
expression was normalised against the expression of GAPDH. Blue line indicate significance, 
p <0.001**, p<0.05*. 
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Immunostaining was performed on BeWo syncytialised cells using the same pan-cadherin 
antibody to visualize if the plasma membrane had started to fuse as it does during the process 
of syncytialisation. BeWo cells treated with 50 μM & 100 μM forskolin for 48 hours 
(Fig.3.7) and 72 hours (Fig.3.8) were subjected to immunofluoresence analysis. 
It is clearly demonstrated that the cell membranes of the mononuclear BeWo cytotrophoblast 
cells started to fuse with each other 48 hours after treatment. Some cells still maintain their 
individual cell membrane at this stage. Following 72 hours of forskolin treatment it had 
become more difficult to visualize the cell borders of individual BeWo cytotrophoblast cell as 
the multinuclear syncytia had started to form.  
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Figure 3.7: Immunostaining with cadherin in BeWo cells treated with 50 μM & 100 μM 
forskolin for 48 hours. White arrows in the panels A and B of the merged images of Pan-
Cadherin and DAPI staining; indicate at both doses the points where the plasma membrane 
has fused. Panels C and D indicate the DAPI stained nuclei whereas E and F Pan-Cadherin 
panels indicate the specific staining of the plasma membrane. 
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Figure 3.8: Immunostaining with cadherin in BeWo cells treated with 50 μM & 100 μM 
forskolin for 72 hours. White arrows in the panels A and B of the merged images of Pan-
Cadherin and DAPI staining, indicate at both doses the points where the plasma membrane 
has fused. Panels C and D indicate the DAPI stained nuclei whereas E and F Pan-Cadherin 
panels indicate the specific staining of the plasma membrane. 
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Immunostaining with Pan- Cadherin antibody on non-treated control BeWo cytotrophoblast 
cells revealed no signs of fusion (Fig. 3.9). In contrast distinct cell borders of individual cells 
were visible. 
 
 
Figure 3.9: Immunostaining using Pan-Cadherin antibody in untreated BeWo cells. No signs 
of plasma membrane fusion are visible (white arrows) in panel A. Panel B indicates the 
staining with DAPI and panel C the cadherin staining.  
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3.1.3. Examining the proliferation and viability of BeWo cells undergoing 
syncytialisation. 
During the process of syncytialisation it is required for the cells to stop proliferating in order 
to syncytialise. Trophoblastic cells though should remain viable during this process. Ceased 
proliferation of BeWo cytotrophoblast cells may also be attributed as cell death due to the 
addition of forkolin. To eliminate the possibility of cell death and to assess the proliferation 
and viability of BeWo cell undergoing chemical syncytialisation, two approaches were used – 
a cell proliferation assay based on 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromide (MTT) and a trypan blue exclusion assay based on the dye trypan blue.  
Once BeWo cells were plated and were chemically syncytialised with 50μM and 100 μM of 
forskolin the MTT assay was performed at both time points (48 hours and 72 hours) to assess 
proliferation of these cells. It would be anticipated for treated cells to show less proliferation 
that the control cells. It should be noted that the control cells were also grown in media 
containing DMSO as it was the vehicle for foskolin. Given that we also tested the effect of 
DMSO alone on cell proliferation. The vehicle (i.e. DMSO) did not exert any proliferative 
effects. 
The principle of this test lays in the ability of the mitochondrial dehydrogenases of the viable 
cells to cleave the tetrazolium ring yielding purple MTT formazan crystals that are further 
dissolved in acidified isopropanol. This results in a purple solution being formed which is 
spectrophotometrically measured. If the cell number has increased the amount of MTT 
formazan formed would increase and subsequently there would be an increase in absorbance. 
Absolute absorbance was calculated by subtracting the absorbance readings of 560nm from 
the absorbance readings of 620nm. A graph displaying the absolute absorbance readings of 
BeWo cells treated with forskolin for 48 and 72 hours with 50 and 100 μM is shown in Fig. 
3.10. It is evident that the forskolin treated BeWo cells showed less proliferation. This is in 
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accordance with the syncytialisation process they were induced to undergo. When comparing 
the BeWo cells treated with 50 μM and 100 μM forskolin for 48 hours with the control BeWo 
cells, a significant decrease in proliferation was observed. Whereas when the BeWo cells 
were treated for 72 hours, a significant decrease was detected only with 100 μM forskolin 
upon comparison with the control BeWo cells. 
 
 
 
Figure 3.10: Graphical representation of the absolute absorbance of BeWo cells treated with 
forskolin for 48 hours and 72 hours with 50 μM and 100 μM. Each histogram represents the 
mean ± SEM of three individual experiments. Red lines indicate significance of treatment 
with 100 μM of forskolin for 72 hours when compared to the control BeWo cells, whereas 
blue line indicates significance of treatment with 50 μM & 100 μM of forskolin for 48 hours 
when compared to the control BeWo cells (p < 0.001 **, p < 0.05 *). 
 
 
 
To determine the percentage of BeWo cells that had died during the syncytialisation process 
the trypan blue exclusion assay was also performed. The principle of this assay lays in the 
ability of the blue dye to be absorbed by dead cells as their cell membrane is not intact. 
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Therefore the dead cells are stained blue, can be visualised under a microscope and 
subsequently counted. 
Graph displayed in Fig.3.11 shows the percentage of dead BeWo cells. No dead cells were 
seen when the cells were grown in media containing DMSO and BeWo cells maintained in 
culture in standard media indicating that no effect of DMSO is exerted on the cells. BeWo 
cells treated with 50 and 100 μM of forskolin for 48 and 72 hours had a percentage of dead 
cells between 20% - 30%.  
 
 
Figure 3.11: Percentage of dead BeWo CT cells after performing Trypan Blue assay. BeWo 
cells were treated with forskolin 50 & 100 μM, also dead cells were counted for untreated 
BeWo CT cells and BeWo cells cultured in the presence of DMSO. Each histogram 
represents the mean ± SEM of three individual experiments.  
 
 
 
 
3.1.4. Examining the expression of syncytin-2 
The expression of syncytin -2 was chosen to be studied as a syncytialisation marker as it has 
been identified recently to be a placental membrane protein with fusogenic properties 
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(Malassine et al., 2006).  The expression was examined in BeWo cells that were treated with 
50μM and 100μM of forskolin for 48 and 72 hours along with control samples of non-treated 
BeWo CT cells. The Q-PCR results presented in Fig.3.12 indicate that the expression 
detected in BeWo cells treated with 50μM and 100μM forkolin for 48 hours were 
significantly uperegulated when compared to the non-treated cells, a sign that the cells had 
started to fuse into syncytiotrophoblasts (Mparmpakas et al., 2010). After treating the cells 
for 72 hours with 50μM of forkolin a significant up-regulation in the expression of syncytin-2 
was detected compared to the control cells. The relative quantity (RQ) value of the non-
treated BeWo cells was set to 1 as these cells were the control samples (Mparmpakas et al., 
2010). 
 
 
 
Figure 3.12: Expression of syncytin-2 in BeWo cells treated with 50 & 100μM forkolin for 
48 & 72 hours. Each histogram represents the mean ± [2
-ΔΔSD
  (+) - 2
-ΔΔSD
  (-)] of three 
individual experiments and the expression is relative to β-actin housekeping gene. Red lines 
indicate significance of expression after treating cells with 50 μM for 72 hours, whereas blue 
line indicates significance of expression after treating cells with 50 & 100 μM for 48 hours (p 
< 0.0001 ***). 
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3.2. Discussion 
3.2.1. Validation of BeWo syncytialisation model 
BeWo and JEG-3, the two cell lines studied are widely used to investigate placental 
physiology and function (Novakovic et al., 2011; Burleigh et al., 2007). These cell lines have 
distinct fusigenic capacities. The JEG-3 cell line, despite being of choriocarcinoma origin, is 
unable to morphologically differentiate and therefore it resembles the undifferentiated 
cytotrophoblast cells unable to produce hormones thus making it an appropriate in vitro 
model to investigate first trimester placental events (Ntrivalas et al., 2006). BeWo cells are 
fusigenic and when they are fully differentiated (i.e. syncytialised) they resemble a third 
trimester placental model. At this stage the predominant feature of the human placenta is the 
hormonally active syncytiotrophoblast layer. The multinucleated syncytiotrophoblasts cover 
the external surface of the placental villous and are in direct interface with maternal blood 
(Das et al., 2004). Undifferentiated BeWo cells are similar in morphology to primary 
trophoblast cultures, with a monolayer and microvillar projections on the apical side. The 
capability of BeWo cells to differentiate has established these cells as an in vitro model to 
study immune, endocrine and developmental aspects (Heaton et al., 2008; Neelima & Rao, 
2008; Ellinger et al., 1999), as well as placental transport mechanisms (Manley et al., 2005). 
Validation of the syncytialisation model was performed using a wide range of morphological 
markers and examining different aspects of the syncytialisation process. In our hands, 
validating the BeWo syncytialisation model had been also achieved (Zachariades et al., 2011; 
Mparmpakas et al., 2010).  Proliferating Cell Nuclear Antigen (PCNA) is present in the 
nucleus of replicating cells only. Cytotrophoblast cells and thus BeWo cells exit the cell cycle 
to being able to start differentiating (Benirschke et al., 2005). PCNA, a marker of 
proliferation which has been used in the past to assess proliferation of cytotrophoblast cells in 
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gestational trophoblastic diseases (Xue et al., 2003) when used in our BeWo cell preparations 
treated with forskolin (50μΜ & 100μM) for 48 hours demonstrated significant down- 
regulation of PCNA transcript, an indication of ceased proliferation in comparison to non 
treated BeWo cells. Antibodies against cadherin protein have been used as plasma membrane 
markers (Benaitreau et al., 2010). Staining of BeWo cells that were treated with 50μΜ and 
100μM of forskolin using a pan-cadherin antibody showed signs of plasma membrane fusion 
and formation of multinucleated syncytia that became more intense after 72 hours of 
treatment, this is in agreement with previous studies performed confirming syncytia 
formation in in vitro differentiated BeWo cells (Al-Nasiry et al., 2006; Coutifaris et al., 
1991). Cells that were maintained in standard cell culture conditions and were not exposed to 
forskolin when stained with pan-cadherin, had intact plasma membranes with distinct cell 
boundaries. Significant reductions in the levels of cadherin protein were also observed in 
immunoblots performed using cell preparation treated with forskolin (48 & 72 hours with 
50μΜ & 100μM).  
A well accepted characteristic of trophoblast differentiation is the arrest of mitosis, where the 
cells cease proliferating (Anson-Cartwright et al., 2000) without cell viability being 
endangered. Similarly, in the in vitro differentiation model BeWo cytotrophoblast cells will 
stop proliferating in order to form multinucleated syncytia. BeWo cytotrophoblast cells 
though should remain viable during this process. Ceased proliferation of BeWo 
cytotrphoblast cells may also be attributed as cell death due to the addition of forskolin. The 
proliferation assay confirmed that BeWo cells had ceased proliferating after treatment with 
forskolin for 48 and 72 hours with 50μΜ & 100μM. Significant reduction in MTT 
absorbance was observed in the treated cells when compared to the untreated thus leading to 
the conclusion that cells were still viable hence their mitochondria were able to produce 
formazan, corroborating earlier findings (Al-Nasiry et al., 2006).  
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The fusigenic protein syncytin-2 which recently was shown to hold a key role in trophoblast 
differentiation by mediating cell fusion (Vargas et al., 2009) was shown to be significantly 
up-regulated in forskolin treated BeWo cells when compared to the non treated cells 
(Zachariades et al., 2011). This is in accordance with previous studies indicating that 
syncytin-2 was found up regulated in placental cells that had been exposed to forskolin (Chen 
et al., 2008; Blaise et al., 2003). 
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3.3. Expression of Progesterone Receptors in placental cell lines: effects 
of syncytialisation on receptor expression. 
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3.3.1. Evaluation of the expression and the cellular localization of membrane 
progesterone receptors (mPRs) in BeWo and JEG-3 cell lines. 
Up to now, there is no data about the expression of PRs in human choriocarcinoma cell lines, 
which are used extensively as placental experimental models. Therefore the expression of 
progesterone receptors which include the membrane progesterone receptors, the progesterone 
membrane component – 1 and the nuclear progesterone receptor (PR-B) were investigated in 
syncytialised and non syncytliased BeWo cells as well as in JEG-3 cells. 
The expression of membrane progesterone receptors (mPRs) at the gene level was evaluated 
in detail in two cell lines, BeWo and JEG-3. The expression was also assessed in BeWo 
cytotrophoblast (CT) cells and BeWo syncytiotrophoblast (ST) cells. 
Following the extensive evaluation of the syncytialisation model, and based on the following 
reasons, it was agreed that for consistency purposes throughout the study the fully 
syncytialised BeWo cells to be treated with 50μM forskolin for 72 hours.We have shown that 
at 72 hours and treated with 50μM forskolin BeWo cells significantly decreased the 
expression of PCNA and Cadherin proteins (Mparmpakas et al., 2010),  both are important 
markers as PCNA is only found in the nucleus of proliferating cells, therefore it was 
confirmed that BeWo cells had ceased proliferating in order to syncytialise (O’Brien et al., 
2003). Cadherin is another important marker and more specifically it is a plasma membrane 
marker. As the process of differentiation progresses the levels of plasma membrane decrease 
as a sign of fusion and this was confirmed in our model as a significantly decreased 
expression was detected. This was again confirmed at protein level, where antibodies to 
cadherin were used and the results once visualised confirmed the fusion of BeWo cells as no 
distinct cell boundaries were visible. The results obtained from the MTT assay confirmed that 
the cells showed significantly less proliferation than the untreated BeWo cells. Further, the 
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cells that where treated with the 50μM forskolin for the period of 72 hours, showed a 25% 
dead cells following the treatment a percentage that was found to be intermediary in 
comparison to the results seen from the percentage of dead BeWo cells of the 48 hour 
treatments. Lastly, the profound result of the expression of syncytin-2 mRNA was shown to 
be significantly (p <0.0001) upregulated in comparison to the cells treated with 100 μM 
forskolin for the same time period (72 hours) (Mparmpakas et al., 2010).  Q-PCR analysis 
revealed that there was a significant down regulation in the expression of mPRα, mPRδ and 
for mPRγ a more modest decrease was seen in BeWo ST when compared to the expression of 
the same genes in BeWo CT. The expression of mPRβ was found to be significantly 
upregulated in BeWo ST when compared to the expression seen in BeWo CT. The graph in 
Fig. 3.13 shows the results expressed in relative quantity (RQ) values where the expression of 
BeWo CT was set at 1. Table 3.1 below indicates the down regulation and upregulation of 
these genes in percentile.  
 
 
Figure 3.13: Expression of mPRα, mPRβ, mPRγ , mPRδ in control untreated BeWo cells  
(BeWo CT) vs. BeWo ST cells (forskolin 50 μM for 72 hours) (Zachariades et al., 2011). 
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Following, when the non-differentiated but fusigenic BeWo (CT) cells where compared to 
the non-fusigenic JEG-3 cells, it was found that there was a significantly lower expression of 
mPRα, mPRβ, mPRγ (Fig. 3.14), whereas there was no expression of mPRδ in JEG-3 cells. 
In table 3.1, the percentages in the down regulation of the mPRs can be seen. 
 
 
 
Figure 3.14: Expression of mPRα, mPRβ, mPRγ  in control untreated BeWo cells  (BeWo 
CT) vs. JEG-3 cells (Zachariades et al., 2011). 
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Cell line/ cell type comparison 
Gene BeWo ST versus BeWo CT JEG-3 versus BeWo CT BeWo ST versus JEG-3 
mPRα 90% 58% 28% 
mPRβ 127% 50% 120% 
mPRγ 28% 38% 80% 
mPRδ 99% No expression No expression 
mPRε No expression No epxression No expression 
 
 
Table 3.1: Gene expression expressed in percentile in untreated BeWo cells (BeWo CT) vs. 
BeWo ST cells (forskolin 50 μM for 72 hours), in untreated BeWo cells vs. JEG-3 cells and 
in BeWo ST cells (forskolin 50 μM for 72 hours) vs. JEG-3 cells.  
 
The protein expression and cellular localization of mPRs was assessed in JEG-3, non-
syncytialised (CT) and syncytialised (ST) BeWo cells, using immunofluorescent analysis. 
The protein expression of mPRα in JEG-3 was detected on the plasma membrane and in the 
cytoplasm and it appears as a homogenous staining (Fig.3.15).   mPRβ and mPRγ showed a 
cytoplasmic localisation as seen in Fig.3.15 with a dotted appearance. As observed in the 
panel of images below (Fig.3.15) in BeWo CT cells, mPRα, mPRβ and mPRγ are localised in 
the plasma membrane as well as in the cytoplasm and showed a dotted appearance.  When 
observing the images collected for the expression of mPR proteins in BeWo ST cells it was 
seen that mPRα was predominantly localised in the cytoplasm homogeneously,  whereas 
mPRβ was present also on the plasma membrane. mPRβ shows a peri – nuclear dotted 
staining.  mPRγ was expressed intensely on the plasma membrane with some dotted staining 
being visible. (Fig.3.15) (Zachariades et al., 2011). 
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Figure 3.15: Immunofluorescence analysis for mPRα, mPRβ, mPRγ in JEG-3, untreated  
BeWo cells (BeWo CT) and syncytialised BeWo cells (BeWo ST).  
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Below, a summarising table indicating the cellular localisation of mPRs can be found (Table 
3.2).  
 
Cellular localisation 
Receptor JEG-3 BeWo CT BeWo ST 
mPRα 
Cytoplasm + plasma 
membrane 
Cytoplasm + plasma 
membrane 
Cytoplasm 
mPRβ Cytoplasm 
Cytoplasm + plasma 
membrane 
Cytoplasm + 
plasma membrane 
mPRγ Cytoplasm 
Cytoplasm + plasma 
membrane 
plasma membrane 
 
 
Table 3.2: Summary of the cellular localisation of mPRα, mPRβ, mPRγ proteins in JEG-3, 
untreated BeWo cells (BeWo CT) and syncytialised BeWo cells (BeWo ST).  
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3.3.2. Evaluation of the expression and the cellular localisation of 
progesterone receptor membrane component -1 (PGRMC-1) in BeWo 
and JEG-3 cell lines. 
The expression of another membrane receptor able to bind progesterone was examined in our 
cell preparations. The expression of PGRMC-1 mRNA was significantly upregulated in 
BeWo ST cells when compared to BeWo CT cells. This upregulation was found to be of 
77%. When the expression was assessed in JEG-3 cells compared to BeWo CT it was found 
that these non-fusigenic cells express PGRMC-1 at a lower level (68% less). Graph presented 
in Fig.3.16 shows the relative quantitiy (RQ) values of the expression levels. Expression of 
PGRMC-1 in BeWo CT was set to 1.  
 
 
 
Figure 3.16: Expression of PGRMC-1 in control untreated BeWo cells  (BeWo CT), treated 
BeWo cells (forskolin 50μM 72 hours) and JEG-3 cells. 
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Immunofluorescence analysis of the PGRMC-1 protein in JEG-3 cells revealed a strong 
homogeneous peri-nuclear staining as well as cytoplasmic staining (Fig.3.17). In BeWo CT 
cells this protein was localised mainly in the cytoplasm where the staining was dotted and 
some staining being seen on the plasma membrane with a more homogeneous appearance. 
Finally, in BeWo ST dotted staining was evident in the cytoplasm and in the plasma 
membrane of these cells (Fg.3.17). 
 
 
Figure 3.17: Immunofluorescence analysis for PGRMC-1 in JEG-3, untreated BeWo cells 
(BeWo CT) and syncytialised BeWo cells (BeWo ST).  
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3.3.3. Expression of nuclear progesterone receptor (PR-B) in BeWo and 
JEG-3 cell lines. 
To help assess the expression of functional wild-type nuclear PR-B, semi-quantitative RT-
PCR analysis was used. This approach was selected as the primers designed had the 
maximum length of the target gene therefore this restricted the use of Q-PCR. RT-PCR was 
chosen also because of the presence of multiple splice variants of the PR gene. RT-PCR 
analysis of this gene in BeWo CT and BeWo ST cells revealed that no change in the 
expression was present (Fig.3.18). In JEG-3 cells there was a 4-fold increase of PR mRNA 
when compared to both BeWo CT and ST cells.  
 
 
 
Figure 3.18: Illustration of the fold increase in expression of PR-B using semi-quantitative 
RT-PCR. Correcting over β-actin.  
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Western blotting was then utilised to investigate the expression of the protein PR isoforms in 
BeWo (Fig. 3.19A) and JEG-3 (Fig. 3.19B) cells. Specific bands at ~116 and 94 kDa were 
detected in all preparations which were indicative of the expression of the full-length PR-B as 
well as the truncated PR-A, respectively.  
 
 
 
Figure 3.19 : Western blotting of the expression of PR-A (94) kDA and PR-B (116 kDA) in 
cell lysates from BeWo and JEG-3 cells.  
 
 
Using antibodies against PR-B protein we observed in JEG-3 cells this protein to be found 
around the nucleus indicating a speckled peri- nuclear pattern of staining whereas in BeWo 
CT the localisation of this protein is mainly cytoplasmic but also some speckled nuclear 
staining is observed. The staining observed in BeWo ST cells was mainly granular nuclear as 
Fig.3.20 depicts. 
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Figure 3.20: Immunofluorescence analysis for PR-B in in JEG-3, untreated BeWo cells 
(BeWo CT) and syncytialised BeWo cells (BeWo ST).  
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Further, analysis of PR-B localisation in BeWo and JEG-3 was conducted using 
ImageStream
x
. Incubation of cells with fluorescently conjugated progesterone bound to the 
impermeable moiety BSA resulted in binding on the cell membrane of BeWo cells (white 
arrows), indicative of membrane progesterone binding sites (Fig.3.21).  
 
 
 
Figure 3.21: Binding of FITC-P4-BSA on the cell membrane of BeWo cells. A: scatter cell 
imaging, B/C: shows FITC-P4-BSA staining (white arrow; cell membrane), and D is the 
brightfield image of the cell. 
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Below an indicative result obtained is given where the intra-nuclear PR-A/B protein is seen in 
BeWo (white dotted arrows). Strong nuclear expression of PR was evident in most of the 
4,448 single cells studied (Fig. 3.22).  
 
 
 
Figure 3.22: ImageStream analysis of PR-A/B in two representative BeWo cells. Panel A is 
scatter cell imaging, B is the brightfield image of the cells, and C is the specific staining (red) 
for PR-A/B (white-dotted arrows). 
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3.4. Discussion 
3.4.1. Expression of Progesterone Receptors in placental cell lines: effects of 
syncytialisation on receptor expression. 
Over the past 20 years many research groups have shown that steroids also act at the cell 
surface of many target tissues and cell types to initiate rapid responses, via binding to 
membrane receptors (Falkenstein et al., 2000).  However, the lack of comprehensive 
information on the identity and molecular structure of any membrane steroid receptor has 
prevented understanding of critical molecular aspects of steroid actions via this alternative 
mechanism and a more widespread appreciation of its significance (Watson, 2003). Recently, 
new genes exhibiting characteristics of a membrane progestin receptor (mPR) have been 
discovered and separated into 5 subtypes, α, β, γ, (Zhu et al., 2003B) δ, and ε (Smith et al., 
2008). Until now existing knowledge is limited regarding expression of membrane 
progesterone receptors in the human placenta. Results presented from this research comprise 
the first detailed mapping of progesterone receptors in the human placenta integrating 
signalling and functional studies of these receptors.  
In this part of the study a detailed map of the progesterone receptors expression at gene and 
protein levels in two human choriocarcinoma cell lines has been provided. Moreover, the 
effect of the syncytialisation agent forskolin was assessed on the expression of these genes.  
Examining the expression of mPRs and PGRMC-1 by Q-PCR in the pre- and differentiated 
state of BeWo cells it was revealed that in syncytialised BeWo cells, mPRα, mPRγ and mPRδ 
were down-regulated, whereas mPRβ and PGRMC-1 were up-regulated when compared to 
non-syncytialised BeWo cells (Zachariades et al., 2011). Upregulation of mPRβ was very 
distinctive in BeWo ST cells where a 2.25 fold increase over the expression of mPRβ in the 
non-treated BeWo cells was detected. The expression of PGRMC-1 was shown to be 1.75 
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fold above the expression recorded in the BeWo CT cells. These results corroborate a recent 
study where it was shown that forskolin altered the expression of several genes during the 
process of syncytialization in BeWo cells (Neelima & Rao, 2008). Using differential display 
RT-PCR analysis and Northern blot analysis the up-regulation of genes such as secretory 
leukocyte peptidase inhibitor (SLPI), elongation factor-1 alpha-1 (ELF-1α-1) and prolyl 4-
hydroxylase β following treatment with forskolin was detected (Neelima & Rao, 2008). Also 
the elevation of cAMP can activate certain steroid receptors and augment the ligand-
dependent activation (Rowan et al., 2000). For example, 8-bromo-cyclic AMP induces the 
phosphorylation of two sites in SRC-1 that facilitate the ligand-independent activation of the 
chicken PR and are critical for the functional cooperation between SRC-1 and the CREB 
binding protein (Rowan et al., 2000). 
The JEG-3 cell line does not have a fusigenic capacity and responds poorly to inducers of 
syncytialization (Coutifaris et al., 1999). Phenotypically JEG-3 cells resemble the 
undifferentiated cytotrophoblasts, making it a suitable in vitro model to investigate first 
trimester placental function (Ntrivalas et al., 2006). When the expression of mPR and 
PGRMC-1 genes was compared between the non-syncytialised BeWo cells and the JEG-3 
cells, mPRα, mPRβ, mPRγ, and PGRMC-1 mRNA levels were shown to be significantly 
down-regulated in JEG-3 cells. No expression of mPRε was detected using quantitative or 
standard RT-PCR analyses even after 40 cycles of amplification (Zachariades et al., 2011). 
Although both the JEG-3 and BeWo cell lines may represent a cytotrophoblastic state, there 
is evidence that they have inherent gene differences. Microarray analysis revealed that many 
transcripts were differentially expressed between BeWo and JEG-3 cells (Burleigh et al., 
2007), suggesting that each cell line may vary in its capacity to respond to hormones. 
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The full length PR-B is shown from this study to be expressed in JEG-3 cells as well as in 
non - syncytialised BeWo cells and in syncytialised BeWo cells as detected by RT-PCR. 
Expression of PR-A and PR- B was also confirmed at protein level in BeWo CT cells, using 
western blot analysis and an antibody that recognises both isoforms (Zachariades et al., 
2011). This data is in agreement with a recent study where both the PR-A and PR-B proteins 
where shown to be expressed in BeWo cells (Yasuda et al., 2009). The presence of multiple 
PR isoforms may be indicative of the diverse responses to progesterone as for example, in 
BeWo cells tranfected with PR these isoforms were found to differentially regulate the 
expression of the breast cancer resistance protein (Wang et al., 2008). 
In BeWo CT, BeWo ST and JEG-3 cells, mPRα protein was localised in the cytoplasm of 
these cells as shown by immunofluorescence analysis. mPRβ showed a similar 
immunoreactivity pattern with an even stronger cytoplasmic signal in our cell lines. Whereas 
mPRγ revealed substantial cytoplasmic staining in JEG-3 cells where the intensity of the 
same protein in BeWo CT cells had the same localisation but a less intense signal intensity 
was detected.  In BeWo ST, mPRγ was primarily expressed on the plasma membrane of the 
syncytiotrophoblasts (Zachariades et al., 2011). This is not the first time where differences in 
the expression level of mPRβ and mPRγ are reported between tissues with mPRβ 
demonstrating less flactuations (Nutu et al., 2009). Previous studies have identified mPRα on 
the cell surface of human myometrial cells (Foster et al., 2010) whereas mPR-β was reported 
to be localised on the plasma membrane of ocytes collected from pigs (Qiu et al., 2008). 
Furthermore,  mPRβ was shown to be localised in the cilia of the epithelial cells (Nutu et al., 
2009) where mPRγ was found in the apical membrane of ciliated cells facing the lumen in 
human fallopian tubes (Nutu et al., 2007).  
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PGRMC-1 showed strong perinuclear and moderate dispersed cytoplasmic staining in JEG-3 
cells, where in BeWo CT cells the signal detected was mainly cytoplasmic with sporadic 
membrane staining. Upon treatment with forskolin in BeWo cells, the cellular distribution of 
PGRMC-1 showed no remarkable differences (Zachariades et al., 2011). This protein has 
been previously shown to be expressed in placental structures and more specifically in 
smooth muscle cells of the placental vasculature, villous capillaries and the 
syncytiotrophoblast layer (Zhang et al., 2008).  
Following, the expression of the nuclear progesterone receptor (PR-B) in JEG-3 cells and in 
non-syncytialised BeWo cells was localised in the cytoplasm and the nucleus, whereas in the 
forskolin-treated BeWo cells the localisation of PR-B was primarily nuclear (Zachariades et 
al., 2011). The differential localisation of PR-B observed in BeWo cells upon treatment with 
forskolin may be a direct result of the alteration of specific genes as previously shown 
(Neelima & Rao, 2008).  Also emerging data from a recent study have indicated that without 
hormone induction, the PR-B distributes between the cytoplasm and the nucleus (Ellmann et 
al., 2009).  
The existing knowledge on progesterone mediated action in human choriocarcinoma cell 
lines is limited to a few studies only.  For example,  a study where it was shown that 
progesterone can have inhibitory effects on folic acid transport (Keating et al., 2007) and to  
down-regulate human organic anion transporter 4 (hOAT4) transport activity in human 
placental BeWo cells (Zhou et al., 2008). However, none of these studies clearly identifies 
the receptor mechanism via which these progesterone effects are mediated. Our data provide 
evidences for the expression of multiple PRs in human placental cell lines, suggestive of a 
higher order of complexity of progesterone-mediated responses.  
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3.5. Genomic or non-genomic signalling at placental level? 
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3.5.1. Expression of p-ERK1/2 and MAPK in BeWo CT, BeWo ST and JEG-
3 cells. 
Mitogen-activated protein kinase (MAPK) super family consists of three major groups of 
kinases: the extracellular-receptor kinases (ERK) which includes ERK1and ERK2 which are 
studied in this research and two further types of MAPK-related kinases: the c-Jun N-terminal 
kinases/stress-activated protein kinases (JNK/SAPK) and the p38 MAPKinases (Kyriakis & 
Avruch, 2001). It has been proven that in the villous trophoblast pathway which promotes 
cytotrophoblast cell differentiation and proliferation, the group of MAPK that plays a role is 
the ERK1/2 (Daoud et al., 2005). Therefore in this part of the thesis the results of the  
expression of phospho-ERK1/2 (p-ERK1/2) and total MAPK in BeWo CT, BeWo ST and JEG-
3 cells are shown after performing treatments with specific compounds ( table below) able to 
activate the MAPK pathway and phosphorylate the ERK1/2 protein.  
Compound Stock Concentration Final concentration 
Progesterone - a known 
activator of mPRs, 
PGRMC-1 and PRs 
 
10
-1 Μ 
 
100nM ± U0126 (1μM) 
 
10-ethenyl-19-
norprogesterone (OD 02-0) 
– a selective agonist of 
mPRα 
10
-3 Μ 100nM 
 
Promegestone  (R5020) - 
a specific agonist of nPR 
10
-2
 M 30nM ± U0126 
U0126 – a selective 
MEK1/2 inhibitor  
10
-3 
M 1μM 
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Before embarking on the analysis of the activation of ERK1/2 in our cells, representative 
western blots from the study are shown below. 
 
 
Figure 3.23: Cells were treated with either 100nM of OD 02-0, 100nM of P4 or 30nM of 
R5020 for a period of 1 hour. Following, protein was extracted by the cells and the samples 
were electrophoresed on 12.5% SDS-PAGE gels. Phospho-p44/42 MAPK (Erk1/2), p44/42 
MAPK (Erk1/2) and GAPDH antibodies were used. The results are indicated above using 
representative blots from the study. Panel A:  BeWo ST cells treated with R5020; Panel B: 
JEG-3 cells treated with P4; Panel C: BeWo ST cells treated with OD 02-0; Panel D & E: 
JEG-3 cells treated with R5020. 
 
 
The cells were treated with 100 nM Progesterone (P4) to determine whether P4 caused 
ERK1/2 activation in BeWo CT, BeWo ST and JEG-3 cells. ERK1/2 activation was measured 
in a time dependent manner by assessing the expression of phospho-ERK1/2 and total MAPK 
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proteins (Fig.3.24). This time - course was chosen as the aim was to establish the principal 
signalling type in the human placental cell lines i.e genomic or non-genomic. Using 
AlphaEase software the optical density values of the immunocomplexes were calculated. The 
expression of p-ERK1/2 was normalised to total MAPK expression and the relative expression 
of p-ERK1/2 expressed in optical density values are presented in the graph in Fig.3.24. The 
basal ERK1/2 phosphorylation in each cell line was established and is indicated in the graph as 
non supplement (NS) where no treatment was performed on these cells. Western blot analysis 
showed that exposure of JEG-3 cells to P4 resulted in a significant increase of ERK1/2 
phosphorylation at 1 minute (Fig. 3.24). Mean ERK1/2 activation was significantly increased 
1.7 fold over non-supplement (NS) after 1 minute of treatment with 100 nM P4 whereas the 
mean activation of ERK1/2 was significantly decreased 2 fold over NS after 5 minutes of 
treatment with 100 nM of P4. No significant increase or decrease in ERK1/2 phosphorylation 
was detected in BeWo CT cells treated with 100 nM of P4 (Fig.3.24). Progesterone treatment 
of BeWo ST cells resulted in a significant 2.2 fold increase of ERK1/2 phosphorylation over 
NS after 20 minutes of treatment. After 30 minutes of P4 treatment in the BeWo ST cells a 
significant decrease of the ERK1/2 phosphorylation levels was detected compared to the 
phosphorylation levels detected in the non-treated BeWo ST cells (Fig.3.24).  
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Figure 3.24: Densitometric analysis of phosphorylated ERK1/2 protein normalized to total 
ERK1/2 protein and reported as optical density (OD) units ± SEM. Statistically significant 
differences from non supplement were determined by paired t-test, p < 0.05*. JEG-3, BeWo 
CT and BeWo ST cells were treated with 100 nM of P4.  
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OD 02-0, a specific mPR ligand was used to treat JEG-3, BeWo CT and BeWo ST cells at a 
concentration of 100 nM for 1, 3, 5, 10, 20, 30 and 60 minutes and the phosphorylation of 
ERK1/2 was measured. After exposing JEG-3 cells to 100 nM of OD 02-0 no significant 
differences in the activation of ERK1/2 were detected (Fig.3.25). The mean ERK1/2 
phosphorylation was significantly decreased 4.8 fold over NS after 1 minute of treatment 
with 100 nM of OD 02-0 in BeWo CT cells. Also a significant decrease (3.2 fold) over NS 
was detected after 3 minutes of treatment, after 20 minutes a significant 3.6 fold decrease was 
observed and after 30 minutes of treatment a significant 5 fold decrease over NS was detected 
(Fig.3.25). Treatment of BeWo ST cells with 100 nM of OD 02-0 resulted in a significant 
increase in ERK1/2 activity after 20 and 30 minutes where the mean ERK1/2 phosphorylation 
was increased 12 fold and 19 fold over NS respectively. 
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Figure 3.25:Densitometric analysis of phosphorylated ERK1/2 protein normalized to total 
ERK1/2 protein and reported as optical density (OD) units ±SEM. Statistically significant 
differences from non supplement were determined by paired t-test, p < 0.05*. JEG-3, BeWo 
CT and BeWo ST cells were treated with 100 nM of OD 02-0.  
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Next JEG-3, BeWo CT and BeWo ST cells were treated with 30 nM of R5020 a selective 
nuclear PR agonist for 1-60 minutes as previously and the activation of ERK1/2 was 
measured. Treatment of JEG-3 cells with 30 nM of R5020 resulted in a significant increase of 
ERK1/2 phosphorylation after 1 and 20 minutes of treatment (Fig.3.26). The mean ERK1/2 
activation was increased 1.7 fold and 1.6 fold over NS respectively. After treatment of BeWo 
CT and BeWo ST cells with 30 nM of R5020 no significant changes in the activity of ERK1/2 
were detected (Fig.3.26). 
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Figure 3.26: Densitometric analysis of phosphorylated ERK1/2 protein normalized to total 
ERK1/2 protein and reported as optical density (OD) units ±SEM. Statistically significant 
differences from non supplement were determined by paired t-test, p < 0.05*, p < 0.001**. 
JEG-3, BeWo CT and BeWo ST cells were treated with 30 nM of R5020.  
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A selective MEK 1/2 inhibitor, UO126 was used to inhibit the activity of MEK1/2. JEG-3, 
BeWo CT and BeWo ST cells were incubated with 1μM of UO126 and the activity of ERK1/2 
was measured. The basal ERK1/2 activity after MEK1/2 inhibition is shown in graph in Fig 
3.27. Even though MEK1/2 was inhibited, phosphorylation of ERK1/2 was detected in our cells 
(Fig.3.27).  
 
 
Figure 3.27: Densitometric analysis of phosphorylated ERK1/2 protein normalized to total 
ERK1/2 protein and reported as optical density (OD) units ±SEM. JEG-3, BeWo CT and 
BeWo ST cells were treated with 1μM of UO126. 
 
 
 
Following, JEG-3, BeWo CT and BeWo ST cells were pre-incubated with UO126 before 
being treated with 100 nM of P4 for 1- 60 minutes and the activity of ERK1/2 was assessed. 
Co-treatment of JEG-3 cells with these two compounds resulted in a significant increase in 
the phosporylation levels of ERK1/2 after 1 minute of treatment compared to NS whereas at 
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60 minutes of P4 treatment the phorpshorylation of ERK1/2 in JEG-3 cells decreased 
significantly compared to the NS (Fig 3.28). Co-treated BeWo CT cells showed no 
significant changes in the phosphorylation levels of ERK1/2 (Fig 3.28). Exposure of  BeWo 
ST cells to these two compounds  significantly decreased the activity of ERK1/2 after 1, 5, 30 
and 60 minutes of treatment (Fig 3.28). The mean activity of ERK1/2 was decreased by 1.1 
fold, 1.7 fold, 1.8 fold, 1.9 fold and 1.8 fold over NS respectively. 
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Figure 3.28: Densitometric analysis of phosphorylated ERK1/2 protein normalized to total 
ERK1/2 protein and reported as optical density (OD) units ±SEM. Statistically significant 
differences from non supplement were determined by paired t-test, p < 0.05*. JEG-3, BeWo 
CT and BeWo ST cells were pre-incubated with 1μM of UO126 and treated with 100 nM of 
P4.  
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3.6. Discussion 
3.6.1. Evidence for non-genomic signalling at placental level 
The MAP kinase family controls a wide range of cellular events such as the process of 
embryogenesis, cell differentiation, cell proliferation, and cell death as well as regulating 
short term process required for homeostasis and hormonal responses (Lewis et al., 1998).  
More specifically, the expression of total ERK1/2 was shown by Kita et al. (2003) to be 
expressed in the human villous cytotrophoblast cells throughout gestation. Total ERK1/2 was 
exclusively localised in the cytotrophoblast as no expression was detected in the 
syncytiotrophoblasts (Kita et al., 2003).  Further to this, a role of ERK1/2 in the proliferation 
of human villous cytotrophoblast was suggested as the phosphorylated ERK1/2 was detected 
in the cytotrophoblast cells up to 12 weeks of the gestation period (Kita et al., 2003).  The 
role of ERK1/2 in the early differentiation process was supported by experiments performed 
showing that the suppression of ERK1/2 activity early in the differentiation process leads to an 
impaired trophoblast differentiation process as the levels of hCG secretion were dramatically 
reduced compared to non-experimental culture conditions (Daoud et al., 2005). 
Even though both cells lines used in these experiments were of choriocarcinoma origin and 
have known fusigenic differences, interestingly further cell specific differences were evident 
from our results. Similarly, findings from a recent study have indicated that approximately 
20% of genes represented on a microarray analysis were differentially expressed between 
JEG-3 and BeWo choriocarcinoma cell line (Burleigh et al., 2007).  
Rapid activation of ERK1/2 was detected in JEG-3 cells upon stimulation with progesterone 
and the nuclear progesterone receptor agonist R5020 as early as 1 minute of treatment.  Rapid 
stimulation of ERK activity has also been previously reported, upon 2 minutes of treatment 
with R5020 in T47D cells (Migliaccio et al., 1998). Evidence has been provided for the 
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association of the nuclear progesterone receptor with p42 MAPK in the xenopus oocyte 
(Migliaccio et al., 1998) and by ERK activation in mammalian cells mediated by 
progesterone  (Bagowski et al., 2001; Boonyaratanakornkit et al., 2001) as well as activation 
of ERK1/2 through mPR mediated signalling (Zhu et al., 2003
A
). This JEG-3 specific rapid 
activation of ERK1/2 can be attributed as the result of up-regulation of genes involved in the 
MAPK cascade in JEG-3 cells in comparison to BeWo cells. Genes that have been shown to 
be up-regulated include the mitogen-activated protein kinase kinase kinase 7 interacting 
protein 2 (MAP3K7IP2) mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1), 
mitogen-activated protein kinase 1 (MAPK1), mitogen-activated protein kinase 14 
(MAPK14), mitogen-activated protein kinase 3 (MAPK3), GRB2-associated binding protein 
1 (GAB1) and Son of sevenless homolog 1 (SOS1) (Burleigh et al., 2007). Thus, the 
progestin induced rapid ERK1/2 phosphorylation in JEG-3 compared to BeWo can be a direct 
result of an overactive MAPK signalling pathway.  
Heat shock protein 70 and heat shock protein 90 (HSPs) are responsible for maintaining the 
progesterone receptor in an inactive state when not bound to a ligand (Rowan & O’Malley, 
2000). The genes encoding for these two HSPs were shown  to be up-regulated in BeWo cells 
compared to the expression detected in JEG-3 cells (Burleigh et al., 2007). HSP gene 
overexpression in BeWo’s may compromise the signalling capacity of the nuclear 
progesterone receptor in BeWo cells as no significant activation of ERK1/2 was observed 
when stimulating these cells with progesterone or R5020. For examples a recent study 
performed in transgenic mice overepxressing HSP70 showed that glucocorticoid receptor 
expression was suppressed despite the high levels of corticosterone being detected. Also, in 
this mouse model a reduced ligand binding of this steroid receptor has been detected 
(Vanhooren et al., 2008) which can be attributed to the overexpression of HSP70. 
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Activation of ERK1/2 was also examined in the pre differentiated and differentiated state of 
BeWo cells. Minimal ERK1/2 phosphorylation was detected in BeWo CT cells. In BeWo ST 
cells, significant ERK1/2 phosphorylation was induced by stimulating the cells with 
progesterone (at 20 minutes post treatment) or the membrane progesterone agonist OD 02-0 
(at 20 and 30 minutes post treatment). The phosphorylation status of ERK1/2 remained 
unaltered upon stimulation with the nuclear receptor agonist, R5020. As ERK1/2 was 
activated at 20 minutes post treatment with progesterone and at 20 and 30 minutes post 
treatment with OD 02-0 it is attractive to speculate that this rapid ERK1/2 phosphorylation is 
mediated via the mPRs and not the nuclear progesterone receptor. More specifically the 
proposed receptor for mediating this response is mPRβ as the expression of this receptor was 
significantly higher than the expression of the other mPRs in BeWo ST. The involvement of 
PGRMC-1 should not be ruled out as this gene was shown to be highly up-regulated in BeWo 
ST compared to BeWo CT but the expression was lower compared to that of mPRβ.  
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3.7. Human placenta and the expression of progesterone receptors 
 
 
 
 
 
 
 
 
 
 
 
 
Progesterone receptors in human placenta  Chapter 3 
 
117 
3.7.1. Expression of mPRs at gene level in the human placenta 
Human placental tissue was used to map in detail the expression of mPRs in an attempt to 
gain a better insight of their role in vivo. This was performed as these newly described 
membrane receptors still have not had a sole role attributed in the female reproductive system 
and specifically in the placenta. The placental samples were collected from women without 
any pregnancy complications or known pathologies and were grouped according to the time 
of delivery (term or preterm) and according to the contractile state (labour or non-labour). 
Totally forty one (n=41) placental samples were collected and available for further analysis 
(Table 3.3). 
 
Placental samples 
Term   Pre - Term  Labour  Non- Labour  
22 19 27 14 
 
 
Table 3.3: Human placenta tissue sample distribution. 
 
 
Following extraction of RNA and cDNA synthesis, the expression of the three genes of 
interest – mPRα, mPRβ and mPRγ - was assessed in the samples using Q-PCR analysis. 
Considerable variation in the expression of the mPRs between individuals was observed (Fig. 
3.29-3.31). 
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Figure 3.29: Expression of mPRα in human placental samples (experimental triplictaes per 
sample), presented according to the contractile state and the time of delivery. The data are 
presented in arbitrary values (2
-ΔCt
) which is the result of the correction of the gene of interest 
over β-actin house keeping gene of each individual placental sample. 
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Figure 3.30: Expression of mPRβ in human placental samples (experimental triplictaes per 
sample), presented according to the contractile state and the time of delivery. The data are 
presented in arbitrary values (2
-ΔCt
) which is the result of the correction of the gene of interest 
over β-actin house keeping gene of each individual placental sample. 
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Figure 3.31: Expression of mPRγ in human placental samples (experimental triplictaes per 
sample), presented according to the contractile state and the time of delivery. The data are 
presented in arbitrary values (2
-ΔCt
) which is the result of the correction of the gene of interest 
over β-actin house keeping gene of each individual placental sample. 
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The data illustrated in Fig. 3.32-3.34 shows three box plots of median variation with 
associated 25
th
, 50
th
 and 75
th
 percentile ranges, respectively of the results collected from the 
analysis of mPRα, mPRβ and mPRγ. The boundaries of the box indicate the 25th percentile 
and the 75th percentile. The maximum values are indicated in the box below.  
Variability can be determined from the length of the box where the spread of the mpRα data 
is greater in the term and non- labour category and a less great spread is observed in the pre-
term category. Higher expression is seen in the term category as the 75
th
 percentile indicates 
where the maximum values of all four categories are shown in the table below. The lowest 
minimum expression values are detected in the pre term and labour category.  
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Figure 3.32 : Box plot obtained from placental tissue data after performing analysis of the 
mPRα gene. Q1= 1st quartile/ 25th percentile; Min= minimum value; Median= 2nd quartile / 
50
th
 percentile; Max= maximum value; Q3= 3
rd
 quartile / 75
th
 percentile 
 
 
The category that shows the greater variability from the mPRβ data is the pre term and to a 
lesser degree the labour. Higher expression is seen in the pre term category as the 75
th
 
percentile indicates and the maximum values of all four categories are shown in the table 
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below. The lowest minimum expression values are detected in the term and non labour 
category.  
 
 
 
 
Figure 3.33: Box plot obtained from placental tissue data after performing analysis of the 
mPRβ gene. Q1= 1st quartile/ 25th percentile; Min= minimum value; Median= 2nd quartile / 
50
th
 percentile ; Max= maximum value; Q3= 3
rd
 quartile/ 75
th
 percentile.  
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The pre term category as indicatated by the length of its box shows the greater variability 
from the mPRγ data where the other three catgories demonstate less variability in the 
expression. Higher range of expression is seen in the pre term category as the 75
th
 percentile 
indicates and the maximum values of all four categories are shown in the table below. The 
lowest minimum expression values are detected in the term and non labour category.  
 
 
Figure 3.34 : Box plot obtained from placental tissue data after performing analysis of the 
mPRγ gene. Q1= 1st quartile/ 25th percentile; Min= minimum value; Median= 2nd quartile / 
50
th
 percentile ; Max= maximum value; Q3= 3
rd
 quartile/ 75
th
 percentile.  
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The primary transcript therefore can be concluded to be the mPRα, as the expression of this 
gene as seen from the 75
th
 percentile data in all four categories is higher than the values 
obtained from mPRβ and mPRγ.  Also it should be noted that the mPRα transcript is the one 
with the higher maximum values compared to the other two genes of interest although this is 
detected on a sporadic basis.  
3.7.2. Cellular localisation and distribution of mPRs in the human placenta. 
The localisation of mPR proteins was assessed by immunofluorescence. From the 
representative images shown in Fig. 3.35 on the outer site of the chorionic villi, the syncytia 
layer can be seen. Directly beneath, the mononuclear cytotrophoblast cells can be visualised. 
mPRα was seen intensively in the syncytia layer in the cytoplasm and on the plasma  
membrane around the fused syntytiotrophoblast cells (Fig.3.35). The staining of mPRα in the 
cytotrophoblast cells showed to be mainly on the plasma membrane and the intensity is lower 
than in the syncytium. mPRβ showed cytoplasmic and plasma membrane staining in the 
syncytium and in the cytotrophoblas cells, staining of the syncytium was stronger. mPRγ 
protein was also localised in the syncytium and the cytotrophoblast cells with both 
cytoplasmic and plasma membrane staining (Zachariades et al., 2011). 
Progesterone receptors in human placenta  Chapter 3 
 
126 
 
Figure 3.35: Immunofluorescence analysis for mPRα, mPRβ and mPRγ in human placental 
tissue sections. White arrows show the syncytia layer and the white dotted arrows the 
cytotrophoblast cells that lie beneath the syncytia layer.  
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3.7.3. Expression of PGRMC-1 at gene level in the human placenta 
The expression of PGRMC-1 mRNA was examined in the human placental samples obtained 
and the graphs are presented in the panel of Fig.3.36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.36: Expression of PGRMC-1 in human placental samples (experimental triplictaes 
per sample) and are presented according to the contractile state and the time of delivery. The 
data are presented in arbitrary values (2
-ΔCt
) which is the result of the correction of the gene 
of interest over β-actin house keeping gene of each individual placental sample. 
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Below a box plot graph (Fig.3.37) depicting the mean arbitrary values of the four categories 
is presented. The term and the labour categories are the ones demonstating the greater spread 
in the expression values as indicated by the length of the boxes where the other thwo 
catgories demonstate less variability in their expression. Higher range of expression is again 
seen in the term and labour category as the 75
th
 percentile indicates and the maximum values 
of all four categories are shown in the table below. The lowest minimum expression values 
are detected in the pre term and labour category. 
 
 
Figure 3.37: Box plot obtained from placental tissue data after performing analysis of the 
PGRMC-1 gene. Q1= 1
st
 quartile/ 25
th
 percentile; Min= minimum value; Median= 2
nd
 
quartile / 50
th
 percentile ; Max= maximum value; Q3= 3
rd
 quartile/ 75
th
 percentile. 
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3.7.4. Cellular localisation and distribution of PGRMC-1 in the human placenta. 
The PGRMC-1 protein in the human placenta was found predominantly in the syncytium as 
seen in the image of the panel below (Fg.3.38). The staining was seen in both cytoplasm and 
plasma membrane. A distinctive plasma membrane staining was seen at a lesser degree in the 
cytotrophoblast cells.  
 
 
 
Figure 3.38: Immunofluorescence analysis for PGRMC-1 in human placental tissue section. 
White arrows show the syncytia layer and the white dotted arrows the cytotrophoblast cells 
that lie beneath the syncytia layer. 
 
 
3.7.5. Expression of PR-B in the human placenta. 
The expression of PR-B mRNA was examined in the human placental samples obtained and 
the graphs are presented in the panel of Fig.3.39. 
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Figure 3.39: Expression of PR-B in human placental samples (experimental triplictaes per 
sample) and are presented according to the contractile state and the time of delivery. The data 
are presented in arbitrary values (2
-ΔCt
) which is the result of the correction of the gene of 
interest over β-actin house keeping gene of each individual placental sample. 
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A box plot graph illustrated below (Fig.3.40) depicts the mean arbitrary values of the four 
categories.  A very low expression is observed in all four categories, though a greater 
variability is detected in the labour category where the less variability is setected in the non 
labour category. Higher expression values are observed in the term and labour category 
although these values remail below 0.5. 
 
 
 
Figure 3.40: Box plot obtained from placental tissue data after performing analysis of the 
PR-B gene. Q1= 1
st
 quartile/ 25
th
 percentile; Min= minimum value; Median= 2
nd
 quartile / 
50
th
 percentile ; Max= maximum value; Q3= 3
rd
 quartile/ 75
th
 percentile. 
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3.7.6. Statistical Correlations 
The correlation between the expressions of the genes of interest was calculated using SPSS 
statistical software. As the ΔCt values obtained from the Q-PCR analysis of the placental 
samples were not normally distributed, a log transformation action was performed in order to 
normalise the data.  
The expression values of each gene of interest were correlated with the expression values of 
the rest of the genes of interest to detect if a statistical relationship occurred and if so, the 
significance of the correlation reported as Pearson correlation coefficient. The tables below 
(Table 3.4 – 3.7) indicate the levels of the correlation coefficient (r) and the red asterisks 
indicate the levels of significance (* <0.05, ** <0.001). The correlations were performed in 
the four categories separately – term, pre term, labour and non labour. 
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  mPRα 
TERM 
mPRβ 
TERM 
mPRγ 
TERM 
PGRMC-1 
TERM PR-B TERM 
 
 
 
mPRα TERM 
 
Pearson 
Correlation 
 
1 
 
-0.102 
 
0.316 
 
0.890** 
 
-0.134 
 
Sig. (2-
tailed) 
 
 
0.653 
 
0.151 
 
0.000 
 
0.551 
 
 
 
mPRβ TERM 
 
Pearson 
Correlation 
 
-0.102 
 
1 
 
0.239 
 
-.060 
 
0.980** 
 
Sig. (2-
tailed) 
 
0.653  
 
0.284 
 
0.792 
 
0.000 
 
 
 
mPRγ TERM 
 
Pearson 
Correlation 
 
0.316 
 
0.239 
 
1 
 
0.375 
 
0.220 
 
Sig. (2-
tailed) 
 
0.151 
 
0.284  
 
0.086 
 
.324 
 
 
 
PGRMC-1 
TERM 
 
Pearson 
Correlation 
 
0.890** 
 
-0.060 
 
0.375 
 
1 
 
-0.117 
 
Sig. (2-
tailed) 
 
0.000 
 
0.792 
 
0.086  
 
0.604 
 
 
 
PR-B TERM 
 
Pearson 
Correlation 
 
-0.134 
 
0.980** 
 
0.220 
 
-0.117 
 
1 
 
Sig. (2-
tailed) 
 
0.551 
 
0.000 
 
0.324 
 
0.604  
 
 
Table 3.4:Levels of correlation between log values (n=22) of mPRs, PGRMC-1 and PR-B. 
Red asterisks indicate significance of the correlation (** Significant at the 0.01 level - 2-
tailed).  
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For the variables where a positive correlation was seen the ΔCt values of the respective genes 
were plotted against each other. The two variables from the term category, as seen from the 
graph in Fig.3.41 were mPRα and PGRMC-1 showing a positive correlation (r = 0.890**, p 
=0.000, n=22). 
 
 
 
 
 
Figure 3.41: Correlation graph between mPRα and PGRMC-1 in term placentae (n=22, r = 
0.890, p =0.000). 
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The variable mPRβ showed a positive correlation (r = 0.980**, p =0.000, n=22) with PR-B 
variable. This correlation is seen in graph in Fig.3.42.  
 
 
 
Figure 3.42: Correlation graph between mPRβ and PR-B in term placentae (n=22, r = 
0.980**, p =0.000) 
 
 
 
 
 
The next table has been constructed once the correlation of the expression values of the genes 
of interest was examined in the pre term placental samples. The levels of correlation 
coefficient (r) are reported and the red asterisks indicate the levels of significance (* <0.05, 
** <0.001). 
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  mPRα PT mPRβ PT mPRγ PT PGRMC-1 PT PR-B PT 
 
 
 
mPRα PT 
 
Pearson 
Correlation 
 
1 
 
-0.139 
 
-0.114 
 
0.982** 
 
-0.127 
 
Sig. (2-tailed) 
 
 
0.570 
 
0.642 
 
0.000 
 
0.603 
 
 
 
mPRβ PT 
 
Pearson 
Correlation 
 
-0.139 
 
1 
 
0.802** 
 
-0.081 
 
0.376 
 
Sig. (2-tailed) 
 
0.570 
 
 
.000 
 
0.743 
 
.112 
 
 
 
mPRγ PT 
 
Pearson 
Correlation 
 
-0.114 
 
0.802** 
 
1 
 
-0.052 
 
0.527* 
 
Sig. (2-tailed) 
 
0.642 
 
0.000 
 
 
0.832 
 
0.020 
 
 
 
PGRMC-1 
PT 
 
Pearson 
Correlation 
 
0.982** 
 
-0.081 
 
-0.052 
 
1 
 
0.031 
 
Sig. (2-tailed) 
 
0.000 
 
0.743 
 
0.832 
 
 
0.901 
 
 
 
PR-B PT 
 
Pearson 
Correlation 
 
-0.127 
 
0.376 
 
0.527* 
 
0.031 
 
1 
 
Sig. (2-tailed) 
 
0.603 
 
0.112 
 
0.020 
 
0.901 
 
 
Table 3.5: Levels of correlation between log values (n=19) of mPRs, PGRMC-1 and PR-B. 
Red asterisks indicate significance of the correlation (** Significant at the 0.01 level, * 
significant at the 0.05 level).  
 
 
The ΔCt values of the respective genes were plotted against each other for the variables 
where a correlation was seen.  The first two variables from the pre term category, as seen 
from the graph in Fig.3.43 were mPRα and PGRMC-1 showing a positive correlation (r = 
0.982**, p =0.000, n=19). 
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Figure 3.43: Correlation graph between mPRα and PGRMC-1 in pre term placentae (n=19, r 
= 0.982**, p =0.000). 
 
 
 
 
The variable mPRβ showed a positive correlation (r = 0.802**, p =0.000, n=19) with mPRγ 
variable in the pre term category and this correlation is seen in graph in Fig.3.44.  
 
Figure 3.44: Correlation graph between mPRβ and mPRγ in pre term placentae (n=19, r = 
0.802**, p =0.000). 
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The variable mPRγ showed a positive correlation (r = 0.527*, p =0.020, n=19) with PR-B 
variable in the pre term category and this correlation is seen in graph in Fig.3.45.  
 
 
 
Figure 3.45: Correlation graph between mPRγ and PR-B in pre term placentae (n=19, r = 
0.527*, p =0.020). 
 
 
From the next category, placentas from the labouring cohort, a table (Table 3.6) has been 
constructed once the correlations of the expression values of the genes of interest were 
examined in this category. The levels of correlation coefficient (r) are reported and the red 
asterisks indicate the levels of significance (** <0.001).  
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  mPRα L mPRβ L mPRγ L PGRMC-1 L PR-B L 
 
 
mPRα L 
 
Pearson Correlation 
 
1 
 
-0.152 
 
-0.081 
 
0.891** 
 
-0.164 
 
Sig. (2-tailed) 
 
 
0.449 
 
0.688 
 
0.000 
 
0.415 
 
 
mPRβ L 
 
Pearson Correlation 
 
-0.152 
 
1 
 
0.687** 
 
-0.115 
 
0.590** 
 
Sig. (2-tailed) 
 
0.449 
 
 
0.000 
 
0.566 
 
0.001 
 
 
mPRγ L 
 
Pearson Correlation 
 
-0.081 
 
0.687** 
 
1 
 
-0.052 
 
0.279 
 
Sig. (2-tailed) 
 
0.688 
 
0.000 
 
 
0.797 
 
0.159 
 
 
PGRMC-1 L 
 
Pearson Correlation 
 
0.891** 
 
-0.115 
 
-0.052 
 
1 
 
-0.119 
 
Sig. (2-tailed) 
 
0.000 
 
0.566 
 
0.797 
 
 
0.553 
 
 
PR-B L 
 
Pearson Correlation 
 
-0.164 
 
0.590** 
 
0.279 
 
-0.119 
 
1 
 
Sig. (2-tailed) 
 
0.415 
 
0.001 
 
0.159 
 
0.553 
 
 
Table 3.6: Levels of correlation between values (n=27) of mPRs, PGRMC-1 and PR-B. Red 
asterisks indicate significance of the correlation (** Significant at the 0.01 level).  
 
 
The first correlation observed in this category, were the variables mPRα and PGRMC-1, 
where a positive correlation was seen (r = 0.891**, p =0.000, n=27) in Fig.3.46. 
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Figure 3.46: Correlation graph between mPRα and PGRMC-1 in labouring placentae (n=27, 
r = 0.891**, p =0.000). 
 
 
Following, a correlation between the expression of mPRβ and mPRγ (Fig.3.47) was detected 
with a correlation coefficient (r) value of 0.687** and sifnificance (0.000). 
 
 
Figure 3.47: Correlation graph between mPRβ and mPR in labouring placentae (n=27, r = 
0.687**, p =0.000). 
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Again in the labouring samples, variable mPRβ showed a positive correlation (r = 0.590**, p 
=0.001, n=27) with PR-B variable and this correlation is seen in graph in Fig.3.48.  
 
 
Figure 3.48: Correlation graph between mPRβ and PR-B in labouring placentae (n=27, r = 
0.590**, p =0.001). 
 
 
A table (Table 3.7) has been constructed from the values obtained in the non labouring 
placental samlples once the correlations of the expression values of the genes of interest were 
examined in this category.  
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  mPRα NL mPRβ NL mPRγ NL PGRMC-1 NL PR-B NL 
 
 
mPRα NL 
 
Pearson 
Correlation 
 
1 
 
-0.205 
 
-0.124 
 
0.998** 
 
-0.140 
 
Sig. (2-tailed) 
 
 
0.482 
 
0.674 
 
0.000 
 
0.633 
 
 
mPRβ NL 
 
Pearson 
Correlation 
 
-0.205 
 
1 
 
0.620* 
 
-0.177 
 
0.736** 
 
Sig. (2-tailed) 
 
0.482 
 
 
.018 
 
0.546 
 
0.003 
 
 
mPRγ NL 
 
Pearson 
Correlation 
 
-0.124 
 
0.620* 
 
1 
 
-0.092 
 
0.927** 
 
Sig. (2-tailed) 
 
0.674 
 
0.018 
 
 
0.754 
 
0.000 
 
 
PGRMC-1 NL 
 
Pearson 
Correlation 
 
0.998** 
 
-0.177 
 
-0.092 
 
1 
 
-0.101 
 
Sig. (2-tailed) 
 
0.000 
 
0.546 
 
0.754 
 
 
0.731 
 
 
PR-B NL 
 
Pearson 
Correlation 
 
-0.140 
 
0.736** 
 
0.927** 
 
-0.101 
 
1 
 
Sig. (2-tailed) 
 
0.633 
 
0.003 
 
0.000 
 
0.731 
 
 
Table 3.7: Levels of correlation between log values (n=27) of mPRs, PGRMC-1 and PR-B. 
Red asterisks indicate significance of the correlation (** Significant at the 0.01 level, * 
significant at the 0.05 level).  
 
The ΔCt values of the respective genes were plotted against each other for the variables 
where a correlation was seen in the non labouring placenta.  The first two variables as seen 
from the graph in Fig.3.49 were mPRα and PGRMC-1 showing a positive correlation (r = 
0.998**, p =0.000, n=14). 
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Figure 3.49: Correlation graph between mPRα and PGRMC-1 in non labouring placentae 
(n=14, r = 0.998**, p =0.00). 
 
 
 
Variable mPRβ showed a positive correlation (r = 0.736*, p =0.003, n=14) with PR-B 
variable in the non labouring category and this correlation is seen in graph in Fig.3.50.  
 
Figure 3.50: Correlation graph between mPRβ and PR-B in labouring placentae (n=14, r = 
0.736**, p =0.003). 
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Lastly, a correlation was detected between the variable mPRγ showed a positive correlation (r 
= 0.927**, p =0.000, n=14) and PR-B variable in the non labouring category and this 
correlation is seen in graph in Fig.3.51.  
 
 
 
Figure 3.51: Correlation graph between mPRγ and PR-B in non labouring placentae (n=14, r 
= 0.927**, p =0.000). 
 
 
Information on placental weight was obtained from only 23 patients participating in the 
study, as the sample number was relatively small the samples were treated as one group 
instead of four separate categories. The information was used to correlate the weight of the 
placenta with the expression of PRs and establish significance. No correlation was found for 
placental weight and mPRα, mPRβ, mPRγ and PGRMC-1 although the expression of mPRα 
and mPRγ in correlation with placental weight showed a trend, albeit non-significant. A 
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negative correlation (r= -0.462, p= 0.040, n=23) was detected between PR-B and the weight 
of the placentae (Table 3.8).  
 
 
Correlation of PR with placental weight  
Log_mPRα 
Pearson Correlation 
 
Significance 
0.419 
0.066 
Log_mPRβ 
Pearson Correlation 
 
Significance 
-0.284 
0.225 
Log_mPRγ 
Pearson Correlation 
 
Significance 
-0.433 
0.057 
Log_PGRMC-1 
Pearson Correlation 
 
Significance 
-0.264 
0.261 
Log-PR-B 
Pearson Correlation 
 
Significance 
-0.462 
0.040* 
 
Table 3.8: Correlation of placental weight of 23 samples with the expression of mPRs, 
PGRMC-1 and PR-B. 
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3.8. Discussion 
3.8.1. Human placenta and the expression of progesterone receptors 
In order to gain a better insight and to correlate our in vitro findings with clinical samples a 
large human placenta tissue bank was set up comprising of samples at different contractile 
states (labour or non-labour) and times of delivery (term or pre-term). All mPR isoforms 
were expressed in our placental tissues, with mPRα and PGRMC-1 genes showing the 
highest expression in the term and labour group whereas mPRβ and mPRγ were shown to 
have the highest expression in the pre term group and the labour group. Variation in the 
expression of these genes was observed among the individual patients. Our study was drawn 
entirely from Cretan patients, a genetically homogenous Caucasian population. Caution must 
be taken when comparing these results with studies where a high ethnical diversity is 
observed in the population.  
The presence of mPRα transcript was shown previously in the human placenta by the Thomas 
group and at the time it had been suggested that as this was the major transcript it would also 
be the major subtype mediating the rapid, non-genomic actions of progesterone in the 
placenta (Zhu et al., 2003
B
). Our study though shows the presence of all three mPR subtypes 
as well as PGRMC-1 in the human placenta and when category analysis was performed, 
mPRα was found to be the major transcript in two categories (labour and term) and also 
exhibited a high 75
th
 percentile in the non labour category thus leading to the conclusion that 
the expression of mPRα depend on the time and mode of delivery.  
In the human placenta mPRα was localised in the synsytia layer demonstrating a higher 
intensity signal compared to that detected in the cytotrophoblast cells.  This is in agreement 
with a study by Fernandes et al, demonstrating that mPRα expression is restricted to the 
syncytiotrophoblast at the periphery of term chorionic villi (Fernandes et al., 2005). mPRβ 
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was localised in the syncytia layer and the cytotrophoblast cells beneath the multinucleated 
layer, where a higher signal intensity was detected. mPRγ was also localised in both cell 
types of the human placenta, this time the signal intensity observed in the cytotrophoblasts 
was almost the same as the signal intensity in the syncytia layer. Apart from mPRα, which its 
presence was reported in term placentae, mPRβ and mPRγ have not been localised in the 
human placenta before.  
We have localised the PGRMC-1 protein in the syncytium, where it is present in the 
cytoplasm as well as in the plasma membrane and also in the cytotrophoblast cells exhibiting 
mainly membrane staining. These findings agree and also extend the results described by 
Zhang et al., where they only detected this protein in the syncytiotrophoblast cells (Zhang et 
al., 2008).  
Earlier studies demonstrated expression of PR mRNA in human term placental samples 
(Shanker & Rao, 1998). At protein level, they demonstrated only the presence of PR-A but 
not PR-B in their samples (Shanker & Rao, 1998). At gene level, we identified the presence 
of PR-B in our placental tissue bank with the highest expression of PR-B being detected in 
the term and labour category.   
Interestingly, the tissue expression of the mPRα transcript was correlated with the expression 
of PGRMC-1 in all four categories where this protein – protein interaction is supported by the 
STRING analysis.   Expression of mPRβ was significantly correlated in a positive manner to 
the expression of mPRγ and PR-B. No predicted interactions with either protein were 
detected by the STRING database. The placental expression of mPRγ transcript was 
significantly correlated to the expression the nuclear PR-B in the pre term and the non labour 
caegories, an interaction indicated also by the STRING database (See Appendix I). 
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It is evident that the nuclear PR-B is the only transcript that shows positive and negative 
correlations with all mPR gene transcripts in the human placenta suggesting a differential 
regulatory pathway for these receptors in the human placenta as these receptors have a 
different expression pattern distinguished by time and mode of delivery. A plausible 
explanation for the correlation between mPRs and PR-B may be the transactivation ability of 
PR-B by mPRs which has been reported to exist in the human myometrium (Karteris et al., 
2006).   
The placental weight in our cohort showed a negative correlation with the expression of the 
nuclear PR-B indicating a possible inverse relationship between the growth ability of this 
organ and the progesterone receptor. A positive trend, albeit non-significant, between the 
expression of mPRα and mPRγ was also detected indicating a possible differential regulation 
of these genes arising from the actions of progesterone mediated by these receptors. The 
growth of the human placenta may indeed be regulated in a positive manner by the membrane 
progesterone receptors and in a negative manner by the nuclear receptors.  PRs may stimulate 
the production and secretion of progesterone at the beginning of the pregnancy where the 
need of progesterone to support the pregnancy is more demanding and as a steady rise is seen 
during the gestation period this may create an internal feedback loop in this transient 
reproductive organ.  
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3.9. Functionality of membrane Progesterone Receptors – mPRs & 
PGRMC-1 
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The functionality of progesterone receptors (mPRs & PGRMC-1) was investigated once the 
detailed expression of these receptors in two placental cell lines and in human placental 
samples was accomplished. IL-1β, a pro-inflammatory cytokine was used to treat BeWo CT 
and JEG-3 cells for 24 hours. This cytokine has been shown to be able to modulate the 
proliferation of trophoblast cells and also it has been associated with trophoblast 
differentiation. In abnormal pregnancy pathophysiologies such as pre-eclpampsia, IUGR and 
preterm labour the levels of IL-1β cytokine are elevated (Rossi et al., 2005). 
Once BeWo CT and JEG-3 cells were grown to confluence (~70%) combination treatments 
at different concentrations were performed and trypan blue assay was used to investigate the 
effect of the treatments on trophoblast cell death. 
The following compounds and concentrations were used during the treatments:  
Compound Stock Concentration Final concentration 
Progesterone - a known 
activator of mPRs, 
PGRMC-1 and PRs 
 
10
-1 Μ 
 
1nM, 10nM, 100nM, 
1000 nM ± U0126 (1μM) 
 
10-ethenyl-19-
norprogesterone (OD 02-0) 
– a selective agonist of 
mPRα 
10
-3 Μ 
1nM, 10nM, 100nM, 
1000 nM ± U0126 (1μM) 
 
Promegestone  (R5020) - 
a specific agonist of nPR 
10
-2
 M 30nM ± U0126 
U0126 – a selective 
MEK1/2 inhibitor  
10
-3 
M 1μM 
IL-1β  10ng/μl 
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Fig. 3.52 depicts the percentage of dead cells following a 24 hour treatment with P4 and OD 
02-0. Controls (NS) cells were not treated and established the “baseline” of cell death in 
BeWo CT cells. Exposure of BeWo CT cells to 10 nM, 100 nM and 1000 nM of P4 
significantly decreased the percentage of dead cells by 5.5 fold, 1.8 fold and 6.7 fold 
respectively over the untreated BeWo CT cells.  When the BeWo CT cells were incubated 
with OD 02-0 no significant changes in the percentage of dead cells were observed, although 
there was a general trend towards a reduction in cell death. 
 
 
 
Figure 3.52: Percentage of dead BeWo CT cells following treatment with 1nM, 10nM, 
100nM, 1000nM of Progesterone (red) and OD 02-0 (blue) following a 24hr incubtation. 
Each histogram represents the mean ± SEM of three individual experiments. Red and blue 
lines indicates significance of treated cells with NS (p< 0.05*). 
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BeWo CT cells were co-incubated with 10ng/μl of the cytokine IL-1β and 1 nM –1000 nM 
P4 or OD 02-0 before assessing cell death by trypan blue exclusion assay. Fig. 3.53 shows 
that the percentage of dead BeWo CT cells after treatment with IL-1β significantly increased 
3 fold over the NS BeWo CT cells.When BeWo CT cells were treated with 100 nM of P4 in 
the presence of 10ng/μl IL-1β it significantly reduced 5.5 fold the percentage of dead cells 
compared to the IL-1β treated BeWo CT cells. A significant 3.3 fold reduction in the 
percentage of dead BeWo CT cells was detected when the cells were treated with 1000nM of 
P4 in parallel with 10ng/μl IL-1β compared to the IL-1β treated BeWo CT cells. When the 
cells were incubated with OD 02-0 in parallel to 10ng/μl IL-1β, a significant decrease in the 
percentage of dead cells was detected, specifically with 10 nM a 6.4 fold decrease, with 100 
nM a 7.6 fold decrease   and with 1000nM a 2.6 fold decrease compared to the BeWo CT 
cells treated with 10ng/μl IL-1β alone (Fig 3.53). 
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Figure 3.53: Percentage of dead BeWo CT cells following combination treatment with IL-1β 
(10ng/μl) and various concentrations of progesterone (red) or OD 02-0 (blue) (1-1000nM) 
following a 24hr incubtation. Each histogram represents the mean ± SEM of three individual 
experiments. Red and blue lines indicate significance of NS with IL-1β alone and treated 
cells with IL-1β alone (p< 0.05*). 
 
 
 
BeWo CT cells were pre-incubated with the MEK1/2 inhibitor, UO126 prior to treating with 
P4 or OD 02-0 at a range of concentrations (1 nM – 1000 nM) in the presence of 10ng/μl of 
IL-1β. The graph in Fig.3.54 illustrates the percentage of dead BeWo cells obtained after 
performing a trypan blue exclusion assay.  Cells exposed to 1000 nM of P4 in the presence of 
IL-1β and having MEK1/2 activity inhibited by UO126, showed a significant 5.5 fold decrease 
in the percentage of BeWo CT dead cells compared to the percentage of dead cells detected 
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after exposure to IL-1β alone. The percentage of dead cells was significantly higher when 
cells were treated with IL-1β compared to the non-treated cells. When OD 02-0 was used to 
treat the UO126 pre-incubated cells in the presence of IL-1β a significant lower percentage of 
dead cells was observed when using 10 and 100 nM of OD 02-0. The percentage of dead cells 
was decreased by 3.2 fold and 5.4 fold respectively in comparison to the percentage of dead 
cells detected when treating the cells with IL-1β only (Fig 3.54).  
 
 
 
Figure 3.54: Percentage of dead BeWo CT cells after pre-incubating cells with UO126 
(1μM) and performing combination treatment with IL-1β (10ng/μl) and various 
concentrations of progesterone (red) or OD 02-0 (blue) (1-1000nM) following a 24hr 
incubtation. Each histogram represents the mean percentage ± SEM of three individual 
experiments (p < 0.05*). Red and blue lines indicate significance of NS with IL-1β alone and 
IL-1β alone with treated cells. 
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A specific nPR agonist, R5020 was used to treat BeWo CT cells at a concentration of 30 nM. 
This compound was used alone to treat cells,  in the presence of IL-1β (10ng/μl) and 
repeating the combination treatment but pre-incubating the cells with UO126 for 30 minutes 
prior to adding the 24 hour treatment.  Graphical representation in Fig.3.55 shows the 
percentage of dead BeWo CT cells following the treatments and assessing cell death by 
trypan blue exclusion assay. BeWo CT cells treated with IL-1β  showed significant increase 
in the percentage of cell death when compared to NS and R5020 treated cells. In comparison 
to IL-1β only treated cells, the percentage increased significanlty (2 fold) when the cells were 
pre-incubated with UO126 and co-treated with R5020 and  IL-1β (Fig 3.55). 
 
Figure 3.55: Percentage of dead BeWo cells after treating cells with R5020, R5020 + IL-1β 
(10ng/μl) and pre-incubating cells with UO126 and combination treatment with IL-1β 
(10ng/μl) + R5020 following a 24hr incubtation. Each histogram represents the mean ± SEM 
of three individual experiments (p < 0.05*). Blue line indicates significance of the percentage 
of dead cells obtained after treating cells with IL-1β alone compared to NS and R5020 and 
upon comparison of  pre-incubating cells with UO126 and treating with R5020 + IL-1β with 
IL-1β treated cells.  
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The same sets of treatments were performed in the second in vitro model the JEG-3 cell line. 
The percentage of dead cells was assessed by trypan blue exclusion assay after the period of 
24 hour. The first set of results is presented in Fig.3.56 where the percentage of dead JEG-3 
cells was identified following treatment with P4 and OD 02-0 at different concentrations 
(1nM, 10nM, 100nM, 1000nM). Exposure of JEG-3 cells to 100 and 1000 nM of P4 
significantly increased the percentage of dead cells 2.4 fold and 3.3 fold respectively over 
NS. Exposure of JEG-3 cells to OD 02-0 resulted in a significant increase of the percentage 
of dead cells detected. At 1 nM of OD 02-0 the increase over NS was 3.8 fold, at 10 nM of 
OD 02-0 was 5 fold, at 100 nM of OD 02-0 was 6.7 fold and at 1000 nM the increase was 2.3 
fold over NS (Fig 3.56). 
 
 
 
Figure 3.56: Percentage of dead JEG-3 cells following treatment with 1nM, 10nM, 100nM, 
1000nM of Progesterone (red) and OD 02-0 (blue) following a 24hr incubtation. Each 
histogram represents the mean ±SEM of three individual experiments (p < 0.05*). Red and 
blue lines indicate significance of treated cells with NS.  
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JEG-3 cells were then treated with the cytokine IL-1β (10ng/μl) alone and in the presence of  
P4 or OD 02-0 at the same concentration range as before. By staining with trypan blue the 
number of dead JEG-3 cells was calculated and the percentage of dead cells is depicted in 
Fig.3.57. Incubating JEG-3 with 10ng/μl of IL-1β resulted in an 18 fold increase of the 
percentage of dead cells over the percentage of dead cells  of the non treated cells. When 
JEG-3 cells were co-incubated with 10ng/μl of IL-1β and 1-1000 nM of P4 the high 
incidence of cell death was  reduced significantly. 1 nM of P4 reduced the percentage of dead 
JEG-3 cells by 8 fold, 10 nM of P4 reduced the rate of cell death by 7.5 fold, 100 nM of P4 
by 8.3 fold wehereas 1000 nM of P4 significanly reduced the rate of cell death by 208 fold  
compared to the percentage of dead cells detected when treating the cells with IL-1β alone 
(Fig 3.57) . When OD 02-0 was used to treat cells in parallel to IL-1β, significant reduction in 
the percentage of dead cells recorderd was achieved when 1 nM, 100 nM and 1000 nM where 
applied. The mean percentage of dead cells was significanlty reduced by 11 fold, 3 fold and 
24 fold respectively compared to the percentage of dead cells detected when treating the cells 
with IL-1β alone (Fig 3.57). 
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Figure 3.57: Percentage of dead JEG-3 cells following treatment with IL-1β (10ng/μl) and 
various concentrations of progesterone (red) and OD 02-0 (blue) (1-1000nM) following a 
24hr incubtation. Each histogram represents the mean ±SEM of three individual experiments. 
Red and blue lines indicate significance of NS with IL-1β alone and treated cells with IL-1β 
alone (p < 0.05*, p < 0.001 **). 
 
 
For the next set of treatments, before treating JEG-3 cells with IL-1β (10ng/μl) and either of 
the two compounds P4 and OD 02-0 (1 nM – 1000 nM), the cells were pre-incubated with 
UO126 (1 μM) for 30 minutes. The results obtained from the trypan blue exclusion assay are 
illustrated below in Fig.3.58.  
The 18 fold increase in the percentage of JEG-3 dead cells treated with IL-1β over the non-
treated cells was significanlty reduced when the UO126 pre- treated cells were co-incubated 
with IL-1β and 1, 100 and 1000 nM of either P4 or OD 02-0. JEG-3 cells pre-treated with 
UO126 and then co-incubated with 10ng/μl of  IL-1β and 1nM of P4 showed a significant 
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reduction in the percentage of dead cells recorded by 2.8 fold compared to the IL-1β only 
treated cells. Whereas when 100nM of P4 was used it reduced the cell death by 3.7 fold and a 
4.5 fold reduction was recorded when 1000nM of P4 was used in this set of co-treatments. 
When the second compound (OD 02-0)was used to treat the pre-treated with UO126 JEG-3 
cells in the presecne of 10ng/μl of  IL-1β, a subtle reduction (1.7 fold) in the percentage of 
dead cells was detected when 1nM of OD 02-0 was used compared to the percentage of dead 
cells recorded once cells were treated with 10ng/μl of  IL-1β alone. When 100nM of OD 02-0 
were used to co-incubate cells with, a 2.5 fold decrease in the percentage of dead cells was 
observed and the same fold decrease was also detected when 1000nM of OD 02-0 were 
administrated, all compared to the IL-1β only treated JEG-3 cells.  
 
 
 
Figure 3.58: Percentage of dead JEG-3 cells after pre-incubating cells with UO126 and 
combination treatment with IL-1β (10ng/μl) and various concentrations of progesterone (red) 
and OD 02-0 (blue) following a 24hr incubtation. Each histogram represents the mean ± SEM 
of three individual experiments (p < 0.05*). Red and blue lines indicate significance of NS 
with IL-1β alone and treated cells with IL-1β alone. 
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Lastly, the nPR specific activator R5020 (30 nM) was administrated to the JEG-3 cells either 
alone, in parallel with 10ng/μl IL-1β and repeating the combination treatment but pre-
incubating the cells with with UO126 for 30 minutes prior to adding the 24 hour treatment.  
Fig. 3.59 depicts the percentage of JEG-3 dead cells recorded after performing the treatments 
and assessing cell death by trypan blue exclusion assay.  
Exposure of JEG-3 to IL-1β significanlty increased the percentage of dead cells by 18 fold 
and 6.6 fold over NS and R5020 respectively. When cells were co-incubated with R5020 and 
IL-1β a significant 20 fold decrease was detected compared to the IL-1β only treated cells. 
When the same co-incubation was performed on UO126 pre-treated cells a significant 10 fold 
reduction was detected compared to the IL-1β only treated JEG-3 cells (Fig. 3.59). 
 
Figure 3.59: Percentage of dead JEG-3 cells after treating cells with R5020, R5020 + IL-1β 
(10ng/μl) and pre-incubating cells with UO126 and combination treatment with IL-1β 
(10ng/μl) + R5020 following a 24hr incubtation. Each histogram represents the mean ± SEM 
of three individual experiments (p < 0.05*). Blue lines indicate significance of the increase in 
percentage of dead cells after treating cells with IL-1β compared to NS and R5020. 
Significant decrease obtained after pre-incubating cells with UO126 and treating cells with 
R5020 + IL-1β, and by treating cell with R5020 + IL-1β compared to IL-1β only treated cells. 
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3.9.1. Effect of IL-1β combinational treatments on the expression of 
membrane Progesterone Receptors (mPRs and PGRMC-1). 
As the objective was to examine the functionality of the membrane progesterone receptors in 
our placental cell lines, BeWo CT and JEG-3 cells were treated with IL-1β (10ng/μl), P4 
(100nM), OD 02-0 (100nM) and combination treatments of IL-1β (10ng/μl) + P4 (100nM) 
and IL-1β (10ng/μl) + OD 02-0 (100nM) for 24 hours. The expression of membrane 
progesterone receptors (mPRs and PGRMC-1) was assessed by Q-PCR analysis to establish 
the relative quantity values (RQ). 
 The expression of mPRα in both cell lines following the 24 hour treatments was obtained 
and the RQ values are depicted in Fig.3.60. In BeWo CT cells the expression of mPRα was 
significantly down-regulated 6.8 fold after treating the cells with P4 in the presence of IL-1β. 
Even though an altered expression in comparison to non-treated cells was seen for mPRα in 
BeWo CT cells following different treatments, the results were not significant. After treating 
JEG-3 cells with IL-1β the expression of mPRα was detected to be significantly 7.1 fold 
down regulated compared to NS (Fig. 3.60). Also significant down-regulation of this gene 
was detected following the next set of treatments. With P4 a 5.2 fold decrease was detected, 
with OD 02-0 a 7 fold decrease, P4 and IL-1β a 9.9 fold decrease and OD 02-0 and IL-1β a 
5.5 decrease in mPRα gene expression compared to NS. 
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Figure 3.60: RQ values of the expression of mPRα in BeWo and JEG-3 cells after treating 
with IL-1β, P4, OD 02-0, IL-1β + P4, IL-1β + OD 02-0. Each histogram represents the mean 
± [2-ΔΔSD (+) - 2-ΔΔSD (-)]   of three individual experiments. Statistical significant differences 
are shown by blue and red lines and were determined using t-test (p < 0.05*, p < 0.001**). 
Red line indicates significant decrease in the expression of mPRα in BeWo CT cells treated 
with IL-1β + P4 compared to the NS. Blue lines indicates significant decrease in the 
expression of mPRα in JEG-3 cells treated with IL-1β, P4, OD 02-0, IL-1β + P4, IL-1β + OD 
02-0 compared to the NS. 
 
 
The expression levels of mPRβ were evaluated in BeWo CT and JEG-3 cells after treating the 
cells with the compounds stated above. The RQ values are indicated in the graph in Fig.3.61. 
In BeWo CTcells, the expression of mPRβ was significanlty 7.1 fold down-regulated after 
treating cells with P4, it was 15.4 fold downregulated when cells where treated with P4 in the 
presence of  IL-1β compared to the expression in the non-treated cells. Treating BeWo CT 
cells with OD 02-0 in the presence of IL-1β resulted in a 3 fold increase in the expression 
levels of mPRβ over the expression levels detected in NS (Fig. 3.61).  
mPRα 
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When JEG-3 cells were treated with IL-1β a significant 7.1 fold decrease in the expression of 
mPRβ was detected compared to the expression in the non-treated cells. Treatment of JEG-3 
cells with P4 in the presence of IL-1β resulted in a significant 8.6 increase in the expression 
levels of this gene compared to NS, whereas co-treatment with OD 02-0 in the presence of 
IL-1β indicated a significant 8.7 increase in the expression levels of mPRβ compared to the 
non treated cells (Fig. 3.61). 
 
 
Figure 3.61: RQ values of the expression of mPRβ in BeWo and JEG-3 cells after treating 
with IL-1β, P4, O2, IL-1β + P4, IL-1β + O2. Each histogram represents the ± [2-ΔΔSD (+) - 2-
ΔΔSD
 (-)]   of three individual experiments. Statistical significant differences are shown by 
blue and red lines and were determined using t-test (p < 0.05*). Red lines indicate significant 
changes  in the expression of mPRβ in BeWo CT cells treated with P4, IL-1β + P4 and IL-1β 
+ OD 02-0. Blue lines indicate significanct changes in the expression of mPRβ in JEG-3 cells 
treated with IL-1β,  IL-1β + P4, IL-1β + OD 02-0. 
 
After treating the trophoblast cell lines as previously the expression of mPRγ was calculated 
following Q-PCR analysis of the samples. The results are indicated below in Fig.3.62. Co-
mPRβ 
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treatment with  P4 with IL-1β decreased significantly by 9.1 fold the expression of mPRγ in 
BeWo CT cells when compared to the non-treated samples. In JEG-3 cells the expression of 
mPRγ was 11 fold down-regulated following treatment with IL-1β. 
 
 
 
Figure 3.62: RQ values of the expression of mPRγ in BeWo and JEG-3 cells after treating 
with IL-1β, P4, OD 02-0, IL-1β + P4, IL-1β + OD 02-0. Each histogram represents the mean 
± [2-ΔΔSD (+) - 2-ΔΔSD (-)] of three individual experiments. Statistical significant differences 
are shown by blue and red lines and were determined using t-test (p < 0.05*). Red line 
indicates significanct changes in the expression of mPRγ in BeWo cells treated with IL-1β + 
P4. Blue line indicates significanct changes in the expression of mPRγ in JEG-3 cells treated 
with IL-1β. 
 
 
 
 
Lastly, the expression of PGRMC-1 was examined in our placental cell lines that were treated 
with the same compounds as previously. The RQ values obtained are indicated in Fig.3.63. 
The expression of PGRMC-1 was significanly down-regulated by 10.1 fold as a result of 
mPRγ 
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treating the BeWo CT cells with P4 in the presence of IL-1β compared to the NS. In JEG-3 
cells significant increase was detected in the expression of this gene following treatment with 
P4, OD 02-0, and repeating the same treatments in the presence of IL-1β. The fold increase 
over NS respectively was 6.5, 7.6, 4.4 and 6.4. 
 
 
 
Figure 3.63: RQ values of the expression of PGRMC-1 in BeWo and JEG-3 cells after 
treating with IL-1β, P4, O2, IL-1β + P4, IL-1β + O2. Each histogram represents the mean ± 
[2
-ΔΔSD
 (+) - 2
-ΔΔSD
  (-)] of three individual experiments. Statistical significant differences are 
shown by blue and red lines and were determined using t-test (p < 0.05*). Red line indicates 
significance in the expression of PGRMC-1 in BeWo cells treated with IL-1β + P4. Blue 
lines indicate significant changes in the expression of PGRMC-1 in JEG-3 cells treated with 
P4, OD 02-0, IL-1β+P4, IL-1β + OD 02-0. 
 
 
PGRMC-1 
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3.10. Discussion 
3.10.1. Effects of progestins on cell proliferation 
IL-1β is a proinflammatory cytokine which at the early stages of pregnancy is produced and 
secreted by the maternal decidua (Romero et al., 1989). There have been studies suggesting a 
role for this cytokine during pregnancy. Specifically, this cytokine may potentially be an 
inducer of placental trophoblast invasion by stimulating the release of metalloproteinase 
(MMP-9) by human placental cytotrophoblast (Librach et al., 1994). Also it has been 
associated with trophoblast cell differentiation by increasing the production of hCG hormone 
in isolated first trimester villous trophoblast (Yagel et al., 1989) as well as in JEG-3 human 
choriocarcinoma cell line (Seki et al., 1997). The action of this cytokine on the stimulation of 
proliferation of human first trimester extravillous trophoblast cell lines (Nilkaeo et al., 2000
A
) 
was shown by inducing growth factors such as IL-6 and leukemia inhibitory factor (LIF) 
(Nilkaeo et al., 2000
B
; Nilkaeo et al., 2000
C
).  
Cytokines participate in complex networks and under balanced production and function, a 
successful human pregnancy can be achieved (Orsi, 2008). hCG - induced release by IL-1β 
have been shown in first trimester placentae indicating a direct role of IL-1β in pre-eclampsia 
(Masuhiro et al., 1991), as increased concentrations of hCG have been associated with this 
pahtophysiology (Hsu et al., 1994). Recently, a study has shown that in women with pre-
eclapmpsia significantly increased levels of IL-1β and hCG were found compared to controls 
individuals (Kalinderis et al., 2011)  
IL-1β mediated apoptosis in placental cells has been shown in a recent study (Nilkaeo & 
Bhuvanath, 2006); also the involvement of this cytokine in pregnancy pathophysiologies such 
as pre-eclampsia (Wenstrom et al., 1994) and preterm labour (Romero et al., 2005) has been 
documented. Apoptosis has been induced in cytotrophoblast and syncytiotrophoblast in 
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culture by addition of TNF-α and IFN-γ cytokines and the apoptotic action of these cytokines 
has been rescued by EGF (Garcia-Lloret et al., 1996). Further research indicated that 
additional “survival” factors existed able to inhibit these apoptotic actions.  Growth factors, 
such as bFGF, IGF-1, and PDGF-AA were shown to significantly inhibit the TNF-α and IFN-
γ mediated apoptosis in placental cells (Smith et al., 2002). Others have shown anti-apoptotic 
effects of the steroid hormone progesterone in granulosa cells of the ovary, where this effect 
was PR-specific and was reversed when RU486, an antiprogestin was used (Peluso & 
Pappalardo, 1998). Also progesterone - induced suppression of apoptosis was recently 
demonstrated in the rat mammary gland during lactation (Berg et al., 2002). 
As evidence exist of progesterone mediated anti-apoptotic effects in organs of the female 
reproductive system (Berg et al., 2002; Peluso & Pappalardo, 1998), we tested the hypothesis 
that progesterone may have anti apoptotic effect on placental cells reversing the adverse 
effect of treatment with the proinflammatory cytokine IL-1β. 
Our results show increased percentage of BeWo CT cell death upon 24 hour treatment with 
IL-1β compared to the non-treated cells. These findings corroborate a previous study 
performed on JAR choriocarcinoma cells where a dosage of IL-1β induced a 1.8 fold increase 
in cell death (Nilkaeo & Bhuvanath, 2006). 
In accordance with previous studies (Berg et al., 2002), our results illustrate that progesterone 
reduces the percentage of BeWo CT dead cells compared to the basal levels at different 
dosages over a period of 24 hours, a result not seen when using a selective mPRα agonist. 
These findings indicate a level of complexity of the involved progesterone receptors, where 
synergistic actions between all different PRs promote a rescuing effect.  
Co-incubation of BeWo CT cells with IL-1β and different dosages of progesterone or OD 02-
0, an mPRα selective agonist rescued cells from death. A more sensitive response is seen when 
Fu nc t io na l  S tud ie s   Chap te r  3  
 
168 
treating cells with OD 02-0, as being a selective agonist the rescuing effect is detected with a 
lower dose than progesterone.  Treating cells with OD 02-0, inhibition of cell death was 
firstly observed at 10nM, and subsequently at 100nM and 1000nM whereas with 
progesterone the inhibition of cell death was obvious at 100nM and 1000nM. 
As the signalling capacity of nuclear PR can be compromised due to overexpression of the 
chaperone protein hsp 70 and hsp 90 in BeWo cells keeping the receptor in an inactive state, 
this may explain the “inability” to dissociate and act upon co-treatment with the cytokine and 
the nuclear progesterone receptor agonist, R5020.This observation is further strengthened as 
the percentage of cell death was found to be the same when treating the cells with R5020 as 
with the non-treated cells. Pre-incubating cells with a MEK inhibitor, results in an increased 
percentage of cell death which is higher than the percentage recorded when treating cells with 
IL-1β alone. This may be an indicator of the involvement of the MAPK signalling pathway in 
the rescuing effect upon activation of the nuclear PR, where “switching off” this pathway 
renders cells incapable of reversing the effect when the R5020 mediated responses are 
blocked.  In contrast, JEG-3 cells that do not overexpress these chaperone proteins, the 
phenomenon of cell death is rescued upon co-incubation of the cytokine with R5020. 
Compared to the BeWo cells the JEG-3 cells upon treatment with the cytokine showed a 
higher percentage of dead cells. This may be the result of an upreglation of interleukin 1 
receptor, which according to an extensive microaaray analysis in both cell lines, was shown 
to be upregulated in the JEG-3 cells accounting for the sensitivity shown to this cytokine 
(Burleigh et al., 2007). Upon co-treatment of JEG-3 cells with IL-1β and progesterone a 
reduction in the percentage of cell death is seen in comparison to the cytokine only treated 
cells. A dramatic reduction is seen when 1000nM of P4 was used. It should be taken into 
consideration the fact that since treatment was for 24 hours it is plausible that P4 could 
activate multiple PRs in parallel. Beyond the anti apoptotic effects of progesterone, OD 02-0 
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was shown to be able to mediate inhibitory effects as well. Blockage of MEK activity prior to 
treating the cells with progestins and IL-1β was shown to rescue cells from the effect of the 
cytokine. Whereas this rescuing effect is exacerbated when the MEK activity is not blocked 
thus indicating a partial block of the MEK activity was achieved. The rescuing effect seen 
upon treatment with progestins is assumed to be via all receptors as no further distinction can 
be made. Research has shown that MAPK signalling pathway mediates the increase 
proliferation and survival of the extravillous trophoblast cells (Nilkaeo et al., 2001). 
The complex nature of progesterone’s actions are further corroborated by recent studies that 
show P4 induced inhibition of cisplatin-mediated apoptosis in ovarian cancer cells both in 
vitro and in vivo (Wehling & Losel, 2006). The ability of progesterone to either induce or 
inhibit apoptosis has been a reason why ovarian cancer clinical trials have failed to present a 
beneficial effect of progesterone on the progression of this cancer (Cahill, 2007). The anti-
apoptotic effects of progesterone cannot be attributed to be solely mediated by PRs, as other 
putative mediators of the action of progesterone have been shown to be expressed, such as the 
mPRs (Zhu et al., 2003
B
) and PGRMC-1 (Meyer et al., 1996). 
It is evident from our study that a PR synergy could be in place leading to the “rescuing” 
effect observed. A ligand dependent PR-B transactivation by mPRs has been described 
previously in the human myometrium (Karteris et al., 2006), a scenario that cannot be ruled 
out in this study where progesterone or OD 02-0 activation of mPR signalling may potentiate 
the nuclear PR, thus having an inhibitory effect on cell apoptosis.  Indeed, we speculate on 
the potential cross talk or complex formations leading to a synergistic effect between mPRs 
and PGRMC-1 enhancing the anti apoptotic effects, as PGRMC-1 has received attention as 
being an anti apoptotic mediator of progesterone. Evidence has been presented from a recent 
study strengthening the significance of PGRMC-1 as the receptor mediating the progesterone 
induced anti apoptotic effects in human granulosa/luteal cells of the ovary. When activated, it 
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potentially triggers the activation of signal transduction pathways that prevent the apoptosis 
of these cells (Engmann et al., 2006).  
3.10.2. Hormonal regulation of membrane PRs 
The expression of the progesterone receptor gene has been previously reported to be 
regulated by sex steroid hormones including progesterone in the rabbit hypothalamus 
(Camacho-Arroyo et al., 1996) and therefore we examined the effects of progesterone, a 
progestin compound and a cytokine on the expression of mPRs and PGRMC-1 transcripts in 
choriocarcinoma cell lines. The regulation of progesterone receptor genes forms a critical 
aspect of the responsiveness to progesterone hormone in the human placenta during gestation.  
For example nPRs can be modulated at placental level. By treating the placental cells with 
prostaglandins, the expression of PR-B was down -regulated altering the ratio in the placenta 
in favour of the PR-A/PR-B ratio thus altering the pregnancy status (Ziyan et al., 2010). After 
the 37
th
 week which is the hallmark of normal human gestation period, the levels of 
circulating progesterone rise exponentially and this could have an affect on PR expression in 
an autocrine manner. These findings indicate that prostaglandins can regulate the expression 
of PRs in the human placenta and determining any responses of this organ during gestation. 
The gene expression of mPRα, mPRβ, mPRγ and PGRMC-1 was significantly downregulated 
in BeWo cells compared to the non-treated cells upon co-incubation with the cytokine IL-1β 
and progesterone.  The expression of mPRβ was significantly downregulated upon treatment 
with progesterone as well as co-incubation with IL-1β leading to the conclusion that 
progesterone has a negative effect on the expression of this gene. The expression of this gene 
was significantly up - regulated upon treatment with the progestin compound OD 02-0 in 
combination with IL-1β thus allowing us to conclude that a synergistic effect results in the 
upregulation of this receptor on BeWo cells. A plausible synergistic effect is also seen the 
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expression of mPRβ in JEG-3 cells upon con-incubation with progesterone and IL-1β as well 
as with OD 02-0 and IL-1β. 
IL-1β significantly downregulated the expression of all mPRs but did not exert a significant 
effect on the expression of PGRMC-1 in JEG-3 cells. Nonetheless, a differential regulation of 
mPRα is observed upon treatment with progesterone or OD 02-0 and co-incubation of these 
progestagens with IL-1β resulted in significant down - regulation of this transcript in JEG-3 
cells. Possibly, a negative effect is exerted by progestins on the regulation of the expression 
of this gene.  
Our results lead to the conclusions that the progestin compounds when used alone or in 
combination with the cytokine lead to differential regulation of the progesterone receptor 
genes. Our findings are in agreement with earlier studies that have shown differential 
expression of the mPR genes in the endometrium during the different stages of the menstrual 
cycle where the levels of progesterone vary (Fernandes et al., 2005). Expression of PGRMC-
1 gene has also been shown to be regulated by endocrine factors. Dynamic patterns of 
expression were seen under the physiological conditions such as the estrous cycle and 
pregnancy and expression of this gene was shown to be upregulated by P4 in an 
ovariectomised mouse mode (Zhang et al., 2008). 
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CHAPTER 4 
4. GENERAL DISCUSSION 
 
4.1. Concluding remarks 
Preterm labour (PTL) and in particularly before the 32
nd
 weeks of gestation, is associated 
with high fetal morbidity and mortality and thus is the subject of intense research with the 
ultimate goal to devise preventative or therapeutic strategies. Approximately two-thirds of 
preterm deliveries are due to spontaneous onset of preterm labour or to preterm premature 
rupture of membranes (Tattersall et al., 2008). 
The interventions to improve the prognosis of preterm labour are very few (Farine et al., 
2008). Many years ago, Csapo et al., was the first to promote the progesterone see-saw 
theory, stating that high progesterone levels are able to prevent contractions of the uterine 
muscles whereas low levels facilitate such contractions (Caspo, 1956). It emerges that the 
hormonal control of the contractions and labour in humans is more complex in comparison to 
other animals and that the role of progesterone may indeed be more limited than in animal 
models (Norwitz et al., 1999). Many studies have examined the use of progesterone for 
prevention of preterm labour. Mackenzie et al reported that from 735 such existing studies 
only three were found appropriate for inclusion in their meta-analysis on preterm therapy 
during the second trimester, which had showed that the use of progestins by women at risk 
for preterm labour reduced its occurrence by 43% (Mackenzie et al., 2006).   
4 
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At term, the human placenta produces about 250mg of progesterone per day and in order to 
exert its effects it must bind and activate progesterone receptors (Tuckey, 2005). In this study 
we have mapped in detail the expression of all known progesterone receptors. We have 
shown that the canonical nuclear PR-B is barely expressed in the human placenta both at term 
and preterm. However, a multitude of alternative progesterone receptors appear to be 
expressed, including mPRα, mPRβ, mPRγ and PGRMC-1. Of those, mPRβ and mPRγ were 
upregulated in preterm placentas with the latter reaching significance. We then assessed the 
relative abundance of mPRs transcripts relative to mPRα. The ratio of mPRα/mPRβ was 
upregulated in the non labour group when compared to the labour cohort and again 
uperegulated in the term category when compared to the preterm. Similar results were found 
in the ratio of mPRα/mPRγ whereas the ratio of mPRα/PGRMC-1 was upregulated in the non 
labour category and the preterm category compared to labour and term respectively.  
In addition, downregulation of the ratio of mPRα/PR-B in preterm samples when compared 
to term was also evident. However, given that the expression of PR-B was remarkably low 
across all samples tested, that makes its role in mediation of placental progesterone responses 
questionable. 
This is the first study that mapped in detail all three classes of progesterone receptors in term 
and preterm placental tissues. Previous studies have shown changes in the expression of 
mPRs in other intrauterine tissues related to gestational age. Fernandes et al have shown that 
myometrial mPRα but not mPRβ levels also declined upon preterm labour, although the 
differences were not statistically significant. In contrast, term or preterm was not associated 
with statistically significant changes in mPRγ in the human myometrium (Fernandes et al., 
2005). In a recent study, PGRMC-1 had a lower expression in myometrium collected from 
women at term either not in labour or in labour compared with tissues from women in 
preterm non-labour (Wu et al., 2011). In terms of their localisation mPRα was localised 
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around syncytiotrophoblasts with a cytoplasmic localization, whereas mPRβ was expressed 
both in the cytoplasm as well as on the plasma membrane (also around syncytiotrophoblasts), 
and mPRγ was expressed in both syncytiotrophoblasts and cytotrophoblasts. The expression 
was stronger around syncytiotrophoblasts, where mPRγ appeared to be expressed mainly on 
the plasma membrane.  This is in agreement with a study by Fernandes et al., demonstrating 
that mPRα expression is restricted to the syncytiotrophoblast at the periphery of term 
chorionic villi (Fernandes et al., 2005). With regards to PGRMC-1, it has been previously 
shown that it is expressed in smooth muscle of the placental vasculature, villous capillaries 
and the syncytiotrophoblast (Zhang et al., 2008).  However, regulation of mPRs at the cell 
surface is still unclear, since there is still a debate about the cellular distribution of these 
receptors (Krietsch et al., 2006). Membrane localisation of  mPRs has been demonstrated by 
several research groups in a variety of other cell types (Tubbs & Thomas, 2009; Dosiou et al., 
2008; Josefsberg et al., 2007;  Nutu et al., 2007; Thomas et al., 2007; Hanna et al., 2006; Zhu 
et al., 2003). Other researchers have reported that mPRs are localized intracellularlly in the 
endoplasmic reticulum (Lemale et al., 2008; Ashley et al., 2006; Krietsch et al., 2006). An 
answer to these discrepancies could be the trafficking of these receptors. An important 
characteristic of 7TMRs is that they are rapidly internalised upon activation in a ligand-
dependent manner, an event critical for their proper functioning (Moore et al., 2007). Data 
from our laboratory revealed that mPRα can undergo internalisation upon exposure to high 
levels of progesterone in the human myometrium (Foster et al., 2010).  It is possible 
therefore, that in an adjacent intrauterine tissue like the placenta, progesterone acts in an 
autocrine manner to drive mPR internalisation, thus leading to their cytoplasmic appearance. 
Moreover, treatment of JEG-3 cells with P4 led to a significant decrease of mPRα and mPRβ, 
a phenomenon indicative of homologous desensitisation. Downregulation of a 7TMR at 
mRNA level is another feature of agonist-promoted regulation that takes place during 
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homologous desensitisation. For example, in human myometrial cells treated with oxytocin, a 
decrease in oxytocin receptor mRNA expression was accompanied with receptor 
desensitisation (Phaneuf et al., 1998), and as a result subsequent internalisation like the GLP-
1 receptor (Widmann et al., 1997).  Therefore, internalisation provides another explanation of 
why several 7TMRs are found in the cytoplasm (Thompson et al., 2005) and may also 
explain why some investigators have observed mPRs intracellularly.   
In kidney tissue mPRα was found to be restricted to the endoplasmic reticulum (ER) due to a 
C-terminal ER retention motif (Lemale et al., 2008). This is not unusual for 7TMRs, since 
many require accessory proteins to ensure transport to the plasma membrane (Cooray et al., 
2008
A
; Cooray et al., 2008
B
). An example is the melanocortin 2 receptor, which is localised 
within the ER and unable to be transported to the plasma membrane unless it is co-expressed 
with the melanocortin 2 receptor accessory protein (Cooray et al., 2008
A
). It is possible 
therefore that mPRα might require an accessory protein that is expressed in tissue- or cell-
specific manner, thus affecting its transport to the membrane.  A recent study has suggested 
such role for PGRMC-1 that can affect epidermal growth factor receptor (EGFR) signalling, 
by binding EGFR and stabilizing plasma membrane pools of the receptor (Ahmed et al., 
2010). Interestingly, data from our placental tissues points towards a consistent (i.e. 
irrespective of any pathologies) and significant positive correlation between mPRα and 
PGRMC-1. These strong correlations were not influenced by gestational age or labouring 
status. Moreover, we moved to an in silico analysis using Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING 8) which revealed a potential complex formation of 
those two receptors. It is attractive to speculate that PGRMC-1 can act as a potential 
accessory protein and –like EGFR- stabilizes mPRα at the plasma membrane by masking its 
ER retention motif. This might also explain the controversy that surrounds the cellular 
localization of mPRs. 
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There is also a 1.6 fold increase in the mPRα/PGRMC-1 ratio in preterm placentas when 
compared with the term ones. This might result in a compromised function of mPRα in these 
tissues as fewer receptors will be directed to the plasma membrane. However, there is a 
higher order of complexity in preterm labour and other cytokines/hormones acting in an 
autocrine or paracrine manner might also influence progesterone-mediated signalling. One of 
these cytokines –that shows certain cross-talk with progesterone- is interleukin-1β (IL-1β). It 
has been suggested that IL-1β could be a possible predictor of preterm delivery since its 
levels in amniotic fluid are elevated in mid-trimester and positively associated with preterm 
birth (Puchner et al., 2011) as well as microbial invasion of the amniotic cavity (Marconi et 
al., 2011). Dubicke et al have also shown that the actual mRNA levels of IL-1β are elevated 
in the human cervix during preterm labour (Dubicke et al., 2010). However, we have chosen 
not to investigate the expression of IL-1β receptor in our clinical samples, as it has already 
been documented that protein expression of placental IL-1β receptor was neither dependent 
on term or preterm labour, nor on the presence of intrauterine infection (Steinborn et al., 
1998). 
In this study we also provide a novel insight of the role of IL-1β and progesterone within the 
placental microenvironment. In both in vitro models tested (BeWo and JEG-3) IL-1β appears 
to increase cell death, whereas progesterone has an opposite “rescuing” effect. We have 
dissected this response further using specific agonists for mPRs as well as the nuclear PR. 
When both cell lines were treated with OD 02-0 (a specific mPR agonist) a similar inhibition 
of IL-1β’s effects was noted as that of progesterone, indicating that there is involvement of 
mPRs in the rescuing from cell death. When both cell lines were treated with the nuclear 
progesterone receptor agonist, R5020 at a concentration that will only activate the nuclear 
PRs, there was no apparent effect on BeWo cells whereas in JEG-3 it completely abolished 
the IL-1β’s effects. These data indicate a certain amount of synergy amongst multiple PRs at 
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placental level. This is not surprising as previous findings point towards a potential 
transactivation of the nuclear PR by mPRα and mPRβ. In human myometrial cells activation 
of mPRs via coupling to Gi α-subunits serves to potentiate hormone-activated nuclear PR-B 
(Karteris et al., 2006). The expression of the nuclear progesterone receptor (PR)-responsive 
genes is decreased in the uterus of the primate at term , suggesting that functional progestin 
withdrawal involves the repression of the PR transcriptional activity. One potential 
intermediary in this withdrawal is the truncated isoform of PR, PR-A, which is up-regulated 
in laboring myometria and can function as a dominant negative to repress the transcriptional 
activity of PR-B  (Karteris et al., 2006).  
However, cautiousness should be exercised extrapolating in vitro findings as it is evident, 
R5020 only exerted a significant response in JEG-3 but not in BeWo cells were as both cell 
lines are of a choriocarcinoma origin a similar response would be anticipated. As previously 
discussed (chapter 3.6) this could be due to inherent differences in the expression of certain 
components in these immortalised cell lines (Burleigh et al., 2007).  
Given the protective effects of progestins in these placental models, we dissected this 
response further by assessing the capacity of the compounds to alter the phosphorylation 
status of ERK1/2. We have carefully chosen this particular MAPK, since ERK1/2 appears to 
play a key role in promoting cytotrophoblast cell differentiation and proliferation. Moreover, 
activation of mPRs can also rapidly phosphorylate ERK1/2 in vitro. This has been 
demonstrated by several studies where mPRα and mPRβ were stably expressed in the nuclear 
progesterone receptor – deficient mammalian breast cancer cells MDA-MB-23, following 
progestin treatment a significant activation of MAPK was detected within 5 minutes (Thomas 
et al., 2002; Zhu et al., 2003; Hanna et al., 2006). A recent report has also documented the 
activation of  ERK1/2 upon progestin treatment in the granulosa and theca cells isolated from 
the ovaries of the Atlantic croaker (Dressing et al., 2010). Moreover, R5020 has been shown 
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to exert a similar effect in T47D breast cancer cells expressing PR-B (Kariagina et al., 2010). 
Of interest, progesterone as well as R5020 also altered the phosphorylation status of this 
MAPK in our cellular preparations as previously discussed. Pre-treatment with the selective 
MEK1/2 inhibitor U0126 inhibited substantially the cell rescuing effect of progesterone in 
both cell lines. In contrast, U0126 significantly reversed the effects of OD 02-0 and R5020 in 
JEG-3 cells. This dichotomy appears to be consistent with our previous observations, where a 
more pronounced effect was evident in JEG-3 cells. Collectively, these data point towards an 
involvement of a MAPK pathway following activation of multiple activated progesterone 
receptors. This is not the first time that interplays between IL-1β and progesterone have been 
documented. In breast cancer cells, progesterone appears to inhibit IL-1β effects (Hardy et 
al., 2006). Subsequent studies from the same group indicated that PR plays an important anti-
inflammatory role in breast cancer cells via ligand-dependent and ligand-independent 
mechanisms (Hardy et al., 2008). Moreover, in poorly differentiated endometrial cancer cells, 
treatment of progesterone downregulated gene expression of IL-1β (Davies et al., 2004). 
Therefore, we also investigated the combined effects of progesterone and IL-1β in an attempt 
to mimic the hormonal-cytokine cross-talk in a tissue microenvironment. When BeWo cells 
were treated with progesterone and IL-1β, all mPRs and PGRMC-1 were downregulated. 
However, this effect did not reach significance. In JEG-3 cells the combinatorial treatment 
downregulated mPRα and had no apparent effect on mPRγ but surprisingly, it induced an 
upregulation of mPRβ and PGRMC-1.  
Over the past 20 years many research groups have shown that steroids also act at the cell 
surface of many target tissues and cell types to initiate rapid responses, via binding to 
membrane receptors (Falkenstein et al., 2000).  However, the lack of comprehensive 
information on the identity and molecular structure of any membrane steroid receptor has 
prevented understanding of critical molecular aspects of steroid actions via this alternative 
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mechanism and a more widespread appreciation of its significance (Watson, 2003). The 
major scientific contribution from this study was the detailed mapping of progesterone 
receptors in clinical samples (term/preterm and labour/non labour), the elucidation of their 
cellular distribution and their potential cross-talk with the inflammatory cytokine IL-1β. The 
functionality of the various PRs was assessed by using specific ligands for the nuclear and 
membrane PRs. Collectively, our results provide a first insight into a complex regulation of 
PRs in the human placenta. The PR-induced rescuing effect from cell death could provide a 
platform for future therapeutic interventions. 
4.2. Study limitations 
We would also like to acknowledge that our study has a number of limitations. The clinical 
samples come from a relatively homogeneous population of the Greek island of Crete. 
Indeed, it would have been interesting to examine the expression of mPRs in an expanded 
population sample that would provide a better insight and also uncover any mutations that 
may be related to ethnic backgrounds. However, the relative uniformity of our sample could 
also have certain advantages - we do not need to control for the effects of other 
factors/variables such as lifestyle, diet and ethnicity, as these may have been rather similar 
among participants. Another limitation of our studies was the access to clinical samples of the 
first and second trimester, due to ethical considerations. The placental samples could have 
been higher, providing a better insight into the expression patterns of these genes throughout 
pregnancy. Indeed, when we have used a placental synsytialisation model to represent the 
third trimester, significant changes in the expression of all mPRs were observed. As we have 
also demonstrated there are differences in the response of progesterone and IL-1β in the two 
in vitro models we have used. No direct conclusions can be drawn regarding activation of 
certain intracellular signalling pathways unless these studies are repeated in primary cell 
cultures or using placental explants as an ex vivo model. Moreover, the changes seen in the 
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clinical samples using quantitative PCR should be confirmed at protein level. We were also 
unable to study further protein expression and cellular distribution of mPRδ and mPRε due to 
lack of commercially-available antibodies. Finally the rescuing effect of progesterone –in 
terms of induced cell death- should be further evaluated. 
 
4.3. Future studies 
With regards to future studies, they should concentrate addressing some of the limitations of 
the current study as well as dissecting further the progesterone signalling at placental level.   
1. Which G proteins can the mPRs activate in the human placenta?                          
This is an important step, as emerging evidence suggest that mPRs can couple to 
numerous G-proteins (Karteris et al., 2006). This coupling “promiscuity” of 7TMRs is a 
common phenomenon, usually dictated by tissue-specificity and disease state. This first 
objective will be studied using photoaffinity labelling in placental tissues acquired from 
normal and pathological complicated pregnancies.  With the use of specific G-protein α-
subunit antibodies (i.e. Gs, Gi, Gq and Go) and radiolabelled GTP-azidoanalide (GTP-
AA), we will be able to gain a better insight if there is a switch in G protein coupling of 
mPRs in a disease state, i.e. IUGR, pre-eclampsia, or preterm labour. 
2. What are the subsequent downstream signalling pathways affected by mPR 
activation? 
We propose to use commercially-available radioimmunoassays in order to study the effects of 
progestins on second messenger systems such as cAMP, IP3 and cGMP in vitro. Downstream 
effectors will also be studied in detail, by expanding on the repertoire of phosphorylation 
targets, including the remaining MAPKs p38, SAPK/JNK and other related targets such as 
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mTOR, Akt and S6K. We would also like to alter the ratios of mPRs in vitro, in an attempt to 
mimic the changes detected in clinical samples and subsequently assess their signalling 
capacity, by measuring changes in the phosphorylation status of the MAPK cascade.  
 Furthermore, as it is evident from this study, it appears that there is a potential interplay 
between mPR and activated nuclear PR. Therefore, we would like to study further the 
transactivation of PR-B by all three different mPRs in placental cell lines as previously 
described (Karteris et al., 2006) as well as investigate the progesterone-induced 
phosphorylation of PR in the absence of mPRs. We propose to dissect these responses using 
specific agonists, Pertussis toxin as inhibitor of Gi as well as specific siRNAs for all mPRs 
and PGRMC-1. 
3. How is the progesterone “rescuing” effect mediated?   
The progesterone effect on IL-1β induced cell death should be further investigated, as it the 
pathways of necrosis or apoptosis should be determined. Caspases are central regulators of 
apoptosis. Here we propose to use a wide repertoire of caspases:  Cleaved Caspase-3 
(Asp175), Cleaved Caspase-6 (Asp162), Cleaved Caspase-7 (Asp198), and Cleaved Caspase-
9 (Asp315) to assess the effects of IL-1β in the presence of specific progestin ligands. We 
also propose to use the colorimetric TUNEL system so we can determine nuclear DNA 
fragmentation, an important biochemical indicator of apoptosis. 
4. Is PGRMC-1 involved in trafficking of placental mPRs? 
Internalisation and recycling of 7TMRs is a critical regulatory event for their signalling. The 
mechanism(s) by which mPR number is regulated on the cell surface is unclear. A key 
finding from the correlation studies was the highly significant correlation between mPRα and 
PGRMC-1 irrespective of pathologies. Given that PGRMC-1 can act as an adaptor protein we 
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would like to elucidate the role of PGMRC-1 on mPR trafficking in vitro. For this objective, 
two different placental cell lines can be co-transfected with PGMRC-1 and different mPRs. 
PGRMC-1 expression will be modulated using a Tet-On and Tet-Off system, and subsequent 
cellular distribution of mPRs will be determined using immunofluorescent analysis, 
ImageStream and TEM. 
 
5. Should the clinical cohort number be increased? 
Important conclusions arising from the clinical cohort we have used regarding differential 
expression of progesterone receptors in preterm labour for example. However, emerging 
studies emphasise that there is ethnic diversity in expression of certain genes, as well as 
certain polymorphisms. Our samples were obtained from a genetically homogeneous 
population, from the island of Crete. A larger clinical cohort involving tissues from other 
parts of Europe would provide a better insight not only regarding the expression at 
mRNA/protein level but also provide us with an opportunity to assess any correlations of PR 
and IL-1β polymorphisms with certain gestational pathologies. 
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STRING for mPRα: 
 
 
 
 
GPR30 : Adiponectin precursor (Adipocyte, C1q and collagen domain- containing protein) 
PPARA: Chemokine receptor- like 2 (G-protein coupled receptor 30) 
MERTK: Proto-oncogene tyrosine-protein kinase MER precursor 
PGRMC-1: Membrane associated progesterone component 1- Receptor for progesterone 
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STRING for mPRβ: 
 
 
 
 
TMEM14A: EF- hand domain-containing protein 1 
FBXO9: Transmembrane protein 14A 
LRRC1: F-box only protein 9 
TRAM2: Translocation- associated membrane protein 2 
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STRING for mPRγ: 
 
 
HRAS: Neuroendocrine secretory protein 55 
GNAI1: GTPase HRas precursor 
GNB1: Guanine nucleotide- binding protein subunit beta 1 
GNGT 1: Guanine nucleotide-binding protein gamma-T1 subunit precursor 
PGR: Progesterone Receptor (PR) 
PGRMC-1: Membrane associated progesterone component 1- Receptor for progesterone 
AR: Androgen Receptor 
AVP: Vasopressin- neurophysin 2- copeptin precursor 
NR3C1: Glucocorticoid Receptor (GR) 
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Population Count %Gated 
Double positive & Focus cells & Single Cell  4480 100 
 
Double positive & Focus cells & Single Cell Count % 
Nuclear localisation 3808 85 
Cytoplasm localisation 1072 15 
 
Expression of PR-B in BeWo cells using ImageStream analysis 
 
 
Population Count %Gated 
Double positive & Focus cells & Single Cell  1320 100 
 
Double positive & Focus cells & Single Cell Count % 
Nuclear localisation 0 0 
Cytoplasm localisation 118 9 
Membrane localisation 954 91 
 
Binding study using P4-BSA-FITC  in BeWo cells using ImageStream analysis 
 
 
 
